

**CURRICULUM VITAE**

1. **Date:** April, 2021

**I. PERSONAL**

2. **Name:** Timothy Garrett Murray, M.D., M.B.A., F.A.C.S.

3. **Home Phone/Cell Phone** (305) 669-5361/(786) 368-9638

4. **Office Phone:** (786) 567-4403

5. **Home Address:** 1221 S Alhambra Circle  
Coral Gables, Florida 33146

6. **Current Practice:** Founding Director/CEO  
Ocular Oncology and Retina  
6705 Red Road, Suite 412  
Miami, FL 33143  
tmurray@murraymd.com

7. **Current Academic Rank:** Professor Emeritus, Tenured

8. **Primary/Joint Appointment:** Ophthalmology, Radiation Oncology, Medical  
Oncology, Pediatric Retina, Pediatric Oncology  
Baptist Health Systems  
Miami Children's Hospital  
Larkin Community Hospital  
Jackson Memorial Health Systems

9. **Citizenship:** U.S.A.

10. **Family:** Nicole Lynn Murray (Spouse)  
Julianna Elise Murray (Daughter, 17 yo)  
Alessandra Nicole Murray (Daughter, 15 yo)

**II. HIGHER EDUCATION**

**11. Institutional:**

Johns Hopkins University	B.A.	1981
Johns Hopkins School of Medicine	M.D.	1985
University of Miami	M.B.A.	2005

**12. Non-Institutional:**

2012-present Founding Director/CEO, Ocular Oncology and Retina  
2012-present Professor Emeritus, Tenured Ophthalmology and Radiation Oncology  
2002-2012 Professor, Tenured, Ophthalmology and Radiation Oncology  
University of Miami; Miami, Florida  
1997-2002 Associate Professor, Tenured, Ophthalmology and Radiation Oncology  
University of Miami; Miami, Florida  
1991-1997 Assistant Professor, Ophthalmology and Radiation Oncology  
University of Miami; Miami, Florida  
1990-1991 Fellowship, Ophthalmology, Vitreoretinal Surgery  
Medical College of Wisconsin; Milwaukee, Wisconsin

**12. Non-Institutional (continued):**

1989-1990 Fellowship, Ophthalmology, Post Doctoral Retinal Research  
Medical College of Wisconsin; Milwaukee, Wisconsin  
1988-1989 Chief Residency, Ophthalmology  
University of California, San Francisco; San Francisco, California  
1986-1989 Residency, Ophthalmology  
University of California, San Francisco; San Francisco, California  
1985-1986 Internship  
Union Memorial Hospital; Baltimore, Maryland

**13. Certification, licensure:**

1987 State of California  
1988 State of Wisconsin  
1991 American Board of Ophthalmology  
1991 State of Florida  
1998 American College of Surgeons

**III. EXPERIENCE**

**14. Academic:**

2014-present Clinical Professor, Department of Surgery, Division of Ophthalmology  
Nova Southeastern University; Fort Lauderdale-Davie, Florida  
2002-2012 Tenured, Professor, Ophthalmology and Radiation Oncology  
University of Miami; Miami, Florida  
1997-2002 Associate Professor, Ophthalmology and Radiation Oncology  
University of Miami; Miami, Florida  
1991-1997 Assistant Professor, Ophthalmology and Radiation Oncology  
University of Miami; Miami, Florida  
1989-1991 Clinical Consultant; Veterans Administration Hospital; Milwaukee,

Wisconsin

**15. Hospital Appointments:**

Miami Childrens Hospital, 2012-present  
Baptish Health System, 2012-present  
Larkin Hospital, 2012-present  
Anne Bates Leach Eye Hospital, Medical Director, Photography/Imaging, 2009-2010  
Anne Bates Leach Eye Hospital, Medical Director Retinal Oncology, 2009-2012  
Anne Bates Leach Eye Hospital, Medical Director Echography, 2009-2012  
Anne Bates Leach Eye Hospital, Attending Physician, 1991-2012  
Jackson Memorial Hospital, Attending Physician, 1991-present  
University of Miami Hospitals & Clinics, Attending Physician, 1991-2012

**16. Non-Academic:** None

**17. Military:** None

**IV. PUBLICATIONS**

**18a. Books**

1. **Murray TG** (Editor): Retinoblastoma: Clinical Advances and Emerging Technologies. Hong Kong: Future Medicine, 2013: 1-158.
2. Houston SK, **Murray TG**. Laboratory discoveries in retinoblastoma. In: **Murray TG** (Ed): Retinoblastoma: Clinical Advances and Emerging Technologies. Hong Kong: Future Medicine, 2013: 6-16.
3. Houston SK, **Murray TG**. Retinoblastoma treatment. In: **Murray TG** (Ed): Retinoblastoma: Clinical Advances and Emerging Technologies. Hong Kong: Future Medicine, 2013: 90-8.
4. **Murray TG** and Boldt HC (Editors): Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. Hong Kong: Future Medicine, 2013: 1- 243.
5. **Murray TG**, Ehli F, Wildner A, Gold AS. Diagnostic imaging in ocular melanoma. In: **Murray TG** and Boldt HC (Eds): Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. Hong Kong: Future Medicine, 2013
6. **Murray TG**, Boldt HC, Houston SK. Brachytherapy for ocular melanoma. In: **Murray TG** and Boldt HC (Eds): Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. Hong Kong: Future Medicine, 2013
7. **Murray TG**, Houston SK. Surgical management of radiation-related complications. In:

**Murray TG** and Boldt HC (Eds): Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. Hong Kong: Future Medicine, 2013

8. Gold AS, Latiff A, **Murray TG**. Visual rehabilitation for ocular melanoma. In: **Murray TG** and Boldt HC (Eds): Ocular Melanoma: Advances in Diagnostic and Therapeutic Strategies. Hong Kong: Future Medicine, 2013
9. **Murray TG**, Baranick K, and D'Amico D (Editors): ARDS: 40 Years – An Oral History of the Aspen Retinal Detachment Society. Aspen: Aspen Publishing, 2012: 1-128.

**18b. Monographs and Book Chapters:**

1. **Murray TG**, Houston SK: Future Trends: *Retinoblastoma*: Jaypee Brothers Medical Publishers.
2. Wykoff CC, **Murray TG**: Management of Intraocular Tumors. *Current affiliations for Clinical Atlas of Procedures in Ophthalmic Surgery* (2<sup>nd</sup> Edition): Oxford University
3. Houston SK, Markoe AM, Boldt HC, **Murray TG**,: Brachytherapy for Choroidal Melanomas. *Retina* (5<sup>th</sup> Edition): Elsevier. 2012
4. **Murray TG**: Choroidal Melanoma, Choroidal Nevus, Choroidal Osteoma, Hemangiomas of the Posterior Segment, Juvenile Xanthogranuloma, Von-Hippel Lindau: *SD-OCT Book*: Elsevier.
5. Scheffler AC, **Murray TG**: *Retinoblastoma 2011 Update*: BMJ Publishing.
6. Scheffler AC, **Murray TG**: Cataract and Vitrectomy Surgery in Patients with a History of Uveal Melanoma: *Cataract Surgery / Book 1*: InTech Publishing.
7. Scheffler AC, Olsen KR, Johnson RN, Hui JI, **Murray TG**: Brachytherapy for Posterior Uveal Malignant Melanoma. In Albert DM, Jakobiec FA: *Principles and Practice of Ophthalmology* (3rd Edition): Elsevier, 2007.
8. Berrocal AM, Mavrofrides EC, **Murray TG**: Retinoblastoma, In *Retinal Imaging*, Philadelphia: Mosby Elsevier, 2006: 471-479.
9. Amirikia A, **Murray TG**: Choroidal Melanoma. In Singh K, Smiddy WE, Lee AG, eds.: *Ophthalmology Review; a Case-Study Approach*. New York, Thieme, 2002:199-203.
10. Tabandeh H, **Murray TG**: Leukemia and Lymphoma. In Parrish RK II: *The University of Miami Bascom Palmer Eye Institute Atlas of Ophthalmology*. Current Medicine,

- Philadelphia, 2000:409-416.
11. Chaudhry NA, **Murray TG**: Metastatic Ocular Tumors. In Parrish RK II: *The University of Miami, Bascom Palmer Eye Institute Atlas of Ophthalmology*. Current Medicine, Philadelphia, 2000:402-408.
  12. Scott IG, Warman R, **Murray TG**: Retinoblastoma. In Parrish RK II: *The University of Miami, Bascom Palmer Eye Institute Atlas of Ophthalmology*. Current Medicine, Philadelphia, 2000:393-402.
  13. Aaberg TM Jr, Boldt HC, **Murray TG**: Uveal Malignant Melanoma. In Parrish RK II: *The University of Miami Bascom Palmer Eye Institute Atlas of Ophthalmology*. Current Medicine, Philadelphia, 2000:381-392.
  14. Olsen, KR, **Murray TG**, Johnson RN: Enucleation and Plaque Treatment. In Albert DM, Jakobiec FA: *Principles and Practice of Ophthalmology* (2<sup>nd</sup> edition). WB Saunders Company, 2000:358(6)5028, 5046.
  15. Scott IU, Moy CS, **Murray TG**, O'Brien JM: Issues in the diagnosis and management of small choroidal melanocytic lesions. In O'Brien JM eds.: *Ocular Oncology*. WB Saunders Company, 1999: 12(2)149-157.
  16. Harbour JW, **Murray TG**: Management of intraocular tumors. In Albert D, Ed.: *Ophthalmic Surgery: Principles and Techniques*, 1997.
  17. **Murray TG**, O'Brien JM, Cicciarelli N, Smith BJ, Hernandez E, Windle JJ, Ksander B, Markoe AM: Ocular ferromagnetic hyperthermia, external beam radiotherapy, and focal chemotherapy in the treatment of murine retinoblastoma. In Franconi C, Arcangeli G, Cavaliere R, eds: *Hyperthermic Oncology, Volume II*. Rome, Editorgrafica, 1996;811-813.
  18. **Murray TG**, Ksander BR. Immunology of Ocular Tumors. In: Pepose JS, Holland GN, Wilhelmus KR, eds.: *Ocular Infection and Immunology*. Mosby Publishers, 1994:157-182.
  19. **Murray TG**, Mieler WF, Lewandowski MF. Posterior Uveal Melanomas. In: Margo CE, Mames RN, Hamed LM, eds.: *Diagnostic Problems in Clinical Ophthalmology*. WB Saunders Company, 1994:382-393.
  20. Davis T, Ruiz P, Viciano A, Thompson WS, **Murray TG**. Flow Cytometry of Diagnostic Vitrectomy Specimens. In: Nussenblatt RB, Whitcup SM, Caspi RR, Gery I, eds.: *Advances in Ocular Immunology*. Amsterdam: Elsevier, 1994:315-318.
  21. Boldt HC, Abrams GW, **Murray TG**, Han DP, Mieler WF. The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin. In: Stirpe M, ed.: *Advances in Vitreoretinal Surgery*. New York: Ophthalmic Communications Society,

1992:353-361.

22. **Murray TG**, Mieler WF, Steeves RA. Ocular ferromagnetic hyperthermia. In: Bornfeld N, Gragoudas ES, Hopping W, Lommatzsch PK, Wessing A, Zografos L, eds.: *Proceedings of the Second International Tumor Symposium*. Essen, West Germany: Kugler Publications, 1991:473-478.

**19a. Juried or refereed journal articles and exhibitions**

1. Bach A, Gold AS, Villegas VM, Wildner AC, **Murray TG**. Intraocular eyelash. *J Am Osteopath Assoc*. 2015 Feb;115(2):115.
2. Villegas VM, Gold AS, Latiff A, Wildner AC, Ehliès FJ, **Murray TG**. Phacovitrectomy. *Dev Ophthalmol*. 2014;54:102-7.
3. Cavalcante ML, Villegas VM, Gold AS, Cavalcante LL, Lonngi M, Shah NV, **Murray TG**. Treatment of vascular activity secondary to atypical choroidal nevus using intravitreal bevacizumab. *Clin Ophthalmol*. 2014 Jul;8:1377-82.
4. Villegas VM, Gold AS, Berrocal AM, **Murray TG**. Advanced Coats' disease treated with intravitreal bevacizumab combined with laser vascular ablation. *Clin Ophthalmol*. 2014 May;8:973-6.
5. Bach A, McGowan S, Gold AS, Villegas VM, Wildner AC, Ehliès FJ, Thompson JM, Bermudez-Magner JA, Dubovy SR, **Murray TG**. Tapioca Melanoma of the Iris Without Iris Heterochromia. *Optom Vis Sci* 2014 Apr;91(4 Suppl 1):S20-24.
6. **Murray TG**, Gold AS, Markoe AM, Wildner A, Latiff A, Bermudez E, Ehliès F. Spectral-domain optical coherence tomography evaluation of choroidal melanoma and nevus fine-needle aspiration biopsy incision sites. *Ophthalmic Surg Lasers Imaging Retina*. 2014 Mar;45(2):165-8.
7. Philips KB, Kurtoglu M, Leung HJ, Liu H, Gao N, Lehrman MA, **Murray TG**, Lampidis TJ. Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose. *Cancer Chemother Pharmacol*. 2014 Feb;73(2):349-61.
8. Villegas VM, Gold AS, Wildner A, Ehliès F, **Murray TG**. Genomic landscape of retinoblastoma. *Clin Experiment Ophthalmol*. 2014 Jan;42(1):2-3.
9. Gold AS, **Murray TG**, Markoe AM, Ehliès F, Latiff A, Wildner A, Bermudez E. Uveal Melanoma Gene Expression Status Post Radiotherapy. *Optom Vis Sci*. 2014 Jan;91(1):e14-7.
10. Villegas VM, Hess DJ, Wildner A, Gold AS, **Murray TG**. Retinoblastoma. *Curr Opin Ophthalmol* 2013 Nov;24:581–588.

11. Modi Y, John V, Warman R, Hess D, **Murray TG**, Berrocal AM. Retained subretinal date palm tree thorn in a child. *J AAPOS*. 2013 Oct;17(5):545-7.
12. Gold AS, Bermudez E, Latiff A, Wildner AC, Ehliès FJ, **Murray TG**. Posterior uveal melanoma coexistent with macular hole. *Optom Vis Sci*. 2013 Jun;90(6):e156-60.
13. **Murray TG**, Markoe AM, Gold AS, Ehliès F, Bermudez E, Wildner A, Latiff A. Long-term followup comparing two treatment dosing strategies of 125I plaque radiotherapy in the management of small/medium posterior uveal melanoma. *Journal of Ophthalmology*, 2013 Article ID 517032, 5 pages
14. Modi YS, Epstein A, Smiddy WE, **Murray TG**, Feuer W, Flynn HW Jr. Retained Lens Fragments after Cataract Surgery: Outcomes of Same-Day versus Later Pars Plana Vitrectomy. *Am J Ophthalmol*. 2013 Sep;156(3):454-459.e1.
15. Houston SK, Wykoff CC, Berrocal AM, Hess DJ, **Murray TG**. Lasers for the treatment of intraocular tumors. *Lasers Med Sci*. 2013 May;28(3):1025-34.
16. Houston SK, Lampidis TJ, **Murray TG**. Models and discovery strategies for new therapies of retinoblastoma. *Expert Opin Drug Discov*. 2013 Apr;8(4):383-94.
17. Houston SK, Wykoff CC, Berrocal AM, Hess DJ, **Murray TG**. Laser treatment for retinopathy of prematurity. *Lasers Med Sci*. 2013 Feb;28(2):683-92.
18. Lonngi M, Houston SK, **Murray TG**, Sisk RA, Decatur CL, Cavalcante M, Markoe AM. Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma. *Clin Ophthalmol*. 2013;7:427-35
19. **Murray TG**, Layton AJ, Tong KB, Gittelman M, Latiff A, Gologorsky D, Vigoda MM. Transition to a novel advanced integrated vitrectomy platform: comparison of the surgical impact of moving from the Accurus vitrectomy platform to the Constellation Vision System for microincisional vitrectomy surgery. *Clin Ophthalmol*. 2013;7:367-77.
20. Houston SK, Shah NV, Decatur C, Lonngi M, Feuer W, Markoe AM, **Murray TG**. Intravitreal bevacizumab combined with plaque brachytherapy reduces melanoma tumor volume and enhances resolution of exudative detachment. *Clin Ophthalmol*. 2013;7:193-8.
21. Tzu JH, Flynn HW Jr, Berrocal AM, Smiddy WE, **Murray TG**, Fisher YL. Clinical manifestations of optic pit maculopathy as demonstrated by spectral domain optical coherence tomography. *Ophthalmic Surg Lasers Imaging Retina*. 2013 Jan-Feb;44(1):85-90.
22. Lonngi M, Gold AS, **Murray TG**. Combined bevacizumab and triamcinolone acetonide injections for macular edema in a patient with astrocytic hamartomas and tuberous sclerosis. *Ophthalmic Surg Lasers Imaging Retina*. 2013 Jan-Feb;44(1):85-90.

23. Sisk RA, Riemann CD, Petersen MR, Foster RE, Miller DM, **Murray TG**, Augsburger JJ. Fundus autofluorescence findings of choroidal osteoma. *Retina*. 2013 Jan;33(1):97-104.
24. Henry CR, Berrocal AM, Hess DJ, **Murray TG**. Intraoperative spectral-domain optical coherence tomography in coats' disease. *Ophthalmic Surg Lasers Imaging*. 2012 Jul 26;43:e80-4. doi: 10.3928/15428877-20120719-01.
25. Shah NV, Houston SK, **Murray TG**, Markoe AM. Evaluation of the surgical learning curve for I-125 episcleral plaque placement for the treatment of posterior uveal melanoma: a two decade review. *Clin Ophthalmol*. 2012: June; 6:447-452..
26. Parke DW 3<sup>rd</sup>, Sisk RA, Houston SK, **Murray TG**. Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsification. *Clin Ophthalmol*. 2012: June; 6:925-931.
27. Piña Y, Houston SK, **Murray TG**, Koru-Sengul T, Decatur C, Scott WK, Nathanson L, Clarke J, Lampidis TJ. Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors. *Clin Ophthalmol*. 2012;6:817-30. Epub 2012 May 29
28. Aziz HA, Berrocal AM, Sisk RA, Hartley K, Diaz-Barbosa M, Johnson RA, Hess D, Dubovy SR, **Murray TG**, Flynn HW Jr. Intraocular infections in the neonatal intensive care unit. *Clin Ophthalmol*. 2012;6:733-7. Epub 2012 May 14.
29. Leung E, Diaz-Barbosa M, Alabiad C, Hodapp E, Tse D, **Murray TG**, Castaner JC, Martin D, Berrocal AM. Prenatal ultrasonographic detection of ophthalmic diseases. *J Pediatr Ophthalmol Strabismus*. 2012 May 22;49:e26-9. doi: 10.3928/01913913-20120515-02.
30. Bielory BP, Dubovy SR, Sinclair JC, Wykoff C, **Murray TG**. Pseudohypopyon as a clinical manifestation in metastatic lung carcinoma. 2012 Feb 9;43:e1-4. doi: 10.3928/15428877-20120130-01. PMID: 22320830 [PubMed - in process]
31. Houston SK, Wykoff CC, Berrocal AM, Hess DJ, **Murray TG**. Lasers for the treatment of intraocular tumors. *Lasers Med Sci*. 2012 Feb 3. [Epub ahead of print]
32. Sinclair JC, Gold AS, **Murray TG**. Bilateral choroidal metastases from primary esophageal melanoma: a rare case. *Optom Vis Sci*. 2012 Apr;89(4):502-6.
33. Piña Y, Decatur C, **Murray TG**, Houston SK, Lopez-Cavalcante M, Hernandez E, Celdran M, Shah N, Feuer W, Lampidis T. Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. *Invest Ophthalmol Vis Sci*. 2012



Feb 27;53(2):996-1002. doi: 10.1167/iovs.11-8265. Print 2012 Feb.

34. Silva RA, Dubovy SR, Fernandes CE, Hess DJ, **Murray TG**. Retinoblastoma With Coats' Response. *Ophthalmic Surg Lasers Imaging*. 2011 Dec 16;42:e139-43. doi: 10.3928/15428877-20111208-04. PMID: 22165951 [PubMed - in process]
35. Houston SK, Wykoff CC, Berrocal AM, Hess DJ, **Murray TG**. Laser treatment for retinopathy of prematurity. Laser treatment for retinopathy of prematurity. *Lasers Med. Sci.* 2011 Dec. 2 [Epub ahead of print]
36. Shirodkar AR, Pathengay A, Flynn HW Jr, Albini TA, Berrocal AM, Davis JL, Lalwani GA, **Murray TG**, Smiddy WE, Miller D. Delayed-Versus Acute-Onset Endophthalmitis After Cataract Surgery. *Am J Ophthalmol*. 2011 Oct 24. [Epub ahead of print]
37. Houston SK, **Murray TG**. Microarray gene-expression analysis in ocular oncology: uveal melanoma and retinoblastoma. *Expert Rev. Ophthalmol*. 2011 6(4), 477-485
38. Houston SK, Markoe AM, Boldt HC, **Murray TG**. Juxtapapillary Uveal Melanomas Patient Outcomes After Treatment With Proton Irradiation for Peripapillary and Parapapillary Melanomas. *Arch Ophthalmol*. 2011 Sept;129 (9):1218-1220.
39. Khan S, Finger PT, Yu GP, Razzaq L, Jager MJ, Keizer RJ, Sandkull P, Seregard S, Gologorsky D, Scheffler AC, **Murray TG**, Kivela T, Giuliari GP, McGowan H, Simpson ER, Coriveau C, Coupland SE, Damato BE. Clinical and Pathologic Characteristics of Biopsy-Proven Iris Melanoma. *Arch Ophthalmol*. Published online September 12, 2011. doi:10.1001/archophthalmol.2011.286
40. **Murray TG**, Tornambe P, Dugel P, Tong KB. Evaluation of economic efficiencies in clinical retina practice: activity-based cost analysis and modeling to determine impacts of changes. *Clin Ophthalmol*. 2011; July; 5:913-925.
41. Aziz HA, Berrocal AM, Sisk RA, **Murray TG**. Idiopathic infantile chronic rhegmatogenous retinal detachment. *Ophthalmic Surg Lasers Imaging*. 2011 Jul 14;42 Online:e63-4. doi: 10.3928/15428877-20110707-02.
42. Wykoff CC, **Murray TG**, Markoe AM, Feun LG, Scheffler AC, Gayer S. Preoperative Evaluation for Patients with Choroidal/Ciliary Body Melanomas: What Is Necessary? *Am J Ophthalmol*. 2011 June;151(6): 921-924.
43. Emanuelli A, Lalwani GA, Shane T, **Murray TG**, Berrocal AM. Widefield Fluorescein Angiography in Pediatric Retinal Diseases: The Next Frontier. *Retina Today*. 2011 May/June.

44. Houston SK, **Murray TG**, Fernandes CE, Aziz-Sultan MA. Intra-arterial Chemotherapy for Retinoblastoma: A promising treatment modality, with eyes and lives being saved. *Retinal Physician* May 2011, 17-20.
45. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, Schwartz SG, Davis JL, **Murray TG**, Smiddy WE, Berrocal AM, Dubovy SR, Lee WH, Albini TA, Lalwani GA, Kovach JL, Puliafito CA. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. *Retina*. 2011 Apr;31(4):662-8.
46. Houston SK, Berrocal AM, **Murray TG**. The future of diagnostic imaging in retinoblastoma. *J Pediatr Ophthalmol Strabismus*. 2011 April;15: 125-126.
47. Vigoda M, Latiff A, **Murray T**, Tutiven J, Berrocal A, Gayer S. Can children undergoing ophthalmologic examinations under anesthesia be safely anesthetized without using an IV line? *Clin Ophthalmol*. 2011: April; 5:503 – 508. DOI 10.2147/OPHTH.S18605
48. Houston SK, Markoe A, Boldt H, **Murray TG**. "Juxtapapillary Uveal Melanomas - Between a Rock and a Hardplace" - Patient Outcomes after Treatment with Proton Irradiation for Peripapillary and Parapapillary Melanomas. *Arch Ophthalmol*. In Press.
49. Houston SK, Piña Y, **Murray TG**, Boutrid H, Cebulla C, Scheffler AC, Shi W, Celdran M, Feuer W, Merchan J, Lampidis TJ. Novel retinoblastoma treatment avoids chemotherapy: the effect of optimally timed combination therapy with angiogenic and glycolytic inhibitors on LH(BETA)T(AG) retinoblastoma tumors. *Clin Ophthalmol*. 2011: January; 5:129-137.
50. Peterson EC, Elhammady MS, Quintero-Wolfe S, **Murray TG**, Aziz-Sultan MA. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. *J Neurosurg*. 2011 Feb 4.
51. Mutapcic L, **Murray TG**, Aziz-Sultan MA, Scheffler AC, Quintero Wolfe S, Hess D, Fernandes CE, Dubovy SR. Supraselective Intra-Arterial Chemotherapy: Evaluation of Treatment Related Complications in Advanced Retinoblastoma. *Clin Ophthalmol*. 2011: February, 5:171-176.
52. Boutrid H, Wolfe SQ, **Murray TG**, Aziz-Sultan MA, Pina Y, Moftakhar R, Fernandes CE, Reichback J. Bilateral Orbital Vasculature Alterations Following Systemic Chemotherapy and External Beam Radiation Therapy Treatment of Advanced Retinoblastoma: Implications for Intra-arterial Chemotherapy Management. *Retinal Cases Brief Reports* 5:124–127, 2011.
53. Houston, SK, **Murray TG**, Pina Y, Decatur C, Cavalcante L, Markoe AM. Pharmacotherapy for Radiation Retinopathy. *Retina Today*. 2010 Nov/Dec.

54. Bayraktar S, Stefanovic A, Montague N, Davis J, **Murray TG**, Lossos IS. Central nervous system manifestations of marginal zone B-cell lymphoma. *Ann Hematol* 2010 89:1003-1009
55. Suk KK, Berrocal AM, **Murray TG**, Rich R, Major JC, Hess D, Johnson RA. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity. *J Pediatr Ophthalmol Strabismus*. 2010 Dec 22;47.
56. Priest JR, Williams GM, Manera R, Jenkinson H, Bründler MA, Davis S, **Murray TG**, Galliani CA, Dehner LP. Ciliary body medulloepithelioma: four cases associated with pleuropulmonary blastoma--a report from the International Pleuropulmonary Blastoma Registry. *Br J Ophthalmol*. 2010 Dec 13.
57. Vajzovic LM, **Murray TG**, Aziz-Sultan MA, Scheffler AC, Fernandes CE, Wolfe SC, Hess DJ, Dubovy SR. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma. *Arch Ophthalmol*. 2010 Dec;128(12):1619-23.
58. Piña Y, Houston SK, **Murray TG**, Boutrid H, Celdran M, Feuer W, Shi W, Hernandez E, Lampidis TJ. Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. *Invest Ophthalmol Vis Sci*. 2010 Dec;51(12):6149-56.
59. Houston SK, **Murray TG**, Wolfe SQ, Fernandes CE. Current update on retinoblastoma. *Int Ophthalmol Clin*. 2011 Winter;51(1):77-91.
60. Sisk RA, Berrocal AM, Albin TA, **Murray TG**. Bevacizumab for the treatment of pediatric retinal and choroidal diseases. *Ophthalmic Surg Lasers Imaging*. 2010 Nov 1;41(6):582-92.
61. Merchan JR, Kovács K, Railsback JW, Kurtoglu M, Jing Y, Piña Y, Gao N, **Murray TG**, Lehrman MA, Lampidis TJ. Antiangiogenic activity of 2-deoxy-D-glucose. *PLoS One*. 2010 Oct 27;5(10):e13699.
62. Piña Y, Boutrid H, **Murray TG**, Wolfe SQ, Scheffler AC, Houston SS, Moftakhar R, Fernandes CE, Reichbach J, Aziz HA, Markoe AM, Aziz-Sultan MA. Ophthalmic Vasculature Alterations Following Systemic Chemotherapy and Periocular Carboplatin Treatment of Advanced Retinoblastoma. *J Pediatr Ophthalmol Strabismus*. 2010 Sep 22;47.
63. Gold AS, Nguyen JT, **Murray TG**: Macular hole secondary to capillary hemangioblastoma. *Optom Vis Sci*. 2010 Sep;87(9):705-9.
64. Williams BK Jr, Scheffler AC, Garonzik SN, Gologorsky D, Shi W, Cavalcante LL,

- Cavalcante ML, Feuer WJ, **Murray TG**. Frequent Prosthesis Refitting to Prevent Implant Exposure in Patients with Retinoblastoma. *J Pediatr Ophthalmol Strabismus*. 2010 Aug 23;1-9.
65. Sisk RA, **Murray TG**. Combined phacoemulsification and sutureless 23-gauge pars plana vitrectomy for complex vitreoretinal diseases. *Br J Ophthalmol*. 2010 Aug;94(8):1028-32.
66. Gologorsky D, Scheffler AC, Ehlied FJ, Raskauskas PA, Pina Y, Williams BK, **Murray TG**. Clinical imaging and high-resolution ultrasonography in melanocytoma management. *Clin Ophthalmol*. 2010 Aug 9;4:855-9.
67. Davis RP, Scheffler AC, **Murray TG**. Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. *Clin Ophthalmol*. 2010 Jul 30;4:703-7.
68. Jacobs DJ, **Murray TG**, Cubillas AV. Gaze-evoked vitreous hemorrhage in choroidal melanoma. *Retina*. 2010 Jul-Aug;30(7):1159.
69. Cavalcante LL, Cavalcante ML, **Murray TG**, Vigoda MM, Piñón Y, Decatur CL, Davis RP, Olmos LC, Scheffler AC, Parrott MB, Alliman KJ, Flynn HW, Moshfeghi AA. Intravitreal injection analysis at the Bascom Palmer Eye Institute: evaluation of clinical indications for the treatment and incidence rates of Endophthalmitis. *Clin Ophthalmol*. 2010;4 May 25;4:519-24.
70. Aziz HA, Sisk RA, Berrocal AM, **Murray TG**. Optic nerve aplasia in aicardi syndrome. *J Pediatr Ophthalmol Strabismus*. 2010 May 21;47:e1-4.
71. Leng T, Cebulla CM, Scheffler AC, **Murray TG**. Focal periocular carboplatin chemotherapy avoids systemic chemotherapy for unilateral, progressive retinoblastoma. *Retina*. 2010 Apr;30(4 Suppl):S66-8.
72. Sisk RA, Berrocal AM, **Murray TG**, Mavrofrides EC. Extended Endotamponade with Perfluoro-n-Octane in Pediatric Retinal Detachment. *Ophthalmic Surg Lasers Imaging*. 2010 Mar 9:1-3.
73. Aziz HA, Boutrid H, **Murray TG**, Berrocal A, Wolfe SQ, Pina Y, Dorfman M, Moftakhar R, Fernandes CE, Reichbach J, Aziz-Sultan MA. Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma. *Retina*. 2010 Apr;30(4 Suppl):S63-5.
74. Raveesh M, Shanmugam MP, **Murray TG**. Diagnostic and therapeutic challenges. *Retina*. 2010 May;30(5):832-5.

75. Cebulla CM, Ruggeri M, **Murray TG**, Feuer WJ, Hernandez E. Spectral domain optical coherence tomography in a murine retinal detachment model. *Exp Eye Res.* 2010 Apr;90(4):521-7. Epub 2010 Jan 28.
76. Bajenaru ML, Pina Y, **Murray TG**, Cebulla CM, Feuer W, Jockovich ME, Marin Castano ME. Gelatinase expression in retinoblastoma: modulation of LH(BETA)T(AG) retinal tumor development by anecortave acetate. *Invest Ophthalmol Vis Sci.* 2010 Jun;51(6):2860-4. Epub 2010 Jan 27.
77. Pina Y, Boutrid H, **Murray TG**, Jager MJ, Cebulla CM, Scheffler A, Ly LV, Alegret A, Celdran M, Feuer W, Jockovich ME. Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype. *Invest Ophthalmol Vis Sci.* 2010 May;51(5):2671-7. Epub 2010 Jan 6.
78. Williams BK, Cebulla CM, Scheffler AC, Fernandes CE, Gologorsky D, **Murray TG**. Required reduction in dose of chemotherapy for retinoblastoma due to down syndrome-associated chemosensitivity. *Retinal Cases Brief Reports:* 4:59-61, 2010
79. Wester ST, **Murray TG**. Retinal Arteriovenous Malformation Presenting with Retinal Vein Occlusion During Pregnancy. *Retinal Cases & Brief Reports:* 4:112-115, 2010
80. Rich R, Vanderveldt S, Berrocal AM, Mavrofrides EC, **Murray TG**, Gregori N. Treatment of choroidal neovascularization associated with Best's disease in children. *J Pediatr Ophthalmol Strabismus.* 2009 Sep-Oct;46(5):306-11.
81. Seider MI, Lujan BJ, Gregori G, Jiao S, **Murray TG**, Puliafito CA. Ultra-high resolution spectral domain optical coherence tomography of traumatic maculopathy. *Ophthalmic Surg Lasers Imaging.* 2009 Sep-Oct;40(5):516-21. doi: 10.3928/15428877-20090901-16. Erratum in: *Ophthalmic Surg Lasers Imaging.* 2010 Jan-Feb;41(1):144.
82. Patel PD, Klika AK, **Murray TG**, Elsharkawy KA, Krebs VE, Barsoum WK. Influence of Technique With Distally Fixed Modular Stems in Revision Total Hip Arthroplasty. *J Arthroplasty.* 2010 Sep;25(6):926-31.
83. Barsoum WK, **Murray TG**, Klika AK, Green K, Miniaci SL, Wells BJ, Kattan MW. Predicting Patient Discharge Disposition After Total Joint Arthroplasty in the United States. *J Arthroplasty.* 2010 Sep;25(6):885-92.
84. Stepien KE, Rosenfeld PJ, Puliafito CA, Feuer W, Shi W, Al-Attar L, Dubovy SR, **Murray TG**, Davis JL, Lee WH, Schwartz SG, Smiddy WE, Berrocal AM, Flynn HW Jr. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration. *Retina.* 2009 Sep;29(8):1067-73.

85. Leng T, Scheffler AC, **Murray TG**. Retinal vascular tumor and peripheral retinal vasculitis in the setting of systemic tuberculosis. *Ophthalmic Surg Lasers Imaging*. 2009 Jul-Aug;40(4):409-12.
86. Leng T, Flynn HW Jr, Miller D, **Murray TG**, Smiddy WE. Endophthalmitis caused by proteus species: antibiotic sensitivities and visual acuity outcomes. *Retina*. 2009 Jul-Aug;29(7):1019-24.
87. Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, **Murray TG**. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. *Retina*. 2009 Jul-Aug;29(7):913-25.
88. Boutrid H, Pina Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, **Murray TG**. Increased hypoxia following vessel targeting in a murine model of retinoblastoma. *Invest Ophthalmol Vis Sci*. 2009 Dec;50(12):5537-43. Epub 2009 Jul 2.
89. Sisk RA, Berrocal AM, Feuer WJ, **Murray TG**. Visual and Anatomic Outcomes With or Without Surgery in Persistent Fetal Vasculature. *Ophthalmology*. 2010 Nov;117(11):2178-83
90. Gologorsky D, Scheffler AC, Williams BK, Boutrid H, Dubovy SR, **Murray TG**. Medulloepithelioma: Invasive versus Noninvasive Diagnostic Methods and their Impacts on Outcome. *RETINAL Cases & Brief Reports*. 5(1):33-36, Winter 2011
91. Piña Y, Boutrid H, Scheffler A, Dubovy S, Feuer W, Jockovich ME, **Murray TG**. Blood Vessel Maturation in Retinoblastoma Tumors: Spatial Distribution of Neovessels and Mature Vessels and Its Impact on Ocular Treatment. *Invest. Ophthalmol. Vis. Sci*. 2009 50(3): 1020-1024.
92. Scheffler AC, Berrocal AM, **Murray TG**. Advanced Coats' disease. Management with repetitive aggressive laser ablation therapy. *Retina*. 2008 Mar;28(3 Suppl):S38-41. Erratum in: *Retina*. 2009 Jan;29(1):127.
93. Wykoff CC, Dubovy SR, Barredo JC, **Murray TG**. Simultaneous Presentation of Retinoblastoma and Morning Glory Disk Anomaly. *Retinal Cases & Brief Reports*: 3:354-357, 2009.
94. Piña Y, Cebulla CM, **Murray TG**, Alegret A, Dubovy SR, Boutrid H, Feuer W, Mutapic L, and Jockovich ME. Blood Vessel Maturation in Human Uveal Melanoma: Spatial Distribution of Neovessels and Mature Vasculature. *Ophthalmic Res*. 2009; 41: 160-169.
95. Ruggeri M, Tsechpenakis G, Jiao S, Jockovich ME, Cebulla C, Hernandez E, **Murray TG**, Puliafito CA. Retinal tumor imaging and volume quantification in mouse model

- using spectral-domain optical coherence tomography. *Opt Express*. 2009 Mar 2; 17(5):4074-83.
96. Leng T, Scheffler AC, **Murray TG**. Retinal Vascular Tumor and Peripheral Retinal Vasculitis in the Setting of Systemic Tuberculosis. *Ophthalmic Surg Lasers Imaging*. 2009 Jul-Aug;40(4):409-12.
  97. Scheffler AC, **Murray TG**, Markoe A. Radiotherapy in Ocular Oncology: Advances in Brachytherapy for Uveal Melanoma. *Retinal Physician*, July/August 2009, 16-19
  98. Cebulla CM, Alegret A, Ehliès FJ, Davis RP II, Hess DJ, CRA, the Echography Study Group, and **Murray TG**. Echographic Localization of Periocular Carboplatin for Advanced Retinoblastoma. *Retinal Cases Brief Reports*. 2009;3: 4-7
  99. Boutrid H, Pina Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, **Murray TG**. Vessel Targeting Increases Hypoxia in a Murine Model of Retinoblastoma. *Invest Ophthalmol Vis Sci*. 2009;50(0)1-7.
  100. Alegret AM, Cebulla CM, Dubovy SR, Mutapcic L, Hess DJ, **Murray TG**. Photodynamic Therapy And Vitrectomy For A Large Optic Nerve Hemangioma With Neovascularization and Retinal Detachment: A Clinicopathologic Correlation. *Retinal Cases Brief Reports*. 2009;3:93-95.
  101. Scheffler AC, Berrocal AM, **Murray TG**. Advanced Coats' disease. Management with repetitive aggressive laser ablation therapy. *Retina*. 2008 Mar;28(3 Suppl):S38-41. Erratum in: *Retina*. 2009 Jan;29(1):127.
  102. Gaitan JR, Berrocal AM, **Murray TG**, Hess D, Johnson RA, Mavrofrides EC. Anterior segment ischemia following laser therapy for threshold retinopathy of prematurity. *Retina*. 2008 Mar;28(3 Suppl):S55-7. Erratum in: *Retina*. 2009 Jan;29(1):127.
  103. Couvillion SS, Wykoff CC, Tutiven JL, Schaefer AM, **Murray TG**. Diffuse Neonatal Hemangiomatosis Presenting as Bilateral Iris Hemangiomas in an Infant. *Retinal Cases & Brief Reports*: 3:279-282, 2009.
  104. Gregori NZ, Berrocal AM, Gregori G, **Murray TG**, Knighton RW, Flynn HW Jr, Dubovy S, Puliafito CA, Rosenfeld PJ. Macular spectral-domain optical coherence tomography in patients with X linked retinoschisis. *Br J Ophthalmol*. 2009 Mar;93(3):373-8. Epub 2008 Nov 19.
  105. Lalwani GA, Berrocal AM, **Murray TG**, Buch M, Cardone S, Hess D, Johnson RA, Puliafito CA. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. *Retina*. 2008 Mar;28(3

- Suppl):S13-8. Erratum in: *Retina*. 2009 Jan;29(1):127.
106. Vigoda MM, Gayer S, Tutiven J, Mueller A, Murtha M, Scheffler AC, **Murray TG**. Targeting operating room inefficiencies in the complex management of vision-threatening diseases in children. *Arch Ophthalmol*. 2008 Sep;126(9):1241-3.
  107. Cantrill HL, Pulido JS, Donaldson M, Shields CL, **Murray TG**. Diagnostic and therapeutic challenges. *Retina*. 2008 Jul-Aug;28(7):1018-22.
  108. Feilmeier MR, Lossos IS, Malumbres R, Scheffler AC, **Murray TG**. Successful use of semi-nested PCR for the diagnosis of primary intraocular lymphoma. *Leuk Lymphoma*. 2008 Aug;49(8):1612-5.
  109. Hartley KL, Smiddy WE, Flynn HW Jr, **Murray TG**. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. *Retina*. 2008 Mar;28(3):410-9.
  110. Lalwani GA, Flynn HW Jr, Scott IU, Quinn CM, Berrocal AM, Davis JL, **Murray TG**, Smiddy WE, Miller D. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. *Ophthalmology*. 2008 Mar;115(3):473-6.
  111. Miller JJ, Scott IU, Flynn HW, Smiddy WE, **Murray TG**, Berrocal A, Miller D. Endophthalmitis Caused by Bacillus Species. *Am J Ophthalmol*. 2008 May;145(5):883-8.
  112. Gregori NZ, Gaitan J, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE, Schwartz SG, Lee WH, **Murray TG**. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion. *Retina*. 2008 Oct;28(9):1325-37.
  113. Cebulla CM, Jockovich ME, Piña Y, Boutrid H, Alegret A, Kulak A, Hackam AS, Bhattacharya SK, Feuer WJ, **Murray TG**. Basic Fibroblast Growth Factor Impact on Retinoblastoma Progression and Survival. *Invest Ophthalmol Vis Sci*. 2008;49:5215-5221.
  114. Cebulla CM, Alegret AM, Feuer WJ, Shi W, Scheffler AC, **Murray TG**. Tumor volume reduction using combined phacoemulsification and intravitreal triamcinolone injection for the management of cataract with treated uveal melanoma and atypical nevi. *J Cataract Refract Surg*. 2008; 34(10):1669-73.
  115. Jockovich ME, Pina Y, Alegret A, Cebulla CM, Feuer W, **Murray TG**. Heterogeneous Tumor Vasculature in Retinoblastoma: Implications for Vessel Targeting Therapy. *Retina*. 2008. 28: S81-6.



116. Alegret AM; Cebulla CM, Dubovy SR, Mutapcic L, Hess DJ, **Murray TG**. Pediatric Nasopharyngeal Carcinoma with Retinal Metastasis. *Retinal Cases & Brief Reports*. 3(1):8-11, Winter 2009.
117. Cebulla CM, Alegret A, Feun L, Markoe AM, Hess DJ, **Murray TG**. Bilateral Ocular Manifestations of Aggressive Cutaneous Metastatic Melanoma. *Retinal Cases Brief Reports*. 2008;2(4):286-288.
118. Jockovich ME, Suarez F, Alegret A, Piña Y, Hayden B, Cebulla C, Feuer W, **Murray TG**. Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model. *Invest Ophthalmol Vis Sci*. 2007;48(12):5371-6.
119. Boutrid H, Jockovich ME, **Murray TG**, Piña Y, Feuer WJ, Lampidis TL, Cebulla CM. Targeting Hypoxia, a Novel Treatment for Advanced Retinoblastoma. *Invest Ophthalmol Vis Sci*. 2008;49:2799-2805.
120. Cebulla CM, Jockovich ME, Boutrid H, Piña Y, Ruggeri M, Jiao S, Bhattacharya SK, Feuer WJ, **Murray TG**. Effects of SU1498, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2, in a Transgenic Murine Model of Retinoblastoma. *Open Ophthalmol J*. 2008.2(1):62-67.
121. Cebulla CM, Kleinerman RA, Alegret A, Kulak A, Dubovy SR, Hess DJ, **Murray TG**. Rapid Appearance of Rhabdomyosarcoma After Radiation and Chemotherapy for Retinoblastoma: a Clinicopathologic Correlation. *Retinal Cases Brief Reports*. *Retinal Cases & Brief Reports*: 2009 Fall;3(4):343-346.
122. Cebulla CM, Alegret A, Lynn F, Markoe AM, Hess DJ, **Murray TG**. Bilateral ocular manifestations of aggressive cutaneous metastatic melanoma. *Retinal Cases and Brief Report*. 2008; 2:286-288.
123. Bhatt AB, Scheffler AC, Feuer WJ, Yoo SH, **Murray TG**. Comparison of Predictions Made by the Intraocular Lens Master and Ultrasound Biometry. *Arch Ophthalmol*. 2008;126(7):929-933
124. Scheffler AC, Jockovich ME, Lossos IS, Toledano S, Feilmeier M, **Murray TG**. Ocular tumors: update on pharmacology, therapeutics, and ocular imaging. *Retinal Physician*. Oct 2007; 37-44.
125. Albano JD, Ward E, Jemal A, Anderson R, Cokkinides VE, **Murray TG**, Henley J, Liff J, Thun MJ. Cancer mortality in the United States by education level and race. *J Natl Cancer Inst*. 2007 Sept 19;99(18):1384-94.
126. Gregori NZ, Flynn HW Jr, Miller D, Scott IU, Davis JL, **Murray TG**, Williams B Jr.

- Clinical features, management strategies, and visual acuity outcomes of Candida endophthalmitis following cataract surgery. *Ophthalmic Surg Lasers Imaging*. 2007 Sep-Oct;38(5):378-85.
127. Miller DM, **Murray TG**, Suarez F, Cicciarelli NL, Swords GG. Motility assessment and clinical outcomes of a magnetically integrated microporous implant. *Ophthalmic Surg Lasers Imaging*. 2007 Jul-Aug;38(4):339-41.
128. Suarez F, Jockovich ME, Hernandez E, Feuer W, Parel JM, **Murray TG**: Paclitaxel in the Treatment of Retinal Tumors of LH beta-Tag Murine Transgenic Model of Retinoblastoma. *Invest Ophthalmol Vis Sci*. 2007 Aug;48(8):3437-40.
129. Jockovich ME, Bajenaru ML, Pina Y, Suarez F, Feuer W, Fini ME, **Murray TG**: Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model. *Invest Ophthalmol Vis Sci*. 2007 Jun;48(6):2476-82.
130. Schiedler V, Dubovy SR, **Murray TG**: Snare technique for enucleation of eyes with advanced retinoblastoma. *Arch Ophthalmol*. 2007 May;125(5):680-3.
131. Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, **Murray TG**, Lotem M, Ksander BR, Ostrand-Rosenberg S.: MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. *Cancer Res*. 2007 May 1;67(9):4499-506.
132. Jockovich ME, **Murray TG**, Clifford PD, Moshfeghi AA: Posterior juxtасcleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes. *Retina*. 2007 Feb;27(2):247-52.
133. Scheffler AC, Cicciarelli N, Feuer W, Toledano S, **Murray TG**: Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. *Ophthalmol* 2007; 114 (1):162-169.
134. Miller DM, Vedula AS, Flynn HW Jr, Miller D, Scott IU, Smiddy WE, **Murray TG**, Venkatraman AS. Endophthalmitis caused by staphylococcus epidermidis: in vitro antibiotic susceptibilities and clinical outcomes. *Ophthalmic Surg Lasers Imaging*. 2007 Nov-Dec;38(6):446-51.
135. Scheffler AC, Jockovich ME, Toledano S, **Murray TG**: Historical and modern approaches to chemotherapy for retinoblastoma: A review. *Expert Review in Ophthalmology*; 2006: 1: 83-95.
136. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW, Lee JE, Mavroufides EC, Smiddy WE, **Murray TG**, Berrocal AM, Scott IU, Gregori G: One-year safety and efficacy of

- intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. *Retina* 2006; 26 (8):889-895.
137. **Murray TG**: Commentary on “Diagnostic and Therapeutic Challenges,” submitted by: WW Lai, Y-s Zhou, DSC Lam. *Retina* 2006; 26:99-101.
138. **Murray TG**, Sobrin, L: The case for observational management of suspected small choroidal melanoma. *Arch Ophthalmol* 2006; 124(9): 1344-1346.
139. **19a. Juried or refereed journal articles and exhibitions:**
140. Hayden B, Jockovich M-E, **Murray TG**, Kralinger MT, Voigt M, Hernandez E, Feuer W, Parel J-M: Iontophoretic Delivery of Carboplatin in a Murine Model of Retinoblastoma. *Invest Ophthalmolog Vis. Sci* 2006; 47: 3717-3721.
141. Jockovich M-E, **Murray TG**, Escalona- Benz E, Hernandez E, Feuer W: Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LH BETA TAG Mice. *Invest Ophthalmolog Vis. Sci* 2006; 47: 1264-1268.
142. Tell S, Yi H, Jockovich ME, **Murray TG**, Hackam AS: The Wnt signaling pathway has tumor suppressor properties in retinoblastoma. *Biochemical & Biophysical Research Communications* 2006; 349(1): 261-269.
143. Callanan D, Scott IU, **Murray TG**, Oxford KW, Bowman CB, Flynn HW: Early onset endophthalmitis caused by Aspergillus species following cataract surgery. *Am J Ophthalmol* 2006; 142(3): 509-511.
144. Mavrofrides EC, Berrocal AM, **Murray TG**: Development of multiple subretinal hemorrhages during diode laser supplementation for retinopathy of prematurity. *J Pediatr Ophthalmol Strabismus* 2006; 43(2):110-113.
145. Lai WW, Zhou YS, Lam DS, Freeman WR, Chow DR, **Murray TG**: Diagnostic and therapeutic challenges. *Retina* 2006; 26(1): 96-101.
146. Hui JI, **Murray TG**: Radioactive plaque therapy. [Review] *Int Ophthalmolog Clin* 2006; 46(1): 51-68.
147. Gregori NZ, Rosenfeld PJ, Puliafito CA, Flynn HW, Lee JE, Mavrofrides EC, Smiddy WE, **Murray TG**, Berrocal AM, Scott IU, Gregori G: One-year safety and efficacy of intravitreal triamcinolone acetonide for the management of macular edema secondary to central retinal vein occlusion. *Retina* 2006; 26(8): 889-895.
148. Sobrin L, Schiffman JC, Markoe AM, **Murray TG**: Outcomes of iodine 125 plaque radiotherapy after initial observation of suspected small choroidal melanomas: a pilot study. *Ophthalmol* 2005; 112 (10): 1777-1783.
149. Smiddy WE, Smiddy RJ, Ba’Arath B, Flynn HW, **Murray TG**, Feuer WJ, Miller D:

- Subconjunctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. *Retina* 2005; 25(6): 751-758.
150. Miller DM, **Murray TG**, Cicciarelli NL, Capo H, Markoe AM: Pars plana lensectomy and intraocular lens implantation in pediatric radiation –induced cataracts in retinoblastoma. *Ophthalmol* 2005; 112 (9): 1620-1624.
151. Scott IU, Flynn HW, **Murray TG**, Smiddy WE, Davis JL, Feuer WJ: Outcomes of complex retinal detachment repair using 1000- vs 5000- centistokes silicone oil. *Arch Ophthalmol* 2005; 123(4): 473-478.
152. Sobrin L, Dubovy SR, Davis JL, **Murray TG**: Isolated, bilateral intraocular lymphoma in a 15 year old girl. *Retina* 2005; 25(3): 370-373.
153. Couvillion SS, Margolis R, Mavrofrides E, Hess D, **Murray TG**: Laser Treatment of Coats' Disease. *Journal of Pediatric Ophthalmology & Strabismus* 2005; 42:367-368.
154. Smiddy WE, Smiddy RJ, Ba'Arath B, Flynn HW, **Murray TG**, Feuer WJ, Miller D: Subconjunctival antibiotics in the treatment of endophthalmitis managed without vitrectomy. *Retina* 2005; 25(6): 751-758.
155. Escalona-Benz E, Jockovich ME, **Murray TG**, Hayden B, Hernandez E, Feuer W, Windle JJ: Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma. *Invest Ophthalmol Vis Sci* 2005; 46(1):8-11.
156. Conway RM, Wheeler SM, **Murray TG**, Jockovich ME, O'Brien JM: Retinoblastoma: animal models. *Ophthalmol Clin North Am.* 2005; 18(1):25-39.
157. Miller DM, Benz MS, **Murray TG**, Dubovy SR: Intraretinal calcification and osseous metaplasia in Coats disease. *Arch Ophthalmol* 2004; 122:1710-1712.
158. Margolis R, Couvillion SS, Mavrofrides EC, Hess D, **Murray TG**: Progression of familial exudative vitreoretinopathy after laser treatment. *Arch Ophthalmol* 2004;122:1717-1718.
159. Hayden BC, Jockovich ME, **Murray TG**, Voigt M, Milne P, Kralinger M, Feuer WJ, Hernandez E, Parel JM: Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma. *Invest Ophthalmol Vis Sci* 2004; 45:3644-3649.
160. Benz MS, Escalona-Benz EM, **Murray TG**, Eifrig CWG, Yoder DM, Moore JK, Schiffman JC: Immediate postoperative use of a topical agent to prevent intraocular pressure elevation after pars plana vitrectomy with gas tamponade. *Arch Ophthalmol* 2004;122: 705-709.

161. Treichel JL, **Murray TG**, Lewandowski MF, Stueven HA, Eells JT, Burke JM: Retinal toxicity in methanol poisoning. *Retina* 2004;24: 309-312. [RPB Support]
162. Sobrin L, Hayden BC, **Murray TG**, Cicciarelli N, Scott IU, Hernandez E, Wu X, Markoe AM, Feuer W, Fulton L, O'Brien JM: External beam radiation "salvage" therapy in transgenic murine retinoblastoma. *Arch Ophthalmol* 2004;122:251-257.
163. Raja D, Benz MS, **Murray TG**, Escalona-Benz EM, Markoe A: Salvage external beam radiotherapy of retinal capillary hemangiomas secondary to von Hippel-Lindau disease: visual and anatomic outcomes. *Ophthalmol* 2004;111:150-153.
164. Scott IU, Gorscak J, Gass JD, Feuer WJ, **Murray TG**: Anatomic and visual acuity outcomes following thermal laser photocoagulation or photodynamic therapy for symptomatic circumscribed choroidal hemangioma with associated serous retinal detachment. *Ophthalmic Surg, Lasers & Imaging* 2004;35(4):281-91.
165. Chaudhry NA, Cohen KA, Flynn HW Jr, **Murray TG**: Combined pars plana vitrectomy and lens management in complex vitreoretinal disease. *Seminars of Ophthalmol* 2003;18(3)132-141.
166. Moshfeghi DM, Kaiser PK, Scott IU, Sears JE, Benz M, Sinesterra JP, Kaiser RS, Bakri SJ, Maturi RK, Belmont J, Beer PM, **Murray TG**, Quiroz-Mercado H, Mieler WF: Acute endophthalmitis following intravitreal triamcinolone acetonide injection. *Am J Ophthalmol* 2003;136:791-796.
167. Escalona-Benz E, Benz MS, **Murray TG**, Hayden BC, Hernandez E, Garonzik SN, Cicciarelli NL: Magnetically integrated microporous implant. Safety and efficacy of secondary posting. *Arch Ophthalmol* 2003;121:1596-1600.
168. Escalona-Benz E, Benz M, Briggs JW, Budenz DL, Parrish RK II, **Murray TG**: Uveal melanoma presenting as acute angle-closure glaucoma: Report of two cases. *Am J Ophthalmol* 2003;136:756-758.
169. Scott IU, Flynn HW Jr, **Murray TG**, Feuer WJ: Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: A multicenter study. *Am J Ophthalmol* 2003;136:454-463
170. Sussman DA, Escalona-Benz E, Benz MS, Hayden BC, Feuer W, Cicciarelli N, Toledano S, Markoe A, **Murray TG**: Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy. *Arch Ophthalmol* 2003;121:979-984.
171. Scott IU, Flynn HW Jr, Smiddy WE, **Murray TG**, Moore JK, Lemus DR, Feuer WJ: Clinical features and outcomes of pars plana vitrectomy in patients with retained lens fragments. *Ophthalmol* 2003;110:1567-1572

172. Moore JK, Scott IU, Flynn HW Jr, Smiddy WE, **Murray TG**, Kim JE, Vilar NF, Pereira MB, Jorge R: Retinal detachment in eyes undergoing pars plana vitrectomy for removal of retained lens fragments. *Ophthalmology* 2003;110:709-714
173. Scott IU, Lieb DF, Flynn HF Jr, Dessouki A, **Murray TG**, Miller D: Endophthalmitis caused by *Mycobacterium chelonae*: selection of antibiotics and outcomes of treatment. *Arch Ophthalmol* 2003;121:573-576
174. Benz MS, **Murray TG**, Dubovy SR, Katz RS, Eifrig CWG: Endophthalmitis caused by *Mycobacterium chelonae abscessus* after intravitreal injection of triamcinolone. *Arch Ophthalmol* 2003;121:271-273.
175. Sobrin L, Berrocal AM, **Murray TG**: Retinal detachment 7 years after prophylactic schisis cavity excision in juvenile x-linked retinoschisis. *Ophthalmic Surg, Lasers & Imaging* 2003;34:401-402.
176. Scott IU, McCabe CM, **Murray TG**, Rosa RH Jr, Toledano S, Markoe AM: Eyelid and scleral necrosis following bare iridium-192 seed for retinoblastoma. *Ophthalmic Surg, Lasers & Imaging* 2003;34:324-326.
177. Benz MS, Escalona-Caamano EM, **Murray TG**: Simultaneous presentation of retinopathy of prematurity and bilateral familial retinoblastoma in a premature infant. *J Pediatr Ophthalmol Strabismus* 2003;40:98-100.
178. Chaudhry NA, Flynn HW Jr, **Murray TG**, Belfort A: Combined cataract surgery and vitrectomy for breakthrough vitreous hemorrhage from age-related macular degeneration. *Ophthalmic Surg Lasers* 2002;33:16-18.
179. Song A, Dubovy SR, Berrocal AM, **Murray TG**: Endogenous fungal retinitis in a patient with acute lymphocytic leukemia manifesting as uveitis and optic nerve lesions. *Arch Ophthalmol* 2002;120:1754-1756.
180. Scott IU, **Murray TG**, Flynn HW Jr, Feuer WJ, Schiffman JC, and the Perfluoron Study Group: Outcomes and complications associated with giant retinal tear management using perfluoro-n-octane. *Ophthalmology* 2002;109:1828-1833.
181. Hayden BC, **Murray TG**, Cicciarelli N, Scott IU, Alexandridou A, Hernandez E, Wu X, Markoe AM, Feuer W, Fulton L, O'Brien JM: Hyperfractionated external beam radiation therapy in the treatment of murine transgenic retinoblastoma. *Arch Ophthalmol* 2002;120:353-359.
182. Loo RH, Scott IU, Flynn HW Jr, Gass JDM, **Murray TG**, Lewis ML, Rosenfeld PJ, Smiddy WE: Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. *Retina* 2002;22:19-24.

183. Amirikia A, Scott IU, Capo H, **Murray TG**: Increasing hyperopia and esotropia as the presenting signs of bilateral diffuse choroidal hemangiomas in a patient with Sturge-Weber syndrome. *J Ped Ophthalmol & Strab* 2002;39:121-122.
184. Davis JL, Miller D, Gonzales CA, Scott IU, **Murray T**: Reply to letter on *Histoplasma capsulatum var. capsulatum*. *Ophthalmology* 2002;109:218-219.
185. Arroyave CP, Scott IU, Fantes FE, Feuer WJ, **Murray TG**: Corneal graft survival and intraocular pressure control after penetrating keratoplasty and glaucoma drainage device implantation. *Ophthalmology* 2001;108:1978-1985.
186. Roth DB, Scott IU, **Murray TG**, Kaiser PK, Feuer WJ, Hughes JR, Rosa RH Jr.: Echography of retinoblastoma: histopathologic correlation and serial evaluation after globe-conserving radiotherapy or chemotherapy. *J Pediatr Ophthalmol Strabismus* 2001;38:136-143.
187. Johnson RN, McDonald HR, Lewis H, Grand MG, **Murray TG**, Mieler WF, Johnson MW, Boldt HC, Olsen KR, Tornambe PE, Folk JC: Traumatic macular hole. Observations, pathogenesis, and results of vitrectomy surgery. *Ophthalmology* 2001;108:853-857.
188. Duncan JL, Scott IU, **Murray TG**, Gombos DS, van Quill K, O'Brien JM: Routine neuroimaging in retinoblastoma for the detection of intracranial tumors. *Arch Ophthalmol* 2001;119:450-452.
189. Corey RP, Scott IU, Flynn HW Jr, Rosa RH Jr, **Murray TG**: Surgical removal of submacular choroidal neovascularization: a clinicopathologic study and factors influencing outcomes. *Ophthalmic Surg Lasers* 2001;32:406-418.
190. Parel J-M, Qiu H, Manns F, Fujiwara E, Lee W, Salas N, Hayden B, Lee E, Dubovy S, **Murray TG**: Experimental models for transcleral laser thermotherapy of ocular tumors. *Florida Lions Eye Bank*, 2001 Annual Report, pp.10-11.
191. Amirikia A, Scott IU, **Murray TG**, Flynn HW Jr., Smiddy WE, Feuer WJ: Outcomes of vitreoretinal surgery for complications of branch retinal vein occlusion. *Ophthalmology* 2001;108:372-376; discussion by WF Mieler pp. 375-376, February.
192. Smith JH, **Murray TG**, Fulton L, O'Brien JM: Siblings of retinoblastoma patients: are we underestimating their risk? *Am J Ophthalmol* 2000; 129(3): 396-398.
193. Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, **Murray TG**, O'Brien JM: Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. *Arch Ophthalmol* 2001;119:41-48.
194. Chaudhry N, Flynn HW Jr., **Murray TG**, Belfort A, Mello M Jr.: Combined cataract surgery and vitrectomy for recurrent retinal detachment. *Retina* 2000;20:257-261.

195. Eells JT, Henry MM, Lewandowski MF, Seme MT, **Murray TG**: Development and characterization of a rodent model of methanol-induced retinal and optic nerve toxicity. *Neurotoxicology* 2000;21(3):321-330.
196. Foster RE, **Murray TG**, Byrne SF, Hughes JR, Gendron BK, Ehlies FJ, Nicholson DH: Echographic features of medulloepithelioma. *Am J Ophthalmol* 2000;130:364-366.
197. Scott IU, Moy CS, **Murray TG** for the COMS Group: Update on the Collaborative Ocular Melanoma Study (COMS) for the comprehensive ophthalmologist. *Comprehensive Ophthalmol Update* 2000;1:185-191.
198. Hayden BH, **Murray TG**, Scott IU, Cicciarelli N, Hernandez E, Feuer W, Fulton L, O'Brien JM: Subconjunctival carboplatin in retinoblastoma. *Arch Ophthalmol* 2000;118:1549-1554.
199. Amirikia A, Scott IU, **Murray TG**: Bilateral diffuse choroidal hemangiomas with unilateral facial nevus flammeus in Sturge-Weber syndrome. *Am J Ophthalmol* 2000;130:362-364.
200. Anagnoste SR, Scott IU, **Murray TG**, Kramer D, Toledano S: Rhegmatogenous retinal detachment in retinoblastoma patients undergoing chemoreduction and cryotherapy. *Am J Ophthalmol* 2000;129:817-819.
201. **Murray TG**, Cicciarelli NL, Croft BH, Garonzik S, Voigt M, Hernandez E: Design of a magnetically integrated microporous implant. *Arch Ophthalmol* 2000;118:1259-1262.
202. **Murray TG**: Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma (reply to letter by PT Finger). *Am J Ophthalmol* 2000;130:540.
203. Nakagawa N, Parel J-M, **Murray TG**, Oshima K: Effect of scleral shortening on axial length. *Arch Ophthalmol* 2000;118:965-968.
204. Scott IU, **Murray TG**, Flynn HW Jr, Smiddy WE, Feuer WJ, Schiffman JC: Outcomes and complications associated with perfluoro-*n*-octane and perfluoroperhydrophenanthrene in complex retinal detachment repair. *Ophthalmology* 2000;107:860-865.
205. Christmas NJ, Van Quill K, **Murray TG**, Gordon CD, Garonzik S, Tse D, Johnson T, Schiffman J, O'Brien JM: Evaluation of efficacy and complications. Primary pediatric orbital implants after enucleation. *Arch Ophthalmol* 2000;118:503-506.



206. Gonzales CA, Scott IU, Chaudhry NA, Luu KM, Miller D, **Murray TG**, Davis JL: Endogenous endophthalmitis caused by *Histoplasma capsulatum var. capsulatum*. *Ophthalmology* 2000;107:725-729.
207. Benz MS, Scott IU, **Murray TG**, Kramer D, Toledano S: Complications of systemic chemotherapy as treatment for retinoblastoma. *Arch Ophthalmol* 2000;118:577-578.
208. Alexandrakis G, Scott IU, Flynn HW Jr, **Murray TG**, Feuer WJ: Visual outcomes with and without surgery in patients with persistent fetal vasculature. *Ophthalmology* 2000;107:1068-1072.
209. Hasenyager Smith J, **Murray TG**, Fulton L, O'Brien JM: Siblings of retinoblastoma patients: are we underestimating their risk? *Am J Ophthalmol* 2000;129:396-398.
210. Scott IU, Alexandrakis G, Flynn HW Jr, Smiddy WE, **Murray TG**, Schiffman J, Gedde SJ, Budenz DL, Fantes F, Parrish RK II: Combined pars plana vitrectomy and glaucoma drainage implant placement for refractory glaucoma. *Am J Ophthalmol* 2000;129:334-341.
211. Amirikia A, Scott IU, **Murray TG**, Halperin LS: Acute bilateral visual loss associated with retinal hemorrhages following epiduroscopy. *Arch Ophthalmol* 2000;118:287-288.
212. Tabandeh H, Chaudhry NA, **Murray TG**, Ehliès F, Hughes R, Scott IU, Markoe AM: Intraoperative echographic localization of Iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. *Am J Ophthalmol* 2000;129:199-204.
213. Chaudhry NA, Flynn HW Jr, **Murray TG**, Nicholson DN, Palmberg PF: Pars plana vitrectomy during cataract surgery for prevention of aqueous misdirection in high-risk fellow eyes. *Am J Ophthalmol* 2000;129:387-388.
214. Chaudhry NA, Flynn HW Jr, **Murray TG**, Tabandeh H, Mello, MO Jr, Miller D: Emerging ciprofloxacin-resistant *Pseudomonas aeruginosa*. *Am J Ophthalmol* 1999;128(4):509-510.
215. Scott IU, Moy CS, **Murray TG**, O'Brien JM: Issues in the diagnosis and management of small choroidal melanocytic lesions. *Ocular Oncology* 1999;2(2):149-157.
216. Scott IU, **Murray TG**, Feuer WJ, Van Quill K, Markoe AM, Ling S, Roth DB, O'Brien JM: External beam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. *Arch Ophthalmol* 1999; 117:766-770.
217. Scott IU, Alexandrakis G, Cordahi GJ, **Murray TG**: Diffuse and circumscribed choroidal hemangiomas in a patient with Sturge-Weber syndrome. *Arch Ophthalmol* 1999;117:406-407.

218. Gonzales CA, Scott IU, Chaudhry NA, Oster AS, Hess DJ, **Murray TG**: Bilateral rhegmatogenous retinal detachments with unilateral vitreous base avulsion as the presenting signs of child abuse. *Am J Ophthalmol* 1999;127:475-477.
219. Henderer JD, Budenz DL, Flynn HW Jr, Schiffman JC, Feuer WJ, **Murray TG**: Elevated intraocular pressure and hypotony following silicone oil retinal tamponade for complex retinal detachment. *Arch Ophthalmol* 1999;117:1889-195.
220. Scott IU, **Murray TG**, Toledano S, O'Brien JM: New retinoblastoma tumors in children undergoing systemic chemotherapy. *Arch Ophthalmol* 1998;116:1685-1686.
221. Clark WL, Scott IU, **Murray TG**, Rosa RH Jr, Siatkowski RM, Langham MR Jr: Primary intraocular posttransplantation lymphoproliferative disorder. *Arch Ophthalmol* 1998;116:1667-1669.
222. **Murray TG**: Cancer incidence after retinoblastoma: radiation dose and sarcoma risk (comment). *Surv Ophthalmol* 1998;43(3).
223. **Murray TG**: Cancer incidence after retinoblastoma: radiation dose and sarcoma risk (comment). *JAMA* 1998.
224. Christmas NJ, Gordon CD, **Murray TG**, Tse D, Johnson T, Garonzik S, O'Brien JM: Intraorbital implants after enucleation and their complications: a 10-year review. *Arch Ophthalmol* 1998;116(9):1199-1203.
225. Scott IU, **Murray TG**, Hughes JR: Evaluation of imaging techniques for detection of extraocular extension of choroidal melanoma. *Arch Ophthalmol* 1998;116(7):897-899.
226. Gottlieb JL, **Murray TG**, Gass JDM: Low-dose external beam irradiation for bilateral diffuse choroidal hemangioma. *Arch Ophthalmol* 1998;116(6):815-817.
227. Kaiser PK, **Murray TG**, O'Brien JM: Laser photocoagulation of choroidal and retinal tumors (Review). *Ophthalmic Surgery and Lasers* 1998;29(1):59-78.
228. Ksander BR, Geer DC, Chen PW, Salgaller ML, Rubsamen P, **Murray TG**: Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. *Current Eye Research* 1998;17(2):165-173.
229. Weishaar PD, Flynn HW Jr, **Murray TG**, Davis JL, Barr CC, Gross JG, Mein CE, McLean WC Jr, Killian JH: Endogenous *Aspergillus* endophthalmitis. Clinical features and treatment outcomes. *Ophthalmology* 1998;105(1):57-65.
230. **Murray TG**: Small Choroidal Melanoma (editorial comment – review). *Arch Ophthalmol* 1997;115(12):1577-1578.

231. Scott IU, Flynn HW Jr, Schiffman J, Smiddy WE, **Murray TG**, Ehli F: Visual acuity outcomes among patients with appositional suprachoroidal hemorrhage. *Ophthalmology* 1997;104(12):2039-2046.
232. Uno T, Chen PW, **Murray TG**, Podack ER, Ksander BR: Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector. *Invest Ophthalmol Vis Sci* 1997;38(12):2531-2539.
233. **Murray TG**, Cicciarelli N, McCabe CM, Ksander BR, Feuer W, Schiffman J, Mieler WF, O'Brien JM: In vitro efficacy of carboplatin and hyperthermia in a murine retinoblastoma cell line. *Invest Ophthalmol Vis Sci* 1997;38(12):2516-2522.
234. Verbik DJ, **Murray TG**, Tran JM, Ksander BR: Melanomas that develop within the eye inhibit lymphocyte proliferation. *Int J Cancer* 1997;73(4):470-478.
235. **Murray TG**, Cicciarelli N, O'Brien JM, Hernandez E, Mueller RL, Smith BJ, Feuer W.: Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. *Arch Ophthalmol* 1997;115(10):1286-1290.
236. Chen PP, Weishaar PD, **Murray TG**: Blue rubber bleb nevus syndrome. *J Pediatric Ophthalmol & Strabismus* 1997;34(5):321-323.
237. Chen PW, **Murray TG**, Uno T, Salgaller ML, Reddy R, Ksander BR.: Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. *Clinical & Experimental Metastasis* 1997;15(5):509-518.
238. **Murray TG**, Steeves RA, Gentry L, Bresnick G, Boldt HC, Mieler WF, Tompkins D: Ferromagnetic hyperthermia: functional and histopathologic effects on normal rabbit ocular tissue. *Int J Hyperthermia* 1997;13(4):423-436.
239. Chen PW, **Murray TG**, Salgaller ML, Ksander BR: Expression of MAGE genes in ocular melanoma cell lines. *J Immunotherapy*, 1997;20(4):265-275.
240. Vilar NF, Flynn HW Jr, Smiddy WE, **Murray TG**, Davis JL, Rubsamen PE: Removal of retained lens fragments after phacoemulsification reverses secondary glaucoma and restores visual acuity. *Ophthalmology* 1997;104(5):787-791; discussion 1997;104(5):791-792.
241. Scott IU, O'Brien JM, **Murray TG**: Retinoblastoma: A review emphasizing genetics and management strategies. *Seminars of Ophthalmology* 1997;12:59-71.
242. Rosenfeld P, **Murray TG**, Flynn HW Jr.: Management of dislocated crystalline lens during clear-cornea phacoemulsification. *Annals of Ophthalmol* 1997;29(1):7-10.

243. **Murray TG**, Roth DB, O'Brien JM, Feuer W, Cicciarelli N, Markoe AM, Hernandez E, Smith BJ, Windle JJ: Local carboplatin and radiation therapy in the treatment of murine transgenic retinoblastoma. *Arch Ophthalmol* 1996;114(11):1385-1389.
244. **Murray TG**, O'Brien JM, Steeves RA, Smith BJ, Albert DM, Cicciarelli N, Markoe AM, Tompkins DT, Windle JJ: Radiation therapy and ferromagnetic hyperthermia in the treatment of murine transgenic retinoblastoma. *Arch Ophthalmol* 1996;114(11):1376-1381.
245. Eells JT, Salzman MM, Lewandowski MF, **Murray TG**: Formate-induced alterations in retinal function in methanol-intoxicated rats. *Toxicology & Applied Pharmacology* 1996;140(1):58-69.
246. Harbour JW, **Murray TG**, Byrne SF, Hughes JR, Gendron EK, Ehlied FJ, Markoe AM: Intraoperative echographic localization of iodine 125 episcleral radioactive plaques for posterior uveal melanoma. *Retina* 1996;16(2):129-134.
247. Harbour JW, **Murray TG**, Hamasaki D, Cicciarelli N, Hernandez E, Smith B, Windle J, O'Brien JM: Local carboplatin therapy in transgenic murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1996;37(9):1892-1898.
248. Chang TS, Byrne SF, Gass JD, Hughes JR, Johnson RN, **Murray TG**: Echographic findings in benign reactive lymphoid hyperplasia of the choroid. *Arch Ophthalmol* 1996;114(6):669-675.
249. Kim JE, Flynn HW Jr, Rubsamen PE, **Murray TG**, Davis JL, Smiddy WE: Endophthalmitis in patients with retained lens fragments after phacoemulsification. *Ophthalmology* 1996;103(4):575-578.
250. Foster RE, Martinez JA, **Murray TG**, Rubsamen PE, Flynn HW Jr, Forster RK: Useful visual outcomes after treatment of *Bacillus cereus* endophthalmitis. *Ophthalmology* 1996;103(3):390-397.
251. Kangas TA, Bennett SR, Flynn HW Jr, **Murray TG**, Rubsamen PE, Han DP, Mieler WF, Williams DF, Abrams GW: Reversible loss of light perception after vitreoretinal surgery. *Am J Ophthalmol* 1995;120(6):751-756.
252. Steeves RA, Tompkins DT, Nash RN, Blair JR, Gentry LL, Paliwal BR, **Murray TG**, Mieler WF: Thermoradiotherapy of intraocular tumors in an animal model: concurrent vs. sequential brachytherapy and ferromagnetic hyperthermia. *Intl J Rad Oncol Biol Phys* 1995;33(3):659-662.
253. Harbour JW, Smiddy WE, Rubsamen PE, **Murray TG**, Davis JL, Flynn HW Jr: Pars plana vitrectomy for chronic pseudophakic cystoid macular edema. *Am J Ophthalmol* 1995;120(3):302-307.

254. Cohen SM, Flynn HW Jr, **Murray TG**, Smiddy WE: Endophthalmitis after pars plana vitrectomy. The Postvitrectomy Endophthalmitis Study Group (Review). *Ophthalmology* 1995;102(5):705-712.
255. Ksander BR, **Murray TG**: Immunotherapy of ocular tumors using lymphokine gene transfer. *J Ophthalmic Photogr* 1995;17(1):36-37.
256. Munoz M, Parrish RK, **Murray TG**: Open-angle glaucoma after pars plicata lensectomy and vitrectomy for congenital cataracts. *Am J Ophthalmol* 1995;119(1):103-104.
257. **Murray TG**: Retinoblastoma; current understanding and management. *Fla Ophthalmologist* 1994;15(4):8.
258. Han DP, Nanda SK, O'Brien WJ, Guy J, **Murray TG**, Boldt HC: Evaluation of anterior segment tolerance to short-term intravitreal perfluoron. *Retina* 1994;14(3):219-224.
259. Han DP, Wang Q, Hartz A, Jaffe GJ, **Murray TG**, Boldt HC, Arrindell EL, Coe E, Abrams GW, Mieler WF: Postoperative fibrin formation and visual outcome after pars plana vitrectomy. *Retina* 1994;14(3):225-230.
260. Campochiaro PA, Lim JI, Bloome MA, Conway BP, Flynn HW Jr, Grand MG, Ibanez HE, Meredith TA, **Murray TG**, Myers S, Packo KH, Pheasant T, Richmond PP, Ridley M, Weiter JJ, Wilkinson CP: Aminoglycoside toxicity in the treatment of endophthalmitis. *Arch Ophthalmol* 1994;112:48-53.
261. Kim JE, Flynn HW Jr, Smiddy WE, **Murray TG**, Rubsamens PE, Davis JL, Nicholson DH: Retained lens fragments after phacoemulsification. *Ophthalmology* 1994;101(11):1827-1832. Comment: 1995;102:1735-1736
262. Rubsamens PE, Flynn HW Jr, Civantos JM, Smiddy WE, **Murray TG**, Nicholson DH, Blumenkranz MS: Treatment of massive subretinal hemorrhage from complications of scleral buckling procedures. *Am J Ophthalmol* 1994;118(3):299-303.
263. Sharkey JA, **Murray TG**: Safety of vitrectomy instruments: implication of design. *Retina* 1994;14(2):188-189.
264. Sharkey JA, **Murray TG**: Identification of the ora serrata and ciliary body by transillumination in eyes undergoing transscleral fixation of posterior chamber intraocular lenses. *Ophthalmic Surgery* 1994;25(7):479-480.
265. Aaberg TM Jr, Flynn HW Jr, **Murray TG**: Intraocular ceftazidime as an alternative to the aminoglycosides in the treatment of endophthalmitis. *Arch Ophthalmol* 1994;112:18-19.

266. Irvine WD, Flynn HW Jr, **Murray TG**, Rubsamens PE: Retained lens fragments after phacoemulsification manifesting as marked intraocular inflammation with hypopyon. *Am J Ophthalmol* 1992;114(5):610-614.
267. Boldt HC, Abrams GW, **Murray TG**, Han DP, Mieler WF: The lowest effective dose of tissue plasminogen activator for fibrinolysis of postvitrectomy fibrin. *Retina* 12(3 Suppl.):1992;S75-S79.
268. Steeves RA, **Murray TG**, Moros EG, Boldt HC, Mieler WF, Paliwal BR: Concurrent ferromagnetic hyperthermia and 125I brachytherapy in a rabbit choroidal melanoma model. *Intl J Hyperther* 1992;8(4):443-449.
269. **Murray TG**, Jaffe GJ, McKay BS, Han DP, Burke JM, Abrams GW: Collagen shield delivery of tissue plasminogen activator: functional and pharmacokinetic studies of anterior segment delivery. *Refractive & Corneal Surgery* 1992;8(1):44-48, discussion 1992;8(1):48-53.
270. **Murray TG**, Boldt HC, Lewis H, Abrams GW, Mieler WF, Han DP: A technique for facilitated visualization and dissection of the vitreous base, pars plana, and pars plicata. *Arch Ophthalmol* 1991;109(10):1458-1459.
271. **Murray TG**, Burton TC, Rajani C, Lewandowski MF, Burke JM, Eells JT: Methanol poisoning. A rodent model with structural and functional evidence for retinal involvement. *Arch Ophthalmol* 1991;109(7):1012-1016.
272. Swift PS, Stauffer PR, Fries PD, Kaleta-Michaels S, **Murray TG**, Sneed PK, Phillips TL, Char DH: Microwave hyperthermia for choroidal melanoma in rabbits. *Invest Ophthalmol Vis Sci* 1990;31(9):1754-1760.
273. **Murray TG**, Abrams GW: A new self-sealing needle for iris suture fixation. *Arch Ophthalmol* 1990;108(5):746-747.
274. **Murray TG**, Abrams GW, Stanley J: Pars plana vitrectomy in the management of dislocated posterior chamber lenses. *Am J Ophthalmol (Letter)* 1990;109(3):362.
275. **Murray TG**, Stern WH, Chin DH, MacGowan-Smith EA: Collagen shield heparin delivery for prevention of postoperative fibrin. *Arch Ophthalmol* 1990;108(1):104-106.
276. Dragon DM, Robin AL, Pollack IP, Quigley HA, Green WR, **Murray TG**, Hotchkiss ML, D'Anna S: Neodymium: YAG laser iridotomy in the cynomolgous monkey. *Invest Ophthalmol Vis Sci* 1985;26(6):789-796.
277. Joiner KA, Schmetz MA, Sanders ME, **Murray TG**, Hammer CH, Dourmashkin R, Frank MM: Multimeric complement component C9 is necessary for killing of *Escherichia coli* J5 by terminal attack complex C5b-9. *Proc Natl Acad Sci*

1985;82(14):4808-4812.

278. **Murray TG**, Green WR, Maumenee IH, Kopits SE: Spondyloepiphyseal dysplasia congenita. Light and microscopic studies of the eye. *Arch Ophthalmol* 1985;103:407-411.
279. Pollack IP, Robin AL, Dragon DM, Green WR, Quigley HA, **Murray TG**, Hotchkiss ML: Use of Neodymium: YAG laser to create iridotomies in monkeys and humans. *Trans Am Acad Ophthalmol Soc* 1984;82:307-328.

**19b. Collaborative Ocular Melanoma Study: Juried or referred journal articles and exhibitions:**

280. COMS Group: I-125 Brachytherapy for Choroidal Melanoma Photographic and Angiographic Abnormalities: The Collaborative Ocular Melanoma Study: COMS Report No. 30. *Ophthalmol.* 2009, Jan;116(1):106-115.
281. COMS Group: Baseline Echographic Characteristics of Tumors in Eyes of Patients Enrolled in the Collaborative Ocular Melanoma Study: COMS Report No. 29. *Ophthalmol.* 2008, Aug;115(8):1390-97.
282. COMS Group: Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative ocular Melanoma Study: COMS Report No. 27. *Ophthalmol.* 2007, Jul;114(7):1363-71.
283. COMS Group: Quality of Life After Iodine I25 Brachytherapy vs Enucleation for Choroidal Melanoma: 5 Year Results From the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. *Arch Ophthalmol.* 2006; 124: 226-238.
284. COMS Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. *Arch Ophthalmol.* 2006, Dec;124(12):1684-93.
285. COMS Group: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. *Arch Ophthalmol.* 2005 Dec;123(12):1639-43.
286. COMS Group: Time trends in personnel certification and turnover in the Collaborative Ocular Melanoma Study. *Clin Trials.* 2004;1(4):377-86.
287. COMS Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of preenucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. *Am J Ophthalmol.* 2004 Dec; 138(6):936-51.

288. COMS Group: Screening for metastasis from choroidal melanoma; the Collaborative Ocular Melanoma Study Group Report 23. *J Clin Oncol.* 2004 June 15;22(12):2438-44.
289. COMS Group: Ten-Year Follow-up of Fellow Eyes of Patients Enrolled in Collaborative Ocular Melanoma Study Randomized Trials. COMS report number 22. *Ophthalmol.* 2004, May;111(5):966-76.
290. COMS Group: Mortality after deferral of treatment or no treatment for choroidal melanoma. *Am J Ophthalmol.* 2003 Jul;136(1):47-54.
291. COMS Group: Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the Collaborative Ocular Melanoma study. COMS Report No. 21. *Arch Ophthalmol* 2003;121:1163-1171
292. COMS Group: Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997. Findings from patients examined at COMS centers: COMS Report No. 20. *Arch Ophthalmol* 2003;121:1156-1162
293. COMS Group: Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS Report No. 2. *Arch Ophthalmol* 2003; 121:1010-1020.
294. COMS Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma. IV. Local treatment failure and enucleation in the first 5 years after brachytherapy; COMS Report No. 19. *Ophthalmology* 2002; 109:2197-2206.
295. COMS Group: Sociodemographic and clinical predictors of participation in two randomized trials: findings from the Collaborative Ocular Melanoma Study COMS report no. 7. *Control Clin Trials.* 2001 Oct; 22(5):526-37.
296. COMS Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: Report No. 18. *Arch Ophthalmol* 2001; 119:969-982.
297. COMS Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: Report No. 17. *Arch Ophthalmol* 2001; 119:951-965.
298. COMS Group: The COMS randomized Trial of I-125 Brachytherapy for Medium Choroidal Melanoma. I. Visual Acuity after 3 years. Report No. 16, Part 1. *Ophthalmol* 2001;108:348-366.
299. COMS Group: Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15. *Arch Ophthalmol* 2001 May; 119(5):670-6.
300. COMS Group: Absence of type I estrogen receptors in choroidal melanoma: analysis



- of Collaborative Ocular Melanoma Study (COMS) eyes. *Am J Ophthalmol*. 2001 June; 131(6):788-91.
301. COMS Group: Cause-specific mortality coding. methods in the collaborative ocular melanoma study. COMS Report No. 14. *Control Clin Trials*. 2001 Jun; 22(3):248-62.
  302. COMS Group: Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study Group (COMS), Report No. 12, Part 1. July/August 1999.
  303. COMS Group: Quality of life assessment in the collaborative ocular melanoma study: design and methods. (COMS-QOLS) Report No. 1. COMS Quality of Life Study Group. *Ophthalmol Epidemiol*. 1999 Mar; 6(1):5-17
  304. COMS Group: The COMS randomized Trial of Pre-Enucleation Radiation of Large Choroidal Melanoma. III: Local complications and observations following enucleation. COMS Report No. 11. *Am J Ophthalmol* 1998; 126:362-372.
  305. COMS Group: The COMS randomized Trial of Pre-Enucleation Radiation of Large Choroidal Melanoma. II: Initial Mortality Findings. COMS Report No. 10. *Am J Ophthalmol* 1998; 125:779-796.
  306. COMS Group: The COMS randomized Trial of Pre-enucleation Radiation of Large Choroidal Melanoma. I: Characteristics of Patients Enrolled and Not Enrolled. COMS Report No. 9. *Am J Ophthalmol* 1998; 125:767-778.
  307. COMS Group: Histopathologic Characteristics of Uveal Melanomas in Eyes Enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6. *Am J Ophthalmol* 1998; 125:745-766.
  308. COMS Group: Factors predictive of growth and treatment of small choroidal melanoma. COMS Report No. 5. *Arch Ophthalmol* 1997;115:1537-1544.
  309. COMS Group: Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. *Ophthalmic Surgery & Lasers*, 1997;28(3):185-194.
  310. COMS Group: Mortality in Patients with small Choroidal Melanoma. COMS Report No. 4. *Arch Ophthalmol* 1997;115:886-893.
  311. COMS Group: Posterior uveal melanoma management: Collaborative Ocular Melanoma Study (COMS). *Fla Ophthalmologist* 1995;17(3):9-11.
  312. COMS Group: Correlation of transillumination size and microscopic measurement of choroidal melanoma. *Invest Ophthalmol Vis Sci* 1994;35(4):1925.
  313. COMS Group: Histopathologic review of 1,901 uveal melanomas. *Invest Ophthalmol Vis Sci* 1994;35(4):1925.

314. COMS Group: Evaluation of radiation retinopathy with color photography alone vs. color photography fluorescein angiography. *Invest Ophthalmol Vis Sci* 1994;35(4):1722.
315. COMS Group: Design and methods of a clinical trial for a rare condition: The Collaborative Ocular Melanoma Study, COMS Report No. 3. *Controlled Clin Trials* 1993;14:362-391.
316. COMS Group: Complications of enucleation surgery. COMS Report 2. Franklin RM, ed.: *Proceedings of the Symposium on Retina and Vitreous*. Kugler Publications, New York, 1993;181-190.
317. COMS Group: Factors predictive of choice of treatment among patients with choroidal melanoma. *Invest Ophthalmol Vis Sci* 1993;34(4):967.
318. COMS Group: Phantom or real? Verification of nonrandomized patients evaluated for randomized clinical trials of a rare disease. *Controlled Clin Trials* 1993;14(5):441.
319. COMS Group: Five-year progress report from the Collaborative Ocular Melanoma Study. *Invest Ophthalmol Vis Sci* 1992;33(4):1254.
320. COMS Group: Socio-demographic factors of patient participation in randomized trials: Findings from the COMS. *Invest Ophthalmol Vis Sci* 1991;32(4):980.
321. COMS Group: Sociodemographic characteristics associated with patient enrollment in the Collaborative Ocular Melanoma Study. *Controlled Clinical Trials* 1991;12(5):657.
322. COMS Group: Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study Report No. 1. *Arch Ophthalmol* 1990;108:1268-1273.
323. COMS Group: Is standardization possible in a multicenter clinical trial in which 45 medical centers and 500 clinical professionals are involved? The COMS experience. *Controlled Clin Trials* 1990;11(4):275.
324. COMS Group: Non-ocular cancers in patients with choroidal melanoma. *Ophthalmol* 1990;97 (7):837-838.

**20. Published Abstracts:**

1. Houston SK, **Murray TG**, Decatur CL, Pina Y, Cavalcante L, Lampidis T. Use of 2-fluorodeoxy-d-glucose (2-FDG) to Target the Chemoresistant, Hypoxic Cell Population in Advanced LH<sub>Beta</sub>T<sub>Ag</sub> Retinal Tumors. [ARVO Abstract]. 2487/D780, 2011

**Timothy G. Murray, M.D., M.B.A.**  
**Curriculum Vitae**

2. **Murray TG**, Decatur C, Pina Y, Houston S, Cavalcante L, Lampidis T. A Novel, Oral, Non-invasive Method of Delivery For The Glycolytic Inhibitor 2-deoxy-d-glucose in the Treatment of Retinoblastoma. [ARVO Abstract]. 1592, 2011.
3. Decatur C, Pina Y, Houston S, Cavalcante L, **Murray TG**, Lampidis T. Evaluating the Glycolytic Pathway in Retinoblastoma: A Molecular Mechanistic Approach Using the Glycolytic Inhibitor 2-deoxy-D-glucose in vitro and in vivo. [ARVO Abstract]. 2483/D776, 2011.
4. Pina Y, Decatur C, Houston S, Cavalcante L, Lampidis T, **Murray TG**. Mammalian Target of Rapamycin In Combination With Chemotherapy: Upstream Regulation of Anaerobic Glycolysis to Target the Chemoresistant Cell Population in Retinoblastoma. [ARVO Abstract]. 2484/D777.
5. Ksander BR, Bosch JJ, Frank NY, Ostrand-Rosenberg S, **Murray TG**, Frank MH, Kolovou PE: T Cells Targeting Cancer Stem Cells in Uveal Melanoma. [ARVO Abstract]. 842/D1054, 2010
6. Pina Y, Houston S, Scott W, Nathanson L, Scheffler A, Lampidis T, Celdran M, Hernandez E, **Murray TG**: Retinoblastoma Molecular Genomics: Regional Differences in the Molecular Genomics Expression Following Treatment With 2-Deoxy-D-Glucose in LH<sub>BETA</sub>T<sub>AG</sub> Retinal Tumors. [ARVO Abstract]. 1576, 2010
7. Mutapcic L, **Murray TG**, Aziz-Sultan MA, Scheffler AC, Quintero Wolfe S, Hess DJ, Fernandes CE, Dubovy SR: Supraselective Intra-Ophthalmic Artery Chemotherapy: Evaluation of Treatment Related Complications in Advanced Retinoblastoma. [ARVO Abstract]. 1579, 2010
8. Houston SK, Pina Y, Scott WK, Nathanson L, Scheffler AC, **Murray TG**: Regional and Temporal Differences in the Genetic Expression of LH<sub>BETA</sub>T<sub>AG</sub> Retinoblastoma Tumors. [ARVO Abstract]. 2066/A6, 2010
9. **Murray TG**, Pina Y, Houston S, Hernandez E, Celdran M, Feuer W, Lampidis T: Retinoblastoma Tumor Burden Control: Periocular m-TOR Inhibitor Rapamycin Decreases Tumor Burden in Advanced LH<sub>BETA</sub>T<sub>AG</sub> Murine Retinoblastoma. [ARVO Abstract]. 2067/A7, 2010
10. Suk KK, Lalwani GA, **Murray TG**, Hess D, Berrocal AM: Retinal Findings in Patients With Aicardi Syndrome. [ARVO Abstract]. 2209/A308, 2010
11. Williams BK, Scheffler AC, Garonzik SN, Shi W, Gologorsky D, Feuer WJ, **Murray TG**: Orbital Disease and Surgery. [ARVO Abstract]. 3528/A33, 2010

12. Berrocal AM, Houston SK, Pina Y, Bascom Palmer Imaging Group, **Murray TG**: Intraoperative Spectral Domain Optical Coherence Tomography (SD-OCT) Imaging of Complex Pediatric Retinal Disease. [ARVO Abstract]. 3861, 2010
13. Khan S, Finger PT, Sankull P, Seregard S, Gologorsky D, **Murray T**, Kivela T, Eskelin S, Raut R, Coriveau C: Clinical and Pathologic Characteristics of Biopsy Proven Iris Melanomas: Results of a Multicenter International Study. [ARVO Abstract]. 3808, 2010
14. Kolovou EP, Frank NY, Giani A, **Murray TG**, Frank MH, Ksander BR: ABCB5: a Novel Cancer Stem Cell Marker in Retinoblastoma. [ARVO Abstract]. 4764, 2010
15. Parke DW, **Murray TG**, Flynn HW: Open Globe Injuries: Computerized Tomography and Echography in Clinical Management. [ARVO Abstract]. 6026/A334, 2010
16. **Murray TG**, Pina Y, Boutrid H, Cebulla CC, Jockovich ME: Role of Matrix Metalloproeinase-9 in LH BETA Tag Retinal tumor Growth. [ARVO Abstract]. 2039, 2009
17. Cebulla CM, Ruggeri M, **Murray TG**, Hernandez E: Optical Coherence Tomography in a Murine Retinal Detachment Model. [ARVO Abstract]. 3798/A358, 2009
18. Alegret AM, Scheffler AC, Pina Y, Boutrid H, Hernandez E, Ruggeri M, Jiao S, **Murray TG**: Recent Advancements in 532 Green Laser Technology and Probe Enhancement: Clinical Assessment and Laboratory Evaluation. [ARVO Abstract]. 2082, 2009
19. Pina Y, Boutrid H, Cebulla CC, Scheffler AC, Alegret A, Jager MJ, Ly LV, Jockovich ME, **Murray TG**: Retinoblastoma Tumor Burden: Effect of Macrophage Depletion on LH<sub>BETA</sub>TAG Retinal Tumor Growth. [ARVO Abstract]. 2038, 2009
20. Boutrid H, Pina Y, Jockovich ME, Cebulla CC, Lampidis TJ, **Murray TG**: Vascular Targeting Agent and Glycolytic Inhibitor Combination Therapy Decreases Tumor Burden in Advanced LH<sub>BETA</sub>TAG Murine Retinoblastoma. [ARVO Abstract]. 2043, 2009.
21. Fernandes CE, Scheffler AC, Reichbach J, Podda A, Davis JA, Alvarez OA, Barredo JC, Lewis N, White E, **Murray TG**: Chemotherapy Plus Cyclosporine A for the Treatment of Intraocular Retinoblastoma. [ARVO Abstract]. 1692/A, 2009

22. Williams SL, Berrocal AM, Hess DJ, Shi W, **Murray TG**: Fundus Pigmentation in Treatment-requiring Retinopathy of Prematurity (ROP). [ARVO Abstract]. 3157/A504, 2009
23. Parrott M, Flynn Jr HW, Wykoff CC, Miller D, **Murray TG**, Smiddy WE, Davis JL: Nosocomial Acute-Onset Postoperative Endophthalmitis at a University Teaching Hospital (1995-2008) [ARVO Abstract] 3557/D1070, 2009
24. Alliman K, Flynn Jr HW, Lalwani G, Quinn C, Davis JL, **Murray TG**, Rosenfeld P, Smiddy WE: Acute-Onset Endophthalmitis Following Clear Corneal Cataract Surgery: A 12-Year Review (1996-2008) [ARVO Abstract] 3564/D1077, 2009
25. Pina Y, Boutrid H, Jockovich ME, **Murray TG**: Spatial Configuration of Neovasculature in Retinoblastoma: A Proposed Model for Tumor Vascular Development. [ARVO Abstract] 18/A6, 2008
26. Boutrid H, Jockovich ME, Cebulla C, Lampidis TJ, **Murray TG**: Vascular Targeting Agent and Cytotoxic Chemotherapy Increase Hypoxia in LH<sub>BETA</sub>TAG Murine Retinoblastoma. [ARVO Abstract] 21/A9, 2008
27. **Murray TG**, Boutrid H, Hernandez E, Shi W, Feuer WJ, Jockovich ME: Antiangiogenic Therapy for Retinoblastoma: Effect of Tumor Burden and Dose Schedule in the Murine LH<sub>BETA</sub>TAG Transgenic Model. [ARVO Abstract] 22/A10, 2008
28. Cebulla CM, Jockovich ME, Boutrid H, Piña Y, Ruggeri M, Jiao S, Bhattacharya SK, Feuer WJ, **Murray TG**: Effect of SU1498, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2, in a Transgenic Murine Model of Retinoblastoma. [ARVO Abstract] 23/A11, 2008
29. Lalwani GA, Scheffler AC, Feuer WJ, Davis II RP, **Murray TG**: Bevacizumab for Radiation Retinopathy After Iodine-125 Plaque Brachytherapy for Posterior Uveal Malignant Melanoma. [ARVO Abstract], 49/A37, 2008
30. Alegret M, Jockovich ME, Pina Y, Boutrid H, Hernandez E, **Murray TG**: Tumor Infiltrating Lymphocytes in Retinal Tumors From LH<sub>BETA</sub>TAG mice. [ARVO Abstract], 75/A63, 2008
31. Jockovich ME, Pina Y, Boutrid H, **Murray TG**: Bone Marrow Derived Macrophages Are Present in Retinal Tumors from LH<sub>BETA</sub>TAG Mice. [ARVO Abstract], 76/A64, 2008
32. Bokhoor PI, Miller D, Scheffler AC, **Murray TG**: Epidemiology and Microbiology of Pediatric Socket/Orbital Implant Infections Following Enucleation Secondary to Retinoblastoma. [ARVO Abstract], 1442/D676, 2008

33. Moshfeghi AA, Flynn Jr HW, **Murray TG**, Rosenfeld PJ, Gaitan J, Lalwani GA, Lujan B, Gallogly P: Endophthalmitis Following Intravitreal Injections Is Very Rare in the Anti-VEGF Era. [ARVO Abstract], 2867, 2008
34. Pina Y, Cebulla CM, **Murray TG**, Alegret A, Dubovy S, Boutrid H, Feuer W, Jockovich ME: Blood Vessel Maturation in Human Uveal Melanoma: Spatial Configuration of Endothelial Vessel Maturation and Neovasculature and Its Impact on Ocular Treatment. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 4780, 2007
35. Bosch JJ, Iheagwara UK, **Murray TG**, Lotem M, Ksander BR, Ostrand-Rosenberg S. Uveal Melanoma Cell-Based Vaccines Activate CD4+ T Lymphocytes That Cross-React With Primary and Metastatic Uveal Melanoma Cells. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 1945, 2007
36. Flynn HW Jr., Gregori NZ, Miller D, Scott IU, Davis JL, **Murray TG**. Candida Endophthalmitis Following Cataract Surgery: Management Strategies, and Visual Acuity Outcomes. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 679, 2007
37. Davis R II, Cebulla CM, Ehlied FJ, **Murray TG**. Echographic Localization of Periocular Carboplatin in Advanced Retinoblastoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 5250, 2007
38. Cebulla CM, Jockovich ME, Pina Y, Alegret A, Boutrid H, Hackam A, Feuer W, **Murray TG**. Basic Fibroblast Growth Factor Expression in Retinoblastoma Progression and Survival [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 3987, 2007.
39. **Murray TG**, Cebulla CM, Alegret A, Pina Y, Boutrid H, Jockovich ME. Targeting the Tumor Microenvironment as a Therapeutic Strategy for Retinoblastoma [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 1585, 2007
40. Jockovich ME, Diaz-Caneja J, Pina Y, Boutrid H, Cebulla CM, **Murray**. Role of Tumor Associated Macrophages in Retinoblastoma Tumor Growth. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 1587, 2007
41. Jiao S, Ruggeri M, Wehbe H, Gregory G, Jockovich ME, Puliafito CA, **Murray TG**. Quantitative Imaging of Eye Tumor in the Mouse Model of Retinoblastoma With Spectral-Domain Optical Coherence Tomography. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 1588, 2007
42. Yi H, Tell S, Jockovich ME, **Murray TG**, Hackam AS. The Wnt Signaling Pathway Has Tumor Suppressor Properties in Retinoblastoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 1593, 2007

43. Alegret AM, Pina Y, **Murray TG**, Suarez F, Hayden B, Cebulla CM, Feuer W, Boutrid H, Jockovich ME. Differential Induction of Apoptosis in the Treatment of LHBETATAG Retinoblastoma Following Vessel Targeting. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 1600, 2007
44. Boutrid H, Cebulla CM, Pina Y, Jockovich ME, Lampidis TJ, and **Murray TG**. Regional Hypoxia in LHBetaTag Murine Retinoblastoma: Implication for Novel Treatments. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 48: Abstract nr E- 1601, 2007
45. Cebulla CM, Jockovich ME, Bajenaru L, **Murray TG**. Gelatinase Activity in Human Retinoblastoma and Choroidal Melanoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E- 2805, 2006
46. Tell S, Yi H, Jockovich ME, **Murray TG**, Hackam AS. The Canonical Wnt Signaling Pathway Regulates the Viability of Retinoblastoma Tumor Cells. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E- 2806, 2006
47. Schiedler V, **Murray TG**, Dubovy SR. Snare Technique For Enucleation Of Eyes With Advanced Retinoblastoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E- 2812, 2006
48. Jockovich ME, Pina Y, Suarez F, Hernandez E, **Murray TG**. Blood Vessel Heterogeneity in Retinal Tumors From LHBETATAG Mice Limits Vessel Targeting Therapy. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E- 2833, 2006
49. Miller JJ, Flynn HW Jr., Smiddy WE, **Murray TG**, Scott IU, Miller D. Endophthalmitis Caused by Bacillus. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E- 5279, 2006.
50. Major JC Jr., Flynn HW Jr., Miller D, Smiddy WE, **Murray TG**. Antibiotic Sensitivities and Visual Acuity Outcomes in Endophthalmitis Caused by Methacillin–Sensitive (MSSA) versus Methacillin–Resistant (MRSA) Staphylococcus aureus. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E- 5282, 2006
51. Flynn HW Jr., Miller JJ, Scott IU, Smiddy WE, **Murray TG**, Miller D. Acute–Onset Endophthalmitis Following Cataract Surgery in a University Teaching Hospital (2000–2005). [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E- 5293, 2006
52. Hartley KL, Smiddy WE, Flynn HW Jr., **Murray TG**, Voo I, Venkatraman AS. Pars Plana Vitrectomy With Internal Limiting Membrane Peeling For Diabetic

- Macular Edema. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E-3866, 2007
53. Hayden BC, Scheffler AC, Abramson DH, **Murray TG**, and Echography Study Group. Echographic Features of Melanocytoma Detected by Standard and High-Resolution Ultrasound. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E- 2260, 2006
54. **Murray TG**, Jockovich ME, Suarez F, Hernandez E, Feuer W. Combined Angiostatic and Periocular Chemotherapy Using Combretastatin A4P and Carboplatin in the Treatment of LHBETATAG Transgenic Murine Model of Retinoblastoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E-2290, 2006
55. Suarez F, Jockovich ME, Hernandez E, Parel JM, **Murray TG**. Taxol in the Treatment of Retinal Tumors of LH BETATAG Murine Transgenic Model of Retinoblastoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E-2801, 2006
56. Bosch JJ, Thompson JA, Dissanayake SK, **Murray TG**, Ksander BR, Ostrand-Rosenberg S. Primary and Metastatic Uveal Melanoma Cells Genetically Modified to Express HLA-DR and CD80 Present Class II Restricted Tumor Antigens and Activate Tumor-Specific CD4+ T Cells. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 47: Abstract nr E- 5165, 2006
57. Miller DM, Flynn HW Jr., Miller D, Scott IU, Smiddy WE, **Murray TG**, Venkatraman AS. Endophthalmitis Caused by Staphylococcus epidermidis: Clinical Outcomes and in vitro Antibiotic Susceptibilities. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 46: Abstract nr E- 3295, 2005
58. Jockovich ME, Moshfeghi AA, Hernandez E, Clifford PD, **Murray TG**. Posterior Juxtasclear Injection of Anecortave Acetate: Localization in Rabbit Eyes by Magnetic Resonance and Ecographic Imaging. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 46: Abstract nr E- 482, 2005
59. Flynn HW, Moshfeghi AA, Davis JL, Kitchens JW, **Murray TG**, Puliafito CA, Rosenfeld PJ, Scott IU, Smiddy. Non-infectious Pseudohypopyon Following Intravitreal Triamcinolone Acetonide (IVTA) Injection. [ARVO Abstract] *Invest. Ophthalmol. Vis. Sc* 46: Abstract nr E- 486, 2005
60. Cebulla CM, Jockovich ME, **Murray TG**. Anecortave Acetate Modulates MMP-2, MMP-9 and Vegf Receptor Expression in the LHBTAG Mouse Model of Retinoblastoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 46: Abstract nr E-1106, 2005



61. Schefler AC, Cicciarelli N, **Murray TG**. Macular Retinoblastoma: Evaluation of Tumor Control, Local Complications, and Visual Outcomes for Eyes Treated With Aggressive Chemotherapy and Laser Ablation. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 46: Abstract nr E- 1110, 2005
62. **Murray TG**, Toledano S, Markoe A, Schefler AC. Failure Analysis for Globe Conservation in Advanced Intraocular Retinoblastoma. [ARVO Abstract] *Invest. Ophthalmol. Vis. Sc* 46: Abstract nr E- 1111, 2005
63. Gallogly P, Moore J, Scott IU, Flynn HW Jr, Smiddy WE, **Murray TG**, Feuer W. Retained Lens Fragment in the New Millenium. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 46: E- 5511, 2005
64. Quinn CD, Flynn HF Jr, Gedde SJ, Budenz DL, Scott IU, Palmberg PF, Smiddy WE, **Murray TG**, Parrish RK II, Fantes FE. Delayed-onset Bleb-Associated Endophthalmitis: Clinical Features and Visual Acuity Outcomes. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 46: Abstract nr E- 5552, 2005
65. Couvillion SS, Flynn HW Jr, **Murray TG**, Ehliès FJ, Miller D, Smiddy WE. Correlation of Echographic Findings With Outcomes in Patients With Endophthalmitis. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 46: Abstract nr E- 5568, 2005
66. **Murray TG**. Combined Anti-angiogenic and Peri-ocular Chemotherapy utilizing Anecortave Acetate and Carboplatin in the Treatment of Retinal Tumors in the LHBETATAG Murine Transgenic Model of Retinoblastoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 45: Abstract nr E- 3362, 2004
67. Berrocal AM, Mavrofrides EC, **Murray TG**, Hess D, Johnson R. Retinopathy of prematurity (ROP) screening and treatment experience at Jackson Memorial Hospital/Bascom Palmer Eye Institute 2002-2003. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 45: Abstract nr E- 4043, 2004
68. Garonzik SN, Margolis R, **Murray TG**. Ocular Prosthetic Management: Evaluation of prospective, serial custom prosthetic refitting on improved socket anatomy, function and cosmesis. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 45: Abstract nr E- 4704, 2004
69. Lee JE, Mavrofrides EC, Smiddy WE, Scott IU, Rosenfeld PJ, Flynn HW Jr, **Murray TG**, Berrocal AM, Puliafito CA. Intravitreal triamcinolone for the treatment of macular edema from central retinal vein occlusion. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 45: Abstract nr E- 5238, 2004
70. Peracha MO, Benz MS, Mieler WF, Holz ER, **Murray TG**, Couvillion SS. Visual Outcomes following Pars Plan Vitrectomy for Complications of Radiation

- Retinopathy. [ARVO Abstract] *Invest. Ophthalmol. Vis. Sc* 45: Abstract nr E-1996, 2004
71. Smiddy RJ, Smiddy WE, Ba'ath B, Flynn HW Jr, **Murray TG**, Feuer W. Endophthalmitis: Are Subconjunctival Antibiotics Necessary? [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 45: Abstract nr E- 524, 2004
72. Rosenberg KD, **Murray TG**, Berrocal A, Ysasaga E, Loo R, Aragon A, Douglas M, Feuer W, Gregori G. Continuous versus Non-continuous Laser Photocoagulation for the Treatment of Threshold Retinopathy of Prematurity. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 44: Abstract nr E- 596, 2003
73. **Murray TG**, Escalona-Benz E, Hayden BC, Cicciarelli N, Hernandez E, Windle JJ. Subconjunctival Anecortave Acetate, an Angiostatic Steroid, in the Treatment of a Murine Model of Retinoblastoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 44: Abstract nr E- 934, 2003
74. Moore JK, Scott IU, Flynn HW Jr., Smiddy WE, **Murray TG**, Pereira MB, Jorge R. Cystoid Macular Edema in Eyes Undergoing Pars Plana Vitrectomy for Retained Lens Fragments. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 44: Abstract nr E- 3110, 2003
75. Escalona-Benz E, **Murray TG**, Benz MS, Villate N, Hayden BC. Correlation between Optos Ultra Widefield Digital Imaging, Standardized Fundus Photography, and B-Scan Echography in the Detection of Posterior Segment Tumors. [ARVO Abstract] *Invest. Ophthalmol. Vis. Sc* 44: Abstract nr E- 3644, 2003
76. Dubovy SR, Colomine C, Jampol LM, **Murray TG**. FNAB in the Evaluation of Atypical Uveal Effusion Syndrome: Histopathological Review. [ARVO Abstract] *Invest. Ophthalmol. Vis. Sc* 44: Abstract nr E- 1591, 2003
77. Benz MS, Escalona-Benz EM, **Murray TG**, Eifrig CW, Yoder DM, Moore JK, Cruz-Villegas V. Immediate Postoperative Use of a Single Topical Agent to Prevent Intraocular Pressure Elevation after Pars Plana Vitrectomy with Long-acting Gas Tamponade. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 44: Abstract nr E- 3014, 2003
78. Moore JK, Scott IU, Flynn HW Jr., **Murray TG**, Smiddy WE, Jorge R, Pereira MB, Kim JE, and Vilar NF. Retinal Detachment in Eyes Undergoing Pars Plana Vitrectomy for Removal of Retained Lens Fragments. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 43: Abstract nr E- 633, 2002
79. Escalona-Caamano EM, **Murray TG**, Benz MS, Hayden BC, Garonzik S, Hernandez E. Magnetically Integrated Microporous Implant: Safety and Efficacy of Secondary Stainless Steel Posting Following Enucleation Surgery. [ARVO Abstract] *Invest. Ophthalmol. Vis. Sc* 43: Abstract nr E- 3048, 2002

80. Flynn HW Jr., Scott IU, **Murray TG**, Feuer WJ, Schiffman J. Outcomes of Surgery for Retinal Detachment Associated with Proliferative Vitreoretinopathy Using Perfluoro-n-octane: A Multicenter Study. [ARVO Abstract] *Invest. Ophthalmol. Vis. Sc* 43: Abstract nr E- 4504, 2002
81. Gaitan JR, Hayden BC, **Murray TG**, Escalona EM, Cicciarelli N, Feuer W. Cellular Viability in Choroidal Melanoma Following Brachytherapy with Subsequent Enucleation. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 43: Abstract nr E- 1132, 2002
82. Bosch JJ, Chen PW, Mensink HW, Jager MJ, **Murray TG**, Ksander BR. Microarray Analysis of Differential Gene Expression in Autologous Primary and Metastatic Uveal Melanoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 43: Abstract nr E- 1860, 2002
83. Sussman DA, Escalona EM, Benz MS, Hess D, Feuer W, Ciciarelli N, Markoe A, Toledano S, **Murray TG**. Globe Conserving Therapy in Retinoblastoma: Comparison of Time Course of Tumor Reduction for Primary Chemoreduction Versus External Beam Radiotherapy. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 43: Abstract nr E- 2590, 2002
84. Hayden BC, **Murray TG**, Gaitan JR, Raja D, Escalona EM, Hernandez E, Cicciarelli N, Windle JJ. Time Course Dependent Apoptosis Following Subconjunctival Carboplatin Therapy in the Treatment of Murine Transgenic Retinoblastoma. [ARVO Abstract]. *Invest. Ophthalmol. Vis. Sc* 43: Abstract nr E- 2593, 2002
85. **Murray TG**, Escalona EM, Hayden BC, Cicciarelli N, Hernandez E, Feuer W, Windle JJ. Combretastatin A4 Prodrug: Subconjunctival delivery of an angiogenesis Inhibitor in the Treatment of a Murine Model of Retinoblastoma.[ARVO Abstract]. *Invest. Ophthalmol Vis. Sc* 43: Abstract nr E- 3917, 2002
86. Hayden, BC, **Murray, TG**, Hernandez, E, Cicciarrelli, N, Fulton, L, O'Brien, JM. Differential Induction of Apoptosis in the Treatment of Murine Transgenic Retinoblastoma.[ARVO Abstract]. *Invest Ophthalmol and Vis Sc* 42(4):Abstract nr 2728, 2001
87. **Murray, TG**, Hayden, BC, Cicciarelli, N, Scott, IU, Hernandez, E, Wu, X, Markoe, AM, Feuer, W, Fulton, L, O'Brien, JM. External Beam Radiation "Salvage" Therapy in the Treatment of Murine Transgenic Retinoblastoma .[ARVO Abstract]. *Invest Ophthalmol and Vis Sc* 42(4):Abstract nr 1786, 2001
88. Voigt M, Hayden, BC, **Murray, TG**, Milne P, Hamasaki D, Parel, JM. Carboplatin Coulomb Controlled Iontophoresis (CCI): Evaluation of ERG and Histopathology

**Timothy G. Murray, M.D., M.B.A.**  
**Curriculum Vitae**

[ARVO Abstract]. *Invest Ophthalmol and Vis Sc* 42(4):Abstract nr 1791, 2001

89. Ciciarelli N, **Murray TG**, Hayden BC, Hernandez E, Milne P, Feuer W, Parel JM. Pharmacokinetics of subconjunctivally administered cyclosporine A: Local Delivery Prior to Chemotherapy for Retinoblastoma [ARVO Abstract]. *Invest Ophthalmol and Vis Sc* 42(4): Abstract nr 1792, 2001
90. ADDIN ENBbu Hayden, BC, **Murray TG**, Scott IU, Ciciarelli N, Hernandez E, Feuer W, Fulton L, O'Brien JM: Subconjunctival carboplatin in retinoblastoma: Impact of tumor burden and dose schedule. *Arch Ophthalmol* 2000;118 (11):1549-1554
91. **Murray TG**, Ciciarelli N, Croft BC, Garonzik S, Voigt M, Hernandez E. Magnetically integrated microporous implant: Evaluation of feasibility and efficacy. *Arch Ophthalmol* 2000; 118 (9):1157-1320
92. Hayden BC, Voigt M, **Murray TG**, Hernandez E, Parel JM, Feuer W, Fulton L, O'Brien JM: Iontophoretic Delivery of Carboplatin in the Treatment of Murine Transgenic Retinoblastoma [ARVO Abstract]. *Invest Ophthalmol and Vis Sci* 41(4):S788. Abstract nr 4178, 2000
93. **Murray TG**, Hayden BC, Voigt M, Milne PJ, Ciciarelli N, Hernandez E, Scott IU, Feuer W, Steele B, Parel JM: An in vivo comparison of systemic versus focal chemotherapy in the management of retinoblastoma [ARVO Abstract]. *Invest Ophthalmol Vis Sci* 41(4):S953. Abstract 5065, 2000
94. Ciciarelli N, **Murray TG**, Hayden BC, Hernandez E, Wu X, Markoe AM, Feuer W, Fulton L, O'Brien JM: A Comparison of radiation hyperfraction in the management of murine transgenic retinoblastoma [ARVO Abstract]. *Invest Ophthalmol Vis Sci* 41(4):S788. Abstract nr4176, 2000
95. Croft BH, **Murray TG**, Ciciarelli N, Hernandez E, Fulton L, O'Brien JM. Efficacy of Locally Delivered Carboplatin as a function of tumor burden and cycle number in murine transgenic retinoblastoma. [Paper] *IX International Congress of Ocular Oncology* 1999.
96. **Murray TG**, Voigt M, Croft BH, Chapon P, Parel J-M, Hernandez E: Iontophoretic delivery of carboplatin: Evaluation of pharmacokinetics and efficacy [ARVO Abstract]. *Invest Ophthalmol Vis Sci* 40(4):S576. Abstract nr3034, 1999
97. Croft BH, **Murray TG**, Ciciarelli N, Fulton L, O'Brien JM: In vitro efficacy of combined carboplatin, etoposide, and/or vincristine with and without hyperthermia in transgenic murine retinoblastoma [ARVO Abstract]. *Invest Ophthalmol Vis Sci* 40(4):S577. Abstract nr3035, 1999
98. Hughes R, Tabandeh H, Chaudhry NA, **Murray TG**: Intraoperative echographic localization of iodine 125 episcleral plaques for choroidal melanoma. *Invest Ophthalmol Vis Sci* 1999:40(4)(Suppl):956.

99. Belfort A, Chaudhry NA, Flynn HW Jr, **Murray TG**: Combined cataract extraction, intraocular lens implantation and pars plana vitrectomy for localized recurrent retinal detachment and cataract. *Invest Ophthalmol Vis Sci* 1999;40(4)(Suppl):946.
100. Chaudhry NA, Belfort A, Flynn HW Jr, Tabandeh H, Smiddy WE, **Murray TG**: Combined lensectomy, vitrectomy and scleral fixation of intraocular lens implant after closed-globe injury. *Ophthalmic Surg & Lasers* 1999;30:375-381.
101. Alexandrakis G, Chaudhry NA, Flynn HW Jr, **Murray TG**: Combined cataract surgery, intraocular lens insertion, and vitrectomy in eyes with idiopathic epiretinal membrane. *Ophthalmic Surg Lasers* 1999;30:327-328.
102. Alexandrakis G, Scott IU, Flynn HW Jr, Feuer W, **Murray TG**: Visual outcomes after surgery for persistent fetal vasculature (Persistent hyperplastic primary vitreous). *Invest Ophthalmol Vis Sci* 1999;40(4)(Suppl):945.
103. Ciciarelli N, **Murray TG**, Croft BH, Voight M, Garonzik S, Hernandez E: Magnetically integrated microporous implant: Evaluation of feasibility and efficacy. *Invest Ophthalmol Vis Sci* 1999;40(4)(Suppl):856.
104. Chaudhry NA, Flynn HW Jr, Tabandeh H, Mello MO, Miller D Jr, **Murray TG**: Ciprofloxacin-resistant *pseudomonas aeruginosa* at a major ophthalmic center. *Invest Ophthalmol Vis Sci* 1999;40(4)(Suppl):689.
105. Ksander BR, **Murray TG**, Verbik D, Chen PW: Immune induced activation of genes that regulate cellular differentiation – A novel effector T cell mechanism. *Invest Ophthalmol Vis Sci* 1999;40(4)(Suppl):591.
106. Croft BH, **Murray TG**, Ciciarelli N, Fulton L, O'Brien JM: In vitro efficacy of combined carboplatin, etoposide, and/or vincristine with and without hyperthermia in transgenic murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1999;40(4)(Suppl):577.
107. **Murray TG**, Voigt M, Croft BH, Chapon P, Parel JM, Hernandez E: Iontophoretic delivery of carboplatin: Evaluation of pharmacokinetics and efficacy. *Invest Ophthalmol Vis Sci* 1999;40(4) (Suppl):576.
108. Cordahi GJ, Alexandrakis G, Scott IU, **Murray TG**: 22mm radioactive <sup>125</sup> iodine plaques for the management of uveal malignant melanoma. *Invest Ophthalmol Vis Sci* 1999;40(4)(Suppl):243.
109. Ciciarelli N, Hamasaki D, **Murray TG**, Carney B, Hernandez E, O'Brien JM: Determination of functional and histologic parameters for toxicity associated with

- subconjunctival carboplatin. *Invest Ophthalmol Vis Sci* 1998;39(4)(Suppl):814.
110. Carney B, **Murray TG**, Cicciarelli N, Mueller R, Hernandez E, Feuer W, O'Brien JM: Efficacy of subconjunctival carboplatin determined by tumor burden and dose schedule in murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1998;39(4)(Suppl):814.
111. **Murray TG**, Carney B, Mueller R, Hernandez E, Feuer W, Nose I, Parel JM, O'Brien JM: Subconjunctival carboplatin and FM hyperthermia in murine transgenic retinoblastoma therapy. *Invest Ophthalmol Vis Sci* 1998;39(4)(Suppl):814.
112. Verbik DJ, **Murray TG**, Ksander BR: Signals emanating from membrane Fas Ligand control the release of cytoplasmic Fas Ligand and the induction of apoptosis. *Invest Ophthalmol Vis Sci* 1998;39(4)(Suppl):606.
113. Verbik DJ, **Murray TG**, Ksander BR: Primary ocular melanomas are immunosuppressive and non-immunogenic. *Invest Ophthalmol Vis Sci* 1997;38(4)(Suppl):803.
114. Chen PW, **Murray TG**, Ksander BR: Mage expression in ocular melanomas during progression from primary to metastatic disease. *Invest Ophthalmol Vis Sci* 1997;38(4)(Suppl):464.
115. Uno T, **Murray TG**, Chen PW, Podack ER, Ksander BR: Gene transfer of the B7-1 co-stimulatory molecule into human ocular melanoma cells. *Invest Ophthalmol Vis Sci* 1997;38(4) (Suppl):463.
116. Cicciarelli N, **Murray TG**, Markoe A, Hernandez E, Smith BJ, O'Brien JM: Efficacy of subconjunctival carboplatin and external beam radiation (EBRT) in murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1997;38(4)(Suppl):448.
117. **Murray TG**, Cicciarelli N, Hernández E, Smith BJ, O'Brien JM: In vivo efficacy of subconjunctival carboplatin with and without cryotherapy in Murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1997;38(4)(Suppl):448.
118. Kaiser PK, Roth DB, Scott IU, **Murray TG**: Serial echographic characterization of retinoblastoma after radiation therapy, laser photocoagulation, and/or cryotherapy. *Invest Ophthalmol Vis Sci* 1997;38(4)(Suppl):384.
119. Del Carmen JF, O'Brien JM, Smith BJ, **Murray TG**: The initial metastatic evaluation in retinoblastoma. *Invest Ophthalmol Vis Sci* 1997;38(4)(Suppl):384.
120. Smith BJ, **Murray TG**, Cicciarelli N, O'Brien JM: Local chemotherapy using VP-16 and vincristine in murine transgenic retinoblastoma. *Invest Ophthalmol Vis Sci*

1997; 38(4) (Suppl):147.

121. Gordon KB, **Murray TG**, Cicciarelli N, Hernandez E, Smith BJ, Mueller RL, O'Brien JM: Subconjunctival chemotherapy using vincristine, etoposide or cyclophosphamide in a transgenic mouse model of retinoblastoma. *Invest Ophthalmol Vis Sci* 1997;28(4)(Suppl):147.
122. Tran JM, **Murray TG**, Uno T, Valor N, Ksander BR: Expression of HLA class I on ocular melanoma during progression from primary to metastatic disease. *Invest Ophthalmol Vis Sci* 1996;37(3)(Suppl):208.
123. McCabe C, **Murray TG**, Cicciarelli N, Hernandez E, Windle JJ, Smith B, Schoenike S, Ksander B, O'Brien JM: In vitro efficacy of focal etoposide, vincristine, or cyclophosphamide in murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1996;37(3)(Suppl):246.
124. **Murray TG**, Cicciarelli N, Keller B, Hernandez E, Smith B, Markoe A, Windle JJ, Ksander B, O'Brien JM: In vivo efficacy of external beam radiation therapy as a function of dose fractionation and total radiation dose in murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1996;37(3) (Suppl):914.
125. Ksander BR, **Murray TG**, Uno T, Geer DC, Podack ER, Chen PW: Activation of tumor-specific T cells by human ocular melanoma cells transfected with cDNA for the B7.1 costimulatory molecule. *Invest Ophthalmol Vis Sci* 1996;37(3)(Suppl):1114.
126. Chen PW, Uno T, **Murray TG**, Podack ER, Ksander BR: Gene therapy of ocular melanoma using a novel episomal vector system. *Invest Ophthalmol Vis Sci* 1996;37(3)(Suppl):1131.
127. Cicciarelli N, **Murray TG**, Smith B, Hernandez E, McCabe C, Schoenike S, Windle JJ, Ksander B, O'Brien JM: Murine transgenic retinoblastoma: tumor control as a function of total dose and cycle number for locally delivered carboplatin. *Invest Ophthalmol Vis Sci* 1996;37(3) (Suppl):1132.
128. Fine SL, **Murray TG**: Collaborative Ocular Melanoma Study: 10 year status. Vitreous Society 1995 Annual Meeting; London, England; August 1995. (Abstract Presentation)
129. Chen PW, Salgaller M, Rosenberg SA, **Murray TG**, Ksander BR: Increased expression of genes encoding tumor specific antigens in ocular melanoma: Potential targets for immunotherapy. *Invest Ophthalmol Vis Sci* 1995;36(4)(Suppl):221.
130. Mieler WF, Steeves RA, Tomkins R, Nash RW, Blair JR, Gentry L, Paliwal B, **Murray TG**: Concurrent versus sequential ferromagnetic hyperthermia and

- iodine-125 brachytherapy in the management of melanoma in an animal model. *Invest Ophthalmol Vis Sci* 1995;36(4) (Suppl):393.
131. O'Brien JM, Harbour JW, Smith B, Cohen J, Char DH, Kroll S, **Murray TG**: Utility of initial metastatic tests and serial bone scans in patients with retinoblastoma. *Invest Ophthalmol Vis Sci* 1995;36(4)(Suppl):494.
  132. **Murray TG**, Valor N, Hernandez E, Schoenike S, O'Brien JM, Ksander BR: In vivo efficacy of focal carboplatin and hyperthermia in murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1995;36(4)(Suppl):773.
  133. Geer DC, O'Brien JM, Smith BJ, **Murray TG**, Valor NL, Ksander BR: Interleukin-12 treatment of retinoblastoma. *Invest Ophthalmol Vis Sci* 1995;36(4)(Suppl):773.
  134. Harbour JW, **Murray TG**, Valor N, Hernandez E, Markoe A, Keller B, Schoenike S, Smith B, O'Brien JM: In vivo efficacy of locally delivered carboplatin and external beam irradiation in murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1995;36(4)(Suppl):774.
  135. Weishaar PD, Flynn HW Jr, **Murray TG**, Davis JL, Barr CC, Gross JC, Mein CE, McLean WC Jr: Endogenous *Aspergillus* endophthalmitis: clinical features and treatment outcomes. *Invest Ophthalmol Vis Sci* 1995;36(4)(Suppl):789.
  136. Cohen SM, Weishaar PD, **Murray TG**: Effect of photocoagulation on laser power transmission through human retina. *Invest Ophthalmol Vis Sci* 1995;36(4)(Suppl):833.
  137. Eells JT, Lewandowski MF, **Murray TG**: Formate-induced retinal dysfunction in methanol-intoxicated rats. *Invest Ophthalmol Vis Sci* 1994;35(Suppl):1516.
  138. Kim JE, Flynn HW Jr, Smiddy WE, **Murray TG**, Rubsamen PE, Davis JL, Nicholson DH: Management of retained lens fragments after phacoemulsification using pars plana vitrectomy. *Invest Ophthalmol Vis Sci* 1994;35(Suppl):1615.
  139. Sharkey JA, Civantos J, Flynn HW Jr, Rubsamen PE, Nicholson DH, Smiddy WE, **Murray TG**: The prognosis of giant retinal tears associated with high axial myopia. *Invest Ophthalmol Vis Sci* 1994;35(Suppl):1615.
  140. Aaberg TM Jr, Potarazu SV, Flynn HW Jr, **Murray TG**: Intraocular ceftazidime as an alternative to the aminoglycosides in the treatment of endophthalmitis. *Invest Ophthalmol Vis Sci* 1994;35(Suppl):1910.
  141. **Murray TG**, Ksander BR, Hamasaki D, Valor N, Hernandez E, Markoe A, Fiedler JA, Schoenike S, O'Brien JM: Efficacy and safety of focally delivered carboplatin and external beam radiation in the treatment of murine retinoblastoma. *Invest*



*Ophthalmol Vis Sci* 1994;35(Suppl):2084.

142. Ksander BR, Geer DC, O'Brien JM, Albert DM, **Murray TG**: Retinoblastoma specific cytotoxic T cells fail to eliminate intraocular tumors. *Invest Ophthalmol Vis Sci* 1993;34(Suppl):974.
143. **Murray TG**, Geer DC, O'Brien JM, Albert DM, Ksander BR: Retinoblastoma cells down-regulate expression of cell-surface class I MHC molecules. *Invest Ophthalmol Vis Sci* 1993;34(Suppl):1227.
144. **Murray TG**, O'Brien JM, Steeves RA, Albert DM: Interaction of ferromagnetic hyperthermia and external beam irradiation in the treatment of murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1992;33(Suppl):877.
145. O'Brien JM, **Murray TG**, Steeves RA, Marcus DM, Brauner E, Albert DM: Application of ferromagnetic hyperthermia in the treatment of murine retinoblastoma. *Invest Ophthalmol Vis Sci* 1992;33(Suppl):877.
146. Hartz A, Han DP, Wang Q, **Murray TG**, Boldt HC, Arrindell E, Jaffe GJ, Coe E, Mieler WF, Abrams GW, Lewis H, Gottlieb M: The association of postvitrectomy fibrin formation with long-term visual outcome. *Invest Ophthalmol Vis Sci* 1992;33(Suppl):898.
147. Mieler WF, **Murray TG**, Steeves RA, Moros EG, Boldt HC: Repetitive ferromagnetic hyperthermia (FMH) achieves enhanced tumoricidal activity. *Invest Ophthalmol Vis Sci* 1992;33(Suppl):1254.
148. Han DP, **Murray TG**, Boldt HC, Palmer M, Abrams GW, Mieler WF: Perfluoro-n-octane: Evaluation of acute anterior segment toxicity with intravitreal use. *Invest Ophthalmol Vis Sci* 1992;33(Suppl):1313.
149. Eells JT, **Murray TG**, Lewandowski MF, Stueven HA, Burke JM: Methanol poisoning: clinical evidence of direct retinal dysfunction. *Invest Ophthalmol Vis Sci* 1991;32(Suppl):689.
150. Hyndiuk RA, **Murray TG**, Palmer M, Boldt HC, Han DP, Mieler WP, Abrams GW: Perfluoro-n-octane: evaluation of anterior segment toxicity associated with intraocular use. *Invest Ophthalmol Vis Sci* 1991;32(Suppl):880.
151. Mieler WF, **Murray TG**, Boldt HC, Zellmer D, Erickson B: Ytterbium-169: experimental evaluation of a new brachytherapy source. *Invest Ophthalmol Vis Sci* 1991;32(Suppl):979.
152. Boldt HC, **Murray TG**, Steeves RA, Moros E, Lewandowski MF, Mieler WF: Combined ferromagnetic hyperthermia and <sup>125</sup>I episcleral plaque therapy: studies of therapeutic dose response curves. *Invest Ophthalmol Vis Sci*

- 1991;32(Suppl):979.
153. **Murray TG**, Boldt HC, Gillin MT, Mieler WF: Sulfur-35 endo-irradiation: dosimetry modeling and experimental efficacy. *Invest Ophthalmol Vis Sci* 1991;32(Suppl):979.
154. Abrams GW, **Murray TG**, Boldt HC, Han DP, Mieler WF: Tissue plasminogen activator (tPA): Determination of clinical limits of efficacy for intracameral delivery. *Invest Ophthalmol Vis Sci* 1991;32(Suppl):1226
155. Eells JT, Rajani C, **Murray TG**, Lewandowski MF, Burke JM: Methanol-induced ocular toxicity: development of a rodent model. *Invest Ophthalmol Vis Sci* 1990;31(Suppl):143.
156. **Murray TG**, Rajani C, Eells JT, Burke JM: Ocular methanol toxicity: cell type specificity in vitro. *Invest Ophthalmol Vis Sci* 1990;31(Suppl):286.
157. Abrams GW, **Murray TG**, McKay BS, Han DP: Transcorneal tissue plasminogen activator delivery: a functional in vivo study. *Invest Ophthalmol Vis Sci* 1990;31(Suppl):404.
158. Burke JM, **Murray TG**: Regional comparisons of cytochrome oxidase activity in retina and RPE. *Invest Ophthalmol Vis Sci* 1990;31(Suppl):492.
159. Eells JT, **Murray TG**, Rajani C, Lewandowski MF, Burke JM: A rodent model of methanol-induced ocular toxicity. *Proc Int Soc Eye Res* 1990;6:115.
160. Rajani C, **Murray TG**, Burke JM, Eells JT: Inhibition of bovine retinal cytochrome oxidase activity by formic acid. *The Pharmacologist* 1990;32:162.
161. Eells JT, **Murray TG**, Rajani C, Burke JM: Formic acid inhibits cytochrome oxidase activity in retina and in cultured retinal cells. *Soc Neurosci* 1990;16:611.
162. **Murray TG**, Stern WH, MacGowan-Smith E, Balyeat E: Transcorneal heparin delivery: physiology, pharmacokinetics and tissue binding. *Invest Ophthalmol Vis Sci* 1989;30(Suppl):258.
163. Kindy-Degnan N, **Murray TG**, Char DH, Swift P, Kurhanewicz J, Kaleta S: Assessment of intraocular tumor viability: a pre- and post-treatment comparison of fine needle biopsy and <sup>31</sup>P magnetic resonance spectroscopy. *Invest Ophthalmol Vis Sci* 1988;29(Suppl):210.
164. Swift PS, **Murray TG**, Char DH, Kindy-Degnan N, Fries P: Quantitative effect of hyperthermic treatment on the Greene melanoma. *Invest Ophthalmol Vis Sci* 1988;29(Suppl):211.

165. Swift PS, Stauffer PR, **Murray TG**, Phillips TL, Char DH: Response of choroidal melanoma in rabbits to 2450-MHz microwave hyperthermia. *Proc Int Soc Eye Res* 1988;5:167.
166. Aguayo J, **Murray TG**, Torentino P, Cousins J, Kan L-S, Stark WJ: Maintenance of human lenses in tissue culture and study by <sup>31</sup>P NMR spectroscopy. *Invest Ophthalmol Vis Sci* 1985;26(Suppl):162.

## **V. PROFESSIONAL**

### **21. Funded Research:**

Principal Investigator, Globe Conservation in Transgenic Retinoblastoma  
National Institutes of Health  
Grant #RO1 EY13629-01A2  
2004 – 2010  
Amount of Award: \$1,022,625

Principal Investigator, Collaborative Ocular Melanoma Study  
National Institutes of Health Grant  
Grant #5U10EY06275-08  
1991 - 2015  
Amount of Award: \$957,690

Principal Investigator, Janet Davis, MD  
Co-Investigator, Studies of Ocular Complications of AIDS  
National Institutes of Health  
Grant #EY08057  
1992 -2002  
Amount of Award: \$547,828

Principal Investigator, Hyperthermia Treatment of Retinoblastoma  
Stanley J. Glaser Foundation  
June 1992 - May 1993  
Amount of Award: \$29,890

Principal Investigator, Combined Local Modality Therapy in the Treatment of Ocular Retinoblastoma  
Fight For Sight, Inc.  
July 1997 – December 1998  
Amount of Award: \$11,000.00

Principal Investigator, Combined Local Modality Therapy in the Treatment of Ocular Retinoblastoma  
Fight For Sight, Inc.

September 1996 – August 1997  
Amount of Award: \$11,000.00

Principal Investigator, Combined Local Modality Therapy in the Treatment of Ocular Retinoblastoma  
Fight For Sight, Inc.  
July 1994 - June 1995  
Amount of Award: \$11,000.00

Principal Investigator, Combined Local Modality Therapy in the Treatment of Ocular Retinoblastoma  
American Cancer Society-Institutional Grant Committee  
December 1993 - November 1994  
Amount of Award: \$7,000.00

Co-Investigator, Richard-James Silicone Oil Clinical Investigation  
Richard-James, Inc.  
Principal Investigator, Perfluoron for use in Vitreoretinal Surgery  
Infinitech Corporation

**22. Editorial Responsibilities:**

Associate Editor, Lasers in Medical Science  
Manuscript Reviewer, American Journal of Ophthalmology  
Manuscript Reviewer, Archives of Ophthalmology  
Manuscript Reviewer, Current Opinion in Ophthalmology  
Manuscript Reviewer, Investigative Ophthalmology & Visual Science  
Manuscript Reviewer, Ophthalmology  
Manuscript Reviewer, Retina  
Manuscript Reviewer, Retinal Physician

**23. Professional and Honorary Organizations:**

2012 American Society of Cataract and Refractive Surgery  
2001 American College of Surgeons  
1998 Club Jules Gonin  
1997 Macula Society  
1996 Retina Society  
1994 American Association for Cancer Research  
1994 North American Hyperthermia Society  
1993 American Diabetes Association  
1992 International Society of Ocular Trauma  
1992 Florida Society of Ophthalmology  
1992 American Society of Retinal Specialists (Vitreous Society)  
1991 Miami Ophthalmologic Society

1986 Association for Research in Vision and Ophthalmology  
1986 Cordes Eye Society  
1986 American Academy of Ophthalmology  
1982 American Medical Association

**24. Honors and Awards:**

2011 America's Top Doctors for Cancer  
2007 Senior Achievement Award, American Academy of Ophthalmology  
2005 Senior Achievement Award, American Society of Retinal Specialists  
2001 Achievement Award Recipient, American Academy of Ophthalmology  
1985 Phi Beta Kappa, Johns Hopkins School of Medicine  
1982 Nevada State AMA Award Recipient  
1981 Biology Honors Programs, Johns Hopkins University  
1981 Honors, Johns Hopkins University

**25. Post-Doctoral Fellowships:**

1990-1991 Fellowship, Ophthalmology, Vitreoretinal Surgery  
Medical College of Wisconsin; Milwaukee, Wisconsin  
1989-1990 Fellowship, Ophthalmology, Post Doctoral Retinal Research  
Medical College of Wisconsin; Milwaukee, Wisconsin  
1988-1989 Chief Residency, Ophthalmology  
University of California, San Francisco; San Francisco, California  
1986-1989 Residency, Ophthalmology  
University of California, San Francisco; San Francisco, California  
1985-1986 Internship  
Union Memorial Hospital; Baltimore, Maryland

**26. Other Professional Activities:**

American Biological Society, May 1981

- Humphrey G, **Murray TG**, Pigiet V. Direct quantification of the large (100K) polyoma T-antigen on the nuclear matrix (poster presentation)

Summer Research Fellowship Program; National Institute of Health; Bethesda, MD;  
August 1982

- **Murray TG** and Joiner K. Differential complement activation and septic shock

Association of American Medical Colleges, 94th Annual Meeting, Baltimore, MD,  
November 1983

- McHugh P, Petty B, Lane M, Lattman E, Margolis S, **Murray TG**, Nathans D, Seidel H, Yardley J. Early admission to medical school: a unique approach (poster presentation)

NMR in Medicine Symposium, New York, NY, August 1984

**Timothy G. Murray, M.D., M.B.A.**  
**Curriculum Vitae**

- **Murray TG**, Aguayo J, Stark W, Torentino P, Sulewski M. Viability of the human lens by <sup>31</sup>P nuclear magnetic resonance spectroscopy (abstract presentation)

American Society of Microbiology, October 1984

- Joiner K, Schmetz M, **Murray TG**, Dourmashkin R, Frank M. Importance of C9 multiplicity in direct complement-killing of *E. Coli* J5 (EC) (abstract presentation)

North American Hyperthermia Group, 8th Annual Meeting, April 1987

- Swift PS, Stauffer PR, **Murray TG**, Phillips TL, Char DH. Response of choroidal melanoma in rabbits to 2450-MHz microwave hyperthermia (abstract presentation)

Cordes Eye Society, University of California, San Francisco, San Francisco, CA, 1987

- **Murray TG** et al. Carotid-cavernous fistula and Ehler's-Danlos syndrome: presentation and interventional radiologic management

Resident's Day; University of California, San Francisco, San Francisco, CA, May 1988

- **Murray TG** et al. Ocular hyperthermia: characterization of a 2450-MHz microwave hyperthermia unit utilizing a rabbit Greene melanoma model

Resident's Day; University of California, San Francisco, San Francisco, CA, May 1989

- **Murray TG** et al. Transcorneal heparin delivery

First Midwest Fluorescein Conference, Egg Harbor, WI, August 1989

- **Murray TG** et al. Talc retinopathy/choroidal folds

1990 Winter Retina Symposium, Kohler, WI, February 1990

- **Murray TG** et al. Idiopathic central serous choroidopathy: an update, acquired retinal disease

Resident's and Fellow's Day, Eye Institute, Medical College of Wisconsin, Milwaukee, WI, June 1990

- **Murray TG** et al. Methanol toxicity: new investigations into mechanism of neurotoxicity

Grand Rounds presentation, Eye Institute, Medical College of Wisconsin, Milwaukee, WI, July 1990

- **Murray TG** et al. Formate and methanol poisoning: in vivo and in vitro analysis of ocular toxicity

Second Midwest Fluorescein Conference, Egg Harbor, WI, August 1990

- **Murray TG** et al. Bilateral central retinal vein occlusion/choroideremia

1991 Winter Retina Symposium, Kohler, WI, February 1991

- **Murray TG** et al. Ocular sports injuries/protective eye wear
- **Murray TG** et al. Experimental alternatives in the management of uveal melanoma

Kohler Eye Meeting, Kohler, WI, June 1991

- **Murray TG** et al. Perfluorocarbon liquids: new frontiers in vitreous surgery.

Sixth International Congress on Hyperthermic Oncology; Miami, FL, April 1992

- Steeves RA, **Murray TG**, Tompkins DT, Nanda S, Paliwal BR, Mieler WF: Thermal enhancements with experimental choroidal melanoma: simultaneous versus sequential hyperthermia and brachytherapy (abstract presentation)

International Symposium on Ocular Tumors, New York, NY, April/May 1992

- Geer DC, Ksander BR, **Murray TG**, Rubsamen PE: Tumor-specific immune response to retinoblastomas

28th Annual Residents' Days, Bascom Palmer Eye Institute, University of Miami, Key Biscayne, FL, June 1992

- Weishaar PD, **Murray TG**, Flynn HW Jr: Expanding indications for perfluorocarbon liquids in vitreoretinal surgery

Aspen Retinal Detachment Society, Aspen, CO, March 1993 (invited guest speaker)

- **Murray TG** et al. Immunologic modulation of ocular tumor growth
- **Murray TG** et al. Choroidal hemorrhage/retrobulbar needle penetration

1993 Annual American Association for Cancer Research Meeting, Orlando, FL, April 1993

- Ksander BR, Geer DC, **Murray TG**: Studies of tumor-infiltrating-lymphocytes from human retinoblastoma (abstract presentation)

1993 Annual American Association for Cancer Research Meeting, Orlando, FL, April 1993

- **Murray TG**, Steeves RA, Mieler WF. Repetitive versus single ferromagnetic hyperthermia treatments for choroidal melanomas in rabbits (abstract presentation)

Association for Research in Vision and Ophthalmology 1993 Annual Meeting, Sarasota, FL, May 1993

- Session Moderator – Retinoblastoma

29th Annual Residents' Days, Bascom Palmer Eye Institute, University of Miami, Coral Gables, FL, June 1993

- Hummer J, **Murray TG**. Retinoblastoma: Historical perspective and future

trends, the Bascom Palmer experience

- Luetkemeyer J, **Murray TG**. Use of the laser aiming beam in differentiating retinoschisis from retinal detachment
- Civantos J, **Murray TG**. Management of giant retinal tears in phakic eyes

Trade Secrets, Bascom Palmer Eye Institute, University of Miami, Ocular Tumors, Miami, FL; June 1993

- **Murray TG** et al. Vitrectomy for Macular Disease
- **Murray TG** et al. Differential diagnosis of pigmented lesions of the retina

Asociación Oftálmologica del Norte, San Sebastian, Spain, June 1993

- **Murray TG** et al. Ocular tumors (abstract presentation)
- **Murray TG** and Nicholson DH: Treatment of the retinal detachment

Vitrectomy Workshop, Miami, FL, October 1993

- **Murray TG** et al. Prognosis and results
- **Murray TG** et al. Vitreous substitutes: gas, oil, and perfluorocarbon liquids
- **Murray TG** et al. Pars plana vitrectomy-related pathology and basics

Health Professional Course, Miami, FL, November 1993

- **Murray TG** et al. Diabetic retinopathy (invited guest speaker)

Ophthalmic Update 1994, Miami, FL, January 1994

- **Murray TG** et al. Retinoblastoma (invited guest speaker)
- **Murray TG** et al. Melanoma study: radioactive plaque insertion

1994 Medical Retina Course, Palm Beach, FL, March 1994

- **Murray TG** et al. Diagnosis and treatment of ocular tumors

Sylvester Comprehensive Cancer Center, Miami, FL, April 1994

- **Murray TG** et al. Surgical approaches to retinoblastoma (Grand Rounds presentation)

1994 Annual American Association for Cancer Research Meeting, San Francisco, CA, April 1994

- **Murray TG**, Geer DC, O'Brien JM, Albert DM, and Ksander BR. Retinoblastoma cells down-regulate expression of cell-surface class I MHC molecules (abstract presentation/poster session)
- **Murray TG**, Steeves RA, Gentry L, Tompkins R. Preservation of ocular function and anatomy after ferromagnetic hyperthermia (abstract presentation/poster session)

University of California, San Francisco, San Francisco, CA, April 1994

- **Murray TG** et al. Posterior segment complications of anterior segment surgery (Grand Rounds presentation)



Association for Research in Vision and Ophthalmology Annual Meeting,  
Sarasota, FL, May 1994

- Session Moderator - Intraocular tumors

Health Professional Course, Miami, FL, May 1994

- **Murray TG** et al. Diabetic retinopathy

Sixth International Symposium on the Immunology and Immunopathology of the Eye,  
Washington, DC, June 1994

- Davis T, Ruiz P, Viciano A, Thompson W, **Murray TG**. Flow cytometry of diagnostic vitrectomy specimens (abstract presentation/poster session)

30<sup>th</sup> Annual Residents' Days, Bascom Palmer Eye Institute, University of Miami  
School of Medicine, Key Biscayne, FL, June 1994

- Chang T, Gass JDM, **Murray TG**, Frazier-Byrne S, Hughes R. Echographic findings in lymphoid neoplasia of the choroid (abstract presentation)
- Sharkey JA, **Murray TG**. Etiology and treatment of secondary retinal angiomas (abstract presentation)
- Weishaar P, Cohen SM, **Murray TG**. Effect of photocoagulation on laser power transmission through human retina (abstract presentation)

Vitreous Society Annual Meeting, Aspen, CO, August 1994

- **Murray TG**, Kim JE, Flynn HW Jr, Smiddy WE, Davis JL, Nicholson DH, Rubsamen PE. Retained lens fragments after phacoemulsification (abstract presentation)
- **Murray TG**, Frazier-Byrne S, Hughes JR, Gendron EK. Intraoperative echographic localization for posterior uveal melanoma <sup>125</sup>I brachytherapy treatment (abstract presentation)
- Foster RE, Martinez J, **Murray TG**, Rubsamen PE, Flynn HW Jr, Forster RK. Good visual outcome following treatment of bacillus cereus endophthalmitis (abstract presentation)
- Flynn HW Jr, Cohen SM, **Murray TG**, Smiddy WE. Endophthalmitis after Vitrectomy Study Group: Endophthalmitis after pars plana vitrectomy (abstract presentation)

Trade Secrets: Ophthalmology for the Non-Ophthalmologist, Miami, FL, September 1994

- **Murray TG** et al. Diabetes and the eye

American Society of Ophthalmic of Registered Nurses, Miami, FL, February 1995

- **Murray TG** et al. Vitrectomy for macular diseases

Health Professional Course, Miami, FL, March 1995

- **Murray TG** et al. Diabetic retinopathy

Palm Beach Vitreoretinal Course, Manalapan, FL, March 1995

- **Murray TG** et al. Tumor management and therapy

Palm Beach Vitreoretinal Course, Manalapan, FL, March 1996

Mechanisms of Disease Course, Miami, FL, April 1996

- **Murray TG** et al. Ocular oncology.

Otolaryngology & Ophthalmology for the Generalist, Miami, FL, Jan 1997

- **Murray TG** et al. Melanoma, Advances in Clinical Management and Research

Update on Small Ocular Melanoma Trial, COMS Technical Group Meeting,  
Denver, CO, March 1997.

Aspen Retinal Detachment Society Meeting, Aspen, CO, March 1997

- **Murray TG** et al. Melanoma, Advances in Clinical Management and Research
- **Murray TG** et al. Retinoblastoma, Advances in Clinical Management and Research

Vitreoretinal Course, Bascom Palmer Eye Institute, University of Miami School of  
Medicine, Ft. Lauderdale, FL, May 1997.

- **Murray TG** et al. Current Status of Melanoma Management

33<sup>rd</sup> Annual Residents' Days Bascom Palmer Eye Institute, University of Miami  
School of Medicine, Coral Gables, FL, June 1997

- **Murray TG** et al. Retinoblastoma: Lessons from the Lab

ASORN Meeting, San Francisco, CA, October 1997

- **Murray TG** et al. Vitrectomy Surgery: The Basics
- **Murray TG** et al. Vitrectomy for Macular Diseases

Ophthalmic Photographers Society Meeting, San Francisco, CA, October 1997

- **Murray TG** et al. Clinical Trials and Protocols

American Academy of Ophthalmology meeting, San Francisco, CA, October 1997

- **Murray TG** et al. Combined Pars Plana Vitrectomy, Cataract Extraction & Intraocular Lens Insertion

International Eye Foundation, Ophthalmology/Oncology Seminar, Guatemala, August  
1998 (invited guest speaker)

- Advances in Management of Pediatric Intraocular Malignancies
- Posterior Segment Complications of Anterior Segment Surgery

- Pediatric Orbital Malignancies
- Clinical Case Series: Pediatric Retina
- Advances and Controversies in Management of Posterior Uveal Melanoma
- Clinical Case Series: Retinoblastoma
- Acute Lymphocytic Leukemia: Advances in Management

XXIst Meeting of the Club Jules Gonin, Edinburgh, Scotland, Aug 28-Sept 1, 1998

- Chaudhry NA, **Murray TG**: Simultaneous cataract extraction and pars plana vitrectomy for proliferative diabetic retinopathy (abstract/poster presentation)

Cincinnati Ophthalmological Society meeting, Cincinnati, OH,  
Sept 8, 1999 (invited guest)

- Retinoblastoma
- Posterior segment complications of anterior segment

Vitreous Society, Rome, Italy, Sept 21-26, 1999

American Academy of Ophthalmology Meeting, Orlando, FL, Oct 21-26, 1999

- ASORN Retinal Course

XII Inter-American Course, Miami, FL, Oct 31, 1999 (invited guest)

- **Murray TG** et al. Anterior segment surgery II: choroidal hemorrhage, endophthalmitis

Texas Retina Society, Austin, TX, Nov 11, 1999 (invited guest)

- **Murray TG** et al. Melanoma

American Board of Ophthalmology, Nov 12-14, 1999 (preceptor)

Retina Society, Hawaii, Nov 27-Dec 4, 1999

Miami Beach Kiwani's Club, Miami Beach, FL, Jan 20, 2000 (invited guest)

- Retinoblastoma

Trade Secrets, Bascom Palmer Eye Institute, Miami, FL, Jan 29, 2000

- **Murray TG** et al. Current concepts in posterior uveal melanoma

Macula Society, Puerto Rico, Feb 23-26, 2000

Collaborative Ocular Melanoma Study meeting, Texas, Mar 24-25, 2000

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, Apr 30-May 5, 2000

- **Murray TG** et al. An in vivo comparison of systemic versus focal chemotherapy in the management of RB

36<sup>th</sup> Annual Residents' Days, Bascom Palmer Eye Institute, Miami, FL, June 17, 2000

- **Murray TG** et al. Research and clinical advances in management of retinoblastoma

ACOSOG meeting, Chicago, IL, June 23-24, 2000

- 6/23/00 Eye Organ Site Committee meeting
- 6/24/00 Melanoma Organ Site Committee meeting

Vitreous Society, July 3-7, 2000

AMDRT DSMC Meeting, Philadelphia, PA, August 3, 2000

Club Jules Gonin Society meeting, Taormina, Italy, September 2-6, 2000

- **Murray TG** et al. Acute complications of globe conserving therapy in advanced retinoblastoma

Alcon Retinal Advisory Council 2000 meeting, Las Colinas, TX, October 18-19, 2000

American Academy of Ophthalmology Subspecialty Day [Retina], Dallas, TX, October 20, 2000

American Academy of Ophthalmology annual meeting, Dallas, TX, October 2000

- **Murray TG** et al. Retcam
- **Murray TG** et al. Clinical trials for OPS
- **Murray TG** et al. Widefield imaging of pediatric retinal diseases: a photographer's approach

CURSO Annual meeting, Miami, FL, November 11, 2000

- **Murray TG** et al. Current indications and techniques of subretinal surgery
- **Murray TG** et al. Advances in intraocular tumor management

Retina Society meeting, Miami, FL, December 2000

- **Murray TG** et al. Globe conserving iodine 125 episcleral plaque radiotherapy of large, diffuse choroidal melanoma

American Academy of Optometry meeting, Orlando, FL, December 7, 2000

- **Murray TG** et al. Advances and controversies in the treatment of choroidal neovascular membranes
- **Murray TG** et al. Advances and controversies in retinal and vitreoretinal disease

Vitreous Society meeting, Cancun, Mexico, January 9-11, 2001

- **Murray TG** et al. Pars plana lensectomy and intraocular lens implantation in pediatric radiation-induced cataracts in retinoblastoma
- Moderator – Ocular Oncology and Uveitis

Retina 2001 meeting, Kauai, HI, January 21-26, 2001

- **Murray TG** et al. Widefield imaging of retinopathy of prematurity/retinoblastoma
- **Murray TG** et al. Retinal emergencies
- **Murray TG** et al. Current approach to retinoblastoma
- **Murray TG** et al. Current approach to malignant melanoma
- **Murray TG** et al. Management of nuclear fragments and dislocated intraocular lenses

Koplowitz Memorial Lecture, Wilmer Eye Institute, Philadelphia, PA, February 9, 2001 (invited lecturer)

- Advances and controversies in the management of retinoblastoma

Aspen Retinal Detachment Society Meeting, Aspen, CO, March 5-9, 2001

- **Murray TG** et al. Advances in the diagnosis & therapy of uveal melanoma

Collaborative Ocular Melanoma Study Technical meeting, Denver, CO, March 22-26, 2001

- COMS-QOLS Advisory Committee meeting, March 25, 2001

Vitreous Society Board of Directors meeting, Las Colinas, TX, March 31, 2001

2001 Vitreoretinal Update, Bascom Palmer Eye Institute, Miami, FL, April 27-28, 2001

- **Murray TG** et al. Combined vitrectomy and cataract surgery
- **Murray TG** et al. Retcam images in pediatric retinal diseases
- **Murray TG** et al. Plaque therapy for choroidal melanoma

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, May 1-2, 2001

- **Murray TG** et al. External beam radiation “salvage” therapy in the treatment of murine transgenic retinoblastoma (poster presentation)
- **Murray TG** et al. Carboplatin coulomb controlled iontophoresis (CCI): evaluation of ERG & histopathology (poster presentation)
- Pharmacokinetics of subconjunctivally administered cyclosporine A: local delivery prior to chemotherapy for retinoblastoma (poster presentation)
- Translational research in ocular oncology: from bench to bedside (paper presentation)
- Intraoperative use of perfluoro-n-octane in the repair of complex RD: a prospective, multicenter, observational study (poster presentation)
- Differential induction of apoptosis in the treatment of murine transgenic RB (paper presentation)

**Timothy G. Murray, M.D., M.B.A.**  
**Curriculum Vitae**

- Factors associated with visual loss on long-term follow-up in patients with ICSC (poster presentation)
- Evaluation of the feasibility of macular translocation surgery by laser-induced scleral shortening (poster presentation)

Memorial Sloan Kettering Grand Rounds, New York, NY, 5/17/01 (Guest speaker)

- Advances & controversies in the management of pediatric retinoblastoma

Xth International Congress of Ocular Oncology, Amsterdam,  
The Netherlands, 6/17-21/01

- **Murray TG** et al. External beam radiation “salvage” therapy in the treatment of murine transgenic retinoblastoma: induction of apoptosis

37<sup>th</sup> Annual Residents’ Days, Bascom Palmer Eye Institute, Miami, FL, 6/22-23/01

- **Murray TG** et al. Prognostic value of staging for uveal melanoma
- **Murray TG** et al. New macular retinoblastoma tumors in patients with previously diagnosed bilateral retinoblastoma

Invited speaker, Michigan Ophthalmological Society, 33<sup>rd</sup> Annual Conference, Traverse City, MI, 8/2-5/01

- Advances in choroidal melanoma management
- Posterior segment complications of anterior segment surgery
- Retinoblastoma: clinical case series

American Board of Ophthalmology, Cambridge, MA, 10-26-28/01

American Academy of Ophthalmology, Retina subspecialty meeting,  
New Orleans, LA, 11/9-10/01

- **Murray TG** et al. Retinoblastoma 2001

American Academy of Ophthalmology, New Orleans, LA, 11/11-14/01

- New data from the COMS
- Uveal melanoma
- Metastatic tumors
- Advances in fundus imaging
- Radiation therapy
- Survival outcomes
- Quality of life determination
- COMS
- Retinoblastoma 2001: present and future
- Pediatric wide-field imaging

XXIII Curso Interamericana, Miami, FL, 11/17-20/01

- **Murray TG** et al. Tumor Update

Vitreous Society, Puerto Rico, 11/28-12/2/01

- **Murray TG** et al. Globe conserving therapy in retinoblastoma
- Discussant on panel: The good, the bad and the ugly in vitreous surgery

Bascom Palmer Eye Institute 40<sup>th</sup> Anniversary Scientific Meeting, Miami, FL, 2/21-23/02

- Moderator: Intraocular Tumors section
- Retinopathy of Prematurity/Pediatric Retinal Disease Panel

International Symposium on Ocular Pharmacology & Pharmaceutics, Seville, Spain, 2/28-3/3/02 (invited guest)

- Pharmacokinetics of systemic versus focal carboplatin chemotherapy in the treatment of retinoblastoma

Aspen Retinal Detachment Society meeting, Aspen, CO, 3/5-7/02

COMS Technical Group meeting, Baltimore, MD, 3/17-19/02

BCSC Section 4 meeting, Phoenix, AZ, 4/6-7/02

Vitreous Society Board Meeting, Dallas, TX, 4/13/02

International Congress of Ophthalmology meeting, Sydney, Australia, 4/21-26/02

- **Murray TG** et al. Chemotherapy for retinoblastoma, its present role, including the roles of cyclosporin A and periocular chemotherapy
- **Murray TG** et al. New insights with OCT

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, 5/5-10/02

- **Murray TG** et al. Microarray analysis of differential gene expression in autologous primary and metastatic uveal melanoma
- **Murray TG** et al. Combretastatin A4 prodrug: subconjunctival delivery of an angiogenesis inhibitor in the treatment of a murine model of retinoblastoma
- **Murray TG** et al. Advances in ocular oncology and application of translational research (poster presentation)
- **Murray TG** et al. Retinal detachment in eyes undergoing pars plana vitrectomy for removal of retained lens fragments (poster presentation)
- **Murray TG** et al. Cellular viability in choroidal melanoma following brachytherapy with subsequent enucleation (poster presentation)
- **Murray TG** et al. Globe conserving therapy in retinoblastoma: comparison of time course of tumor reduction for primary chemoreduction versus external beam radiotherapy (poster presentation)
- **Murray TG** et al. Time course dependent apoptosis following subconjunctival carboplatin therapy in the treatment of murine transgenic retinoblastoma (poster presentation)

**Timothy G. Murray, M.D., M.B.A.**  
**Curriculum Vitae**

- **Murray TG** et al. Magnetically integrated microporous implant: safety and efficacy of secondary stainless steel posting following enucleation surgery (poster presentation)
- **Murray TG** et al. Outcomes of surgery for retinal detachment associated with proliferative vitreoretinopathy using perfluoro-n-octane: a multicenter study (poster presentation)

Macula Society Meeting, Barcelona, Spain, 6/12-15/02

- **Murray TG** et al. Globe Conserving (Salvage) Therapy in the Management of Macular Transgenic Retinoblastoma: The Role of Apoptotic Activation (poster presentation)

38<sup>th</sup> Annual Residents' Days, Bascom Palmer Eye Institute, Miami, FL, 6/21/02

Alcon Retinal Advisory Committee (RAC) II Meeting, Palm Beach, FL, 8/16-18/02

Club Jules Gonin Society meeting, Montreux, Switzerland, 8/31-9/4/02

- **Murray TG** et al. Prospective observational study of small/suspicious choroidal melanoma (poster presentation)

Combined Vitreous Society & Retina Society meeting, San Francisco, CA, 9/29-10/3/02

- **Murray TG** et al. Single Use (Disposable) Advanced Vitreoretinal Microsurgical Instruments
- **Murray TG** et al. Prospective observational study of small/suspicious choroidal melanoma
- Moderator for Ocular Oncology/Lasik/Systemic Therapy Session

American Academy of Ophthalmology, Orlando, FL, Subspecialty Day 10/18/02

- **Murray TG** et al. Retinoblastoma: What's new for 2002

American Academy of Ophthalmology, Orlando, FL, 10/20-23/02

- Breakfast with the Experts – Uveal Melanoma and Retinoblastoma Update
- Instruction Course – Retinoblastoma 2002: Present and Future
- **Murray TG** et al. Outcomes of Surgery for Retinal Detachment Associated with Proliferative Vitreoretinopathy Using Perfluoro-N-Octane (poster presentation)
- **Murray TG** et al. Outcomes and Complications Associated with Giant Retinal Tear Management using Perfluoro-N-Octane (poster presentation)
- Salvage External Beam Radiotherapy of Retinal Hemangiomas Secondary to Von Hippel-Lindau Disease (poster presentation)

American Board of Ophthalmology exams, San Francisco, CA, 11/8-10/02

- Examiner



Macular Society meeting, Naples, FL, 2/25-3/1/03

- **Murray TG** et al. Globe conserving (salvage) therapy in the management of macular transgenic retinoblastoma: the role of apoptotic activation

Aspen Retinal Detachment Society meeting, Aspen, CO, 3/2-6/03

Pittsburgh Ophthalmology Society meeting, invited speaker, Pittsburgh, PA, 3/21-22/03

- **Murray TG** et al. Ocular oncology update: focus on COMS outcomes and new treatments in primary retinoblastoma
- **Murray TG** et al. Posterior segment complications associated with anterior segment surgery
- **Murray TG** et al. Advances in surgical management of diabetic retinopathy

Bascom Palmer Eye Institute Aspen meeting, Aspen, CO, 4/3-5/03

- **Murray TG** et al. Advances in diagnosis and management of ocular melanoma
- **Murray TG** et al. Advances in widefield digital pediatric imaging
- **Murray TG** et al. Advances in diagnosis and management of pediatric retinoblastoma

Lecture to Ophthalmic Technicians, Bascom Palmer Eye Institute, Miami, FL, 4/12/03

- Ocular oncology

Bascom Palmer Eye Institute Vitreoretinal meeting, Miami, FL, 5/2/03

- Imaging studies/case presentations
- COMS update

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, 5/4-9/03

- **Murray TG** et al. Continuous vs. non-continuous laser photocoagulation for the treatment of threshold ROP
- Co-moderator: Anatomy and Pathology session
- **Murray TG** et al. Anecortave Acetate, an Angiostatic Steroid, in the Treatment of a Murine Model of Retinoblastoma
- **Murray TG** et al. FNAB in the evaluation of atypical uveal effusion syndrome: histopathological review (poster presentation)
  
- **Murray TG** et al. Immediate postoperative use of single topical agent to prevent IOP elevation after PPV with long acting gas tamponade (poster presentation)
- **Murray TG** et al. CME in eyes undergoing PPV for retained lens fragments (poster presentation)

- **Murray TG** et al. Correlation between Optos ultra widefield digital imaging, standardized fundus photography, and b-scan echography in the detection of posterior segment tumors (poster presentation)

RB & Genetic Eye Disease meeting, Paris, France, 5/19-22/03

- Combretastatin A4 prodrug, an angiogenesis inhibitor in the treatment of the murine model of RB (poster presentation)

Bascom Palmer Eye Institute's Annual Residents' Days, Miami, FL, 6/20-22/03

Vth G.I.V.R.E. meeting, Reggio Calabria, Italy, 6/27-28/03

- **Murray TG** et al. Combined pars plana vitrectomy & lens management in complex vitreoretinal disease

American Society of Retina Specialists meeting, New York, NY, 8/16-20/03

COMS QOLS Advisory Committee meeting, Denver, CO, 9/4-6/03

3rd Southwest Vitreoretinal Symposium with Fellow's Forum,  
San Antonio, TX, 10/17-19/03

- **Murray TG** et al. Wide-Field Viewing in Pediatric Retinal Diseases
- **Murray TG** et al. Diagnostic and Therapeutic Dilemmas in Pediatric Retinal Detachment
- **Murray TG** et al. Globe Conserving Therapy in the Management of Retinoblastoma
- **Murray TG** et al. Application of Clinical Trial Data in the Management of Uveal Melanoma

COG Retinoblastoma Symposium, Dallas, TX, 11/7/03

Bascom Palmer Eye Institute, McKnight Research Retreat, Miami, FL, 1/10/04

Association for Research in Vision and Ophthalmology (ARVO), Program Committee meeting, Baltimore, MD, 1/23-24/04

BPEI Angiogenesis 2004 meeting, Miami, FL, 2/6-7/2004

- **Murray TG** et al. Antiangiogenic therapy for ocular tumors

27th Macula Society Meeting, Las Vegas, NV, 2/25 - 2/28/04

- **Murray TG** et al. Novel anti-angiogenic treatment of murine transgenic retinoblastoma

Aspen Retinal Detachment Society Meeting, Aspen, CO, 2/29-3/4/04

- **Murray TG** et al. Current Directions in Ocular Oncology
- **Murray TG** et al. My approach to vitrectomy combined with scleral buckle

Grand Rounds, University of California, San Francisco, 3/25-26/04

- **Murray TG** et al. Anti-angiogenesis in primary RB: a novel therapeutic approach
- **Murray TG** et al. Posterior segment complications of anterior segment surgery

14th Duke Advanced Vitreous Surgery Course, Durham, NC, 4/22-24/04

- **Murray TG** et al. Widefield Imaging in Pediatric Retinal Disease
- **Murray TG** et al. Advanced Concepts in the Management of Pediatric RB
- **Murray TG** et al. Advanced Concepts in the Management of Complex Uveal Melanoma
- **Murray TG** et al. Complex Surgical Approaches to Advanced Vitreomacular Pathology

Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale, FL, 4/25-30/04

- Moderator: Imaging: Anatomy & Pathology Session
- **Murray TG** et al. Combined anti-angiogenic and periocular chemotherapy utilizing anecortave acetate & carboplatin in the treatment of retinal tumors in the LH betaTag murine transgenic model of RB

Alcon Advisory Board Meeting, Carlsbad, CA, 8/13-15/04

American Society of Retina Specialists, San Diego, CA, 8/16-20/04

- **Murray TG** et al. Vascular targeting (anecortave acetate) & carboplatin chemotherapy enhance tumor control in murine RB (poster presentation)
- Moderator: Symposium 7: Ocular Oncology/Infectious Diseases/Endophthalmitis

American Academy of Ophthalmology, New Orleans, LA, 10/22-27/04

- Retina 2004, Discussion Group Leader
- **Murray TG** et al. Phakomatoses
- **Murray TG** et al. Pharmacotherapies for Ocular Tumors
- Moderator, Autofluorescence in small uveal melanocytic lesions
- Moderator, Macular RB managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors

XXVI Inter-American Course, Miami, FL, 10/31-11/3/04

- Widefield Imaging

Association for Research in Vision and Ophthalmology (ARVO) PC meeting, Bethesda, MD, 1/21-22/05

Association of Pediatric Retinal Surgeons Meeting, Hawk's Cay, Florida Keys, 1/27-30/05

- **Murray TG** et al. Advancement of pharmacotherapies in the management of pediatric retinoblastoma

Macula Society meeting, Key Biscayne, FL, 2/23-26/05

- **Murray TG** et al. Macular retinoblastoma: enhancement of tumor control with immediate, consecutive laser thermotherapy
- **Murray TG** et al. Translation approaches to treatment advances in retinoblastoma: the role of the clinician scientist

Aspen Retinal Detachment Society meeting, Aspen, CO, 3/6-11/05

AAO Mid-year Forum, Washington, DC, 4/6-9/05

Genentech Meeting, Washington, DC, 4/15-16/05

Bascom Palmer Eye Institute 2005 Vitreoretinal Course, Miami, FL, 4/29-30/05

Retinal Advisory Committee II meeting, Washington, DC, 5/13-15/05

Bascom Palmer Eye Institute Annual Resident's Day Meeting, 6/17-18/05

- Moderator, Pediatric Tumors Session

American Society of Retina Specialists meeting, Montreal, International RB Symposium, Fairmont Hotel, Whistler, Canada, 9/1-5/2005

- **Murray TG** et al. Characterization of VEGF Receptor Two expression in the Retinoblastoma mouse model LHBTAG.
- **Murray TG** et al. Vascular Targeting Enhances Focal Chemotherapy in the Control of Retinoblastoma Tumor Burden.
- Scheffler AC, **Murray TG**. Macular Retinoblastoma: Evaluation of Tumor Control, Local Complications, and Visual Outcomes for Eyes treated with Chemotherapy and Repetitive foveal laser ablation
- **Murray TG** et al. Gelatinase Modulation as Treatment for Retinoblastoma (poster presentation)

Retina Society Meeting, Coronado, CA 9/15-18/2005

American Academy of Ophthalmology, Chicago, IL 10/14-19/2005

- Luncheon Discussion Group Schedule--V17: Intraocular Tumor Management Update, Discussion Group Leader.
- **Murray TG** et al. Macular Retinoblastoma Enhancement of Tumor Control with Intermediate Consecutive Laser Thermal Therapy
- Advanced Vitreoretinal Technology and Therapies Symposium
- Moderator, Breakfast with the Experts roundtable (Ocular Oncology Update)
- **Murray TG** et al. Safety and Efficacy of Intravitreal Triamcinolone Acetonide for Macular Edema in Central Retinal Vein Occlusion: One Year Results.

**Timothy G. Murray, M.D., M.B.A.**  
**Curriculum Vitae**

- **Murray TG** et al. Current and new concepts for the ideal socket and prosthesis.
- Moderator, 2005 Breakfast with the Experts Roundtable B329 (Pharmacotherapies for Ocular Tumors)
- **Murray TG** et al. Outcomes of Vitrectomy for retained lens fragment (poster presentation)
- **Murray TG** et al. An Impact Study on the management of retinoblastoma
- **Murray TG** et al. Whole Body PET/CT Imaging for Choroidal Melanoma
- **Murray TG** et al. The potential use of Fibrin Sealant delivery of periocular chemotherapy.

BPEI 2006 Research Retreat 01/06/06

BPEI Angiogenesis 2006, Miami, FL 02/04-05/2006

- **Murray TG** et al. Intraocular Tumor Microvascular Targeting Enhances Tumor Control in Retinoblastoma: In Vivo Modeling of Treatment Parameters.

Miami Nature Biotechnology Winter Symposium, Miami, FL 02/04-5/2006

34<sup>th</sup> Annual Aspen Retinal Detachment Society Meeting, Aspen, CO 03/05-09/2006

ASRS 2006 Mid-Year Board Meeting, Las Vegas, NV April 22, 2006

2006 Retinal Physician Symposium, The Atlantis Paradise Island, Bahamas  
May 31 – June 3, 2006 (Invited Speaker)

- Retinoblastoma Update
- Experimental Therapies for Tumors- Ready for Prime time

ABO Oral Examinations. San Francisco, CA, June 9 – 11, 2006

- Invited Examiner

2006 BPEI Resident's Day – Miami, FL, June 16-17, 2006

18th Annual Midwest Ocular Angiography Conference, Girdwood, Alaska 8/2-5/06

24<sup>th</sup> Annual ASRS Meeting, Cannes, France 9/9-13/06

American Academy of Ophthalmology, Las Vegas, Nevada, 11/11-14/06

- Academy Subspecialty Day – Discussion Group Leader
- Temporary Complete VEGF-A Blockage Study Group
- **Murray TG** et al. Retinoblastoma Treatment Update

Association of Pediatric Retinal Surgeons Meeting, Jan 18-21, 2007

- **Murray TG** et al. Implications of Retinoblastoma Tumor Vasculature on Novel Therapies

Angiogenesis 2007, Miami, Florida, Feb 23-24, 2007

- **Murray TG** et al. Antiangiogenic Therapy for Ocular Tumors

35th Annual Aspen Retinal Detachment Society Meeting, March 3 – 10, 2007

- **Murray TG** et al. Implications of "Off-label" Therapy in Retinal Disease Management
- **Murray TG** et al. Ocular Oncology: Revisiting the Controversies

Retinal Physician Symposium, Sanibel, Florida, April 12-15, 2007

- Tumors: Adult Tumor Update
- Tumors: Tumor cases Panel

Royal Australian & New Zealand College of Ophthalmologists, April 26-29, 2007

- **Murray TG** et al. Macular surgery: Advances in imaging, surgical technology and techniques
- **Murray TG** et al. Ocular tumor management: Applications from the laboratory to the patient
- **Murray TG** et al. Posterior segment complications of anterior segment surgery
- **Murray TG** et al. Complex retinal detachment repair: The new and the old

2007 Vitreoretinal Update Course, Bascom Palmer Eye Institute, Miami, Florida, May 4-5, 2007

- **Murray TG** et al. Choroidal Melanoma: Pearls Long After the COMS
- **Murray TG** et al. Vascular Biology of Retinoblastoma Implications for Novel Treatments

Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale, FL, May 6- 10, 2007

- **Murray TG** et al. Blood Vessel Maturation in Human Uveal Melanoma: Spatial Configuration of Endothelial Vessel Maturation and Neovasculature and Its Impact on Ocular Treatment
- **Murray TG** et al. Uveal Melanoma Cell-Based Vaccines Activate CD4+ T Lymphocytes That Cross-React With Primary and Metastatic Uveal Melanoma Cells
- **Murray TG** et al. Candida Endophthalmitis Following Cataract Surgery: Management Strategies, and Visual Acuity Outcomes
- **Murray TG** et al. Echographic Localization of Periocular Carboplatin in Advanced Retinoblastoma
- **Murray TG** et al. Basic Fibroblast Growth Factor Expression in Retinoblastoma Progression and Survival

**Timothy G. Murray, M.D., M.B.A.**  
**Curriculum Vitae**

- **Murray TG** et al. Targeting the Tumor Microenvironment as a Therapeutic Strategy for Retinoblastoma
- **Murray TG** et al. Role of Tumor Associated Macrophages in Retinoblastoma Tumor Growth
  
- **Murray TG** et al. Quantitative Imaging of Eye Tumor in the Mouse Model of Retinoblastoma With Spectral-Domain Optical Coherence Tomography
- **Murray TG** et al. The Wnt Signaling Pathway Has Tumor Suppressor Properties in Retinoblastoma
- **Murray TG** et al. Differential Induction of Apoptosis in the Treatment of LHBETATAG Retinoblastoma Following Vessel Targeting
- **Murray TG** et al. Regional Hypoxia in LHBetaTag Murine Retinoblastoma: Implication for Novel Treatments

Macula Society, London, England, May 30-June 2, 2007

- **Murray TG** et al. Intravitreal Avastin in the Management of Post-Brachytherapy Radiation Retinopathy in Patients with Posterior Uveal Malignant Melanoma

Reggio Retina 2007, Reggio, Italy, June 6 -10, 2007

- Advanced Pharmacologic Therapy for Intraocular Tumors
- Uveal Melanoma Advances in Radiotherapy: A Ten Year Update

International Society of Ocular Oncology (ISOO), Siena, Italy, June 27-30, 2007

- **Murray TG** et al. Apoptotic cell death in LHBetaTag tumors following vessel targeting therapy
- **Murray TG** et al. Regional hypoxia in LHBetaTag murine retinoblastoma: implications for novel treatments.
- **Murray TG** et al. Characterization of tumor associated macrophages in the LHBetaTage mouse model of retinoblastoma

AVTT/Fellow's Symposium, Chicago, Illinois, Sept. 7-9, 2007

- **Murray TG** et al. Small Gauge Surgery for Management of Dislocated Lens Nucleus Fragments

40th Annual Meeting of the Retina Society, Sept. 27-30, 2007

- Session Moderator - Tumors
- **Murray TG** et al. Long-term Survival Outcomes for Patients Undergoing Observational Management Prior to Definitive 125-Iodine Brachytherapy: Ten-year Follow-up of a Prospective Treatment Cohort

Iowa Clinical Conference - Visiting Professor, Oct. 3 - 7, 2007

- Ocular Oncology Update: Focus on translational research application to advanced patient care

- Vitreoretinal Surgical Update: Microincisional surgery - The new and the old

Alcon Meeting, Oct. 19-21, 2007

American Board of Ophthalmology Oral Examinations, Oct 26 - 28, 2007

- Invited Special Examiner

American Academy of Ophthalmology, New Orleans, Louisiana, Nov. 11-13, 2007

- Academy Subspecialty Day – Discussion Group Leader
- **Murray TG** et al. Sandwich Therapy for Choroidal Melanomas
- Advanced Vitreoretinal Technology and Therapies Symposium
  - Moderator
  - **Murray TG** et al. Best Practices for 23-gauge Success: A Surgeon's Perspective
- Alcon Speaker Forum - Micro-Incision Vitrectomy Surgery - Panel Discussion
- OPS Lecture (Wide Field Pediatric Imaging)

Sylvester Comprehensive Cancer Center Retreat, Marco Island, Florida, Nov. 16-18, 2007

- **Murray TG** et al. Advances in Pediatric Retinoblastoma Management Application of Translational Research

American Society of Retina Specialist Meeting, Indian Wells, California, Dec. 1-5, 2007

- A Roadmap to Emerging Anti-VEGF Therapies: Driving a Successful Practice Management System
- **Murray TG** et al. Juxtapapillary Choroidal Malignant Melanoma: Custom Notched Plaque 125 Iodine Brachytherapy: a Completed 5 year Pilot clinical Trail

Angiogenesis, Miami, Florida, February 22 - 23, 2008

- **Murray TG** et al. Hypoxia Modulation Improves Vessel Targeting in Retinoblastoma

36th Annual Aspen Retinal Detachment Society Meeting, Aspen, Colorado, March 2-6, 2008

31st Annual Macula Society Meeting, Palm Beach, Florida, March 26-29, 2008

- **Murray TG** et al. Targeting Regional Hypoxia Enhances Retinoblastoma Tumor Control: Use of 2-DG as a Novel Therapeutic Strategy

2008 AAO Mid-Year Forum, Washington, DC, April 9 - 12, 2008

ARVO 2008 Annual Meeting, Ft. Lauderdale, Florida, April 27 - May 1, 2008

- Moderator - Retinoblastoma I
-



Retinal Physician Symposium, Naples, Florida, 2008 - May 29-31, 2008

- **Murray TG** et al. Adult Tumor Update
- **Murray TG** et al. Surgery for DME

American Board of Ophthalmology, San Francisco, California, June 4 - 9, 2008

- Examiner

World Ophthalmology Congress 2008, Hong Kong, China, June 28 - July 2, 2008

- **Murray TG** et al. Macrophages and Blood Vessels in Retinoblastoma
- **Murray TG** et al. Visions for Better Therapy: Preclinical Evidence
- Panel Discussion - Retinoblastoma and Uveal Melanomas

Pediatric Retina, Strasbourg, France, August 27 - 30, 2008

- **Murray TG** et al. Antiangiogenic Therapy for Retinoblastoma: Effect of Tumor Burden and Dose Schedule in the Murine LH BETATAG Transgenic Model
- **Murray TG** et al. Tumor Microenvironmental Targeting Therapy Improves Retinoblastoma Tumor Control
- **Murray TG** et al. Vascular Targeting Increases Hypoxia in LHBETATAG Murine Retinoblastoma

Club Jules Gonin, St. Moritz, Switzerland, September 10 - 14, 2008

- **Murray TG** et al. Hypoxic Modulation Enhances Retinoblastoma Tumor Control: A Novel Treatment Strategy

Retina Society Meeting, Scottsdale, Arizona, Sept. 25-28, 2008

- **Murray TG** et al. Intraoperative Echography Enhances Local Tumor Control and Long-term Survival for Brachytherapeutic Treatment of Uveal Melanoma

26th Annual Mtg of the American Society of Retina Specialists, Maui, HI, Oct 11-15, 2008

- **Murray TG** et al. Advances in Ocular Tumor Management – 2008
- Recent Advancements in 532 Green Laser Technology and Probe Enhancement: Clinical assessment and laboratory evaluation

American Academy of Ophthalmology, Atlanta, GA, November 8-12, 2008

- **Murray TG** et al. Laser & Laser Probes
- **Murray TG** et al. Ocular Treatment Options for Retinoblastoma
- **Murray TG** et al. Hypoxia Modulation Improves Vessel Targeting in Retinoblastoma
- Poster: Retinal Detachment Rates and Visual Acuity Outcomes of Patients Undergoing Pars Plana Vitrectomy for Retained Lens Fragments
- Poster: Bevacizumab Reduces Vision Loss From Radiation Retinopathy After Iodine-125 Plaque Brachytherapy for Posterior Uveal Malignant Melanoma
- Poster: Nosocomial Acute-Onset Postoperative Endophthalmitis at a University Teaching Hospital

- **Murray TG** et al. Immunology and retinoblastoma

American Society of Retina Specialists, Strategic Planning Retreat, January 23- 25, 2009

Association of Pediatric Retinal Specialist, Duck Key, Florida, Jan. 29 – Feb. 1, 2009

- **Murray TG** et al. Advances in Retinoblastoma Management: Vascular targeting improves tumor control in combined modality therapy

Angiogenesis, Exudation and Degeneration 2009, Miami, Florida, February 21, 2009

- **Murray TG** et al. The Economics of Anti-VEGF Therapy in an Academic Practice

7th International Spectralis Symposium (ISS), Miami, Florida, February 27-28, 2009

- **Murray TG** et al. Advanced OCT/Autofluorescence Imaging of Posterior Choroidal Tumors

37th Annual Aspen Retinal Detachment Society Meeting, Snowmass Village, Colorado, March 1-5, 2009

- **Murray TG** et al. Complex Case Management - A Roundtable Review

American Society of Retina Specialists, Chicago, Illinois, April 18, 2009

2009 Mid-Year Forum, Washington, D.C., April 22-25, 2009

Vitreoretinal Update 2009, Miami, Florida, May 1-2, 2009

- **Murray TG** et al. Choroidal Melanoma: Pearls Long After the COMS
- **Murray TG** et al. Vascular Biology of Retinoblastoma: Implications for Novel Treatments

ARVO Annual Meeting, Ft. Lauderdale, Florida, May 3-7, 2009

- **Murray TG** et al. Role of Matrix Metalloproeinase-9 in LH BETA Tag Retinal tumor Growth
- **Murray TG** et al. Optical Coherence Tomography in a Murine Retinal Detachment Model.
- **Murray TG** et al. Recent Advancements in 532 Green Laser Technology and Probe Enhancement: Clinical Assessment and Laboratory Evaluation.
- **Murray TG** et al. Retinoblastoma Tumor Burden: Effect of Macrophage Depletion on LH<sub>BETA</sub>TAG Retinal Tumor Growth.
- **Murray TG** et al. Vascular Targeting Agent and Glycolytic Inhibitor Combination Therapy Decreases Tumor Burden in Advanced LH<sub>BETA</sub>TAG Murine Retinoblastoma.
- **Murray TG** et al. Chemotherapy Plus Cyclosporine A for the Treatment of Intraocular Retinoblastoma.
- **Murray TG** et al. Fundus Pigmentation in Treatment-requiring Retinopathy of Prematurity (ROP).

- **Murray TG** et al. Nosocomial Acute-Onset Postoperative Endophthalmitis at a University Teaching Hospital (1995-2008)
- **Murray TG** et al. Acute-Onset Endophthalmitis Following Clear Corneal Cataract Surgery: A 12-Year Review (1996-2008)

SW Regional AAO Tristate Meeting, Flagstaff, Arizona, May 15-17, 2009

- **Murray TG** et al. Advanced Tumor Management 2009: The End of a Remarkable Decade
- **Murray TG** et al. Age Related Macular Degeneration 2009: Imaging and Targeted Vascular Therapy Revolutionize Treatment Success

American Board of Ophthalmology Oral Examinations, Chicago, Illinois, June 5-7, 2009

- Invited Special Examiner

Pediatric Grand Rounds, July 28, 2009

- **Murray TG** et al. Advances in Pediatric Retinoblastoma Management: Application of Translational Research

Michigan Society of Eye Physicians and Surgeons 41st Annual Conference, Mackinac Island, Michigan, August 14 - 16, 2009

- **Murray TG** et al. Age Related Macular Degeneration 2009: Imaging and Targeted Vascular Therapy Revolutionize Treatment Success
- **Murray TG** et al. Advanced Tumor Management 2009: The End of a Remarkable Decade

Alcon Consultant Meeting, Chicago O'Hare, Illinois, August 20 - 21, 2009

2009 Chicago AVTT and Fellow's Forum, Chicago, Illinois, August 21-23, 2009

- Moderator: Diabetes Mellitus and Retinal Vascular Diseases
- **Murray TG** et al. Combined Small Gauge Vitrectomy with Phacoemulsification
- **Murray TG** et al. The Role of anti-VEGF Therapy in the Treatment of Uveal Melanoma
- **Murray TG** et al. Retinoblastoma Update

International Congress of Ocular Oncology, Cambridge, United Kingdom, September 8-12, 2009

- Moderator: Angiogenesis
- **Murray TG** et al. Ocular Tumor Vascular Development: Tumor Angiogenesis and Regionalization of Vascular Progression

Combined Meeting: ASRS, Macula Society and Retina Society, New York City, New York, Sept. 30 - Oct. 4, 2009

- Poster : Focal, Periocular Delivery of 2-Deoxy-D-Glucose Alone and as an Adjuvant to Chemotherapy for Treatment of Advanced Retinoblastoma

Subspecialty Day and American Academy of Ophthalmology Annual Meeting, Oct. 22-27, 2009

- Discussion Group Leader: V11.25- and 23-Gauge Instrumentation for Vitrectomy
- **Murray TG** et al. Intra-operative OCT Analyzing the BPEI Academic, Hospital-based Practice With a Focus on Profitability and Efficiency
- **Murray TG** et al. Vascular Targeting in Ocular Oncology
- **Murray TG** et al. Management of radiation maculopathy and papillopathy

ASRS - Strategy & Business Plan Group Meeting II, Rosemont, IL, January 8-10, 2010

Angiogenesis Meeting, Miami, Florida, February 20, 2010

- **Murray TG** et al. Pharmacotherapies for Ocular Tumors

38th Annual Aspen Retinal Detachment Society Meeting, Aspen, Colorado, March 6-13, 2010

ASRS Mid Year Board Meeting, Chicago, IL, April 17, 2010

Retinal Physician Symposium, Paradise Island, Bahamas, April 21-24, 2010

ARVO Annual Meeting, Ft. Lauderdale, Florida, May 2-6, 2010

- Poster: T Cells Targeting Cancer Stem Cells in Uveal Melanoma
- Paper: Retinoblastoma Molecular Genomics: Regional Differences in the Molecular Genomics Expression Following Treatment With 2-Deoxy-D-Glucose in LHBETATAG Retinal Tumors
- Paper: Supraselective Intra-Ophthalmic Artery Chemotherapy: Evaluation of Treatment Related Complications in Advanced Retinoblastoma
- Moderator - Poster Session # 279, Session Title: AP – Retinoblastoma
- Poster: Retinal Findings in Patients With Aicardi Syndrome
- Poster: Retinoblastoma Tumor Burden Control: Periocular m-TOR Inhibitor Rapamycin Decreases Tumor Burden in Advanced LHBETATAG Murine Retinoblastoma
- Poster: Regional and Temporal Differences in the Genetic Expression of LHBetaTAg Retinoblastoma Tumors
- Paper: Intraoperative Spectral Domain Optical Coherence Tomography (SD-OCT) Imaging of Complex Pediatric Retinal Disease
- Moderator: Poster Session - Tumors and Clinical/Experimental Study
- Poster: Open Globe Injuries: Computerized Tomography and Echography in Clinical Management

World Congress of Ophthalmology, Berlin, Germany, June 5-9, 2010

- Moderator: Retina: Diagnostics 1
- **Murray TG** et al. Angiogenesis in retinoblastoma
- **Murray TG** et al. Combined MIVS 23 Gauge Vitrectomy and Phacoemulsification in the Management of Complex Macular Pathology

ASRS Annual Meeting, Vancouver, Canada, August 28 - Sept. 2, 2010

- **Murray TG** et al. Surgical Comparison of Combined Sutureless Microincisional 23 versus 25+ Gauge Vitrectomy Surgery (MIVS) with Concomitant Phacoemulsification
- Poster: Supraselective Intra-arterial Chemotherapy Utilizing Ophthalmic Artery Delivery for Advanced Retinoblastoma

Retina Consultant and Advisor Mtg, Chicago, IL, September 9-10, 2010

Retina Society, San Francisco, CA, Sept. 23-26, 2010

- **Murray TG** et al. 10,000 Intravitreal Injections: Analysis of impact on the Ocular Oncology Service at BPEI

American Academy of Ophthalmology Meeting, Chicago, IL, Oct. 15-16, 2010

- Moderator: Oculoplastics Original Papers: Tumors

Club Jules Gonin 2010, Kyoto, Japan, Nov. 3-6, 2010

- Poster: Periocular Combined 2-DeoxyGlucose with Carboplatin Chemotherapy increases Retinoblastoma Tumor control through Hypoxia Modulated enhancement of Chemotherapy

Association of Pediatric Retinal Surgeons Meeting, February 24-27, 2011

- **Murray TG** et al. Supraselective Intra-Artrial Melphalan Chemotherapy in Retinoblastoma: Evolving Treatment Schedules and Dosing Regimens

39th Aspen Retinal Detachment Society, Snowmass, Colorado, March 5-9, 2011

- **Murray TG** et al. Retinoblastoma: Unique Diagnosis and Treatment Paradigms in 2011
- **Murray TG** et al. Uveal Melanoma: Applications of High Resolution Imaging and Adjunctive Intravitreal Therapy Enhance Cure in 2011

11<sup>th</sup> Antwerp Vitreoretinal Course, Antwerp, Belgium, March 17-19, 2011

- **Murray TG** et al. Combined Phaco-Vitrectomy
- **Murray TG** et al. Dislocated Nuc Fragments/Displaced IOL
- **Murray TG** et al. Wide Field Viewing
- **Murray TG** et al. Comparison of 23 / 25 G MIVS Systems

ARVO 2011, Fort Lauderdale Convention Center, Ft. Lauderdale, Florida

May 1-5, 2011

- **Murray TG** et al. A Novel, Oral, Non-invasive Method Of Delivery For The Glycolytic Inhibitor 2-deoxy-d-glucose In The Treatment Of Retinoblastoma"
- Moderator: Retinoblastoma II, Poster Session

Kresge Eye Institute's 56<sup>th</sup> Annual Clinical Conference Update in Clinical Ophthalmology  
Detroit, Michigan, June 17-18, 2011

- **Murray TG** et al. Novel Therapeutic Strategies for Advanced Retinoblastoma

Masters in Ophthalmology 2011, Palm Beach, Florida 33480, June 24-26, 2011

- **Murray TG** et al. Ocular Oncology Update: 2011

Advanced Vitreoretinal Techniques & Technology (AVTT) Symposium (and CPE Vitreoretinal  
Fellows Program), W Chicago City Center Hotel, August 12-14, 2011

- **Murray TG** et al. Practice Efficiency: How to Manage "Quality" Care in Today's World
- **Murray TG** et al. Vitrectomy and Cataract Surgery-Combined or Sequential Surgical Approach? Are Outcomes Different?
- **Murray TG** et al. Microincisional Vitrectomy Surgery (MIVS) Instrumentation-Tips and Tricks
- **Murray TG** et al. HD Video-Operative Approaches to Better Video

29<sup>th</sup> American Society of Retina Specialist Annual Meeting, Boston, Massachusetts, August 20-24, 2011

- **Murray TG** et al. "Implications of 23/25+ Gauge Microincisional Vitrectomy Surgery with Adjunctive Intravitreal Steroid Pharmacotherapy"
- **Murray TG** et al. "Clinical Experience case study – ERM"

American Academy of Ophthalmology Meeting, Convention Center, Orlando, Florida, October 21-25, 2011

- Moderator: Retina 2011: The Magical World of Retina – Beauties and the Beasts: Retinoblastoma Roundtable
- Moderator: Advancements in Surgical Technology: A Retina Case Review
- Moderator: Murray - Roundtable Number:B470 Update on Ocular Oncology 2011

XVth Biannual Meeting of the International Society of Ocular Oncology, Buenos Aires, Argentina, November 14-17, 2011

- **Murray TG** et al. "mTOR targeting in combination with chemotherapy: Upstream regulation of anaerobic glycolysis to target the chemoresistant cell population in RB"
- Dr. Murray (Panelist) - RETINOBLASTOMA PANEL 30 RBp127
- Poster: Treatment modulation in retinoblastoma tumorigenesis and its impact on tumor burden
- **Murray TG** et al. A novel, oral, non-invasive method of delivery for the glycolytic inhibitor 2-deoxy-D-glucose in the treatment of Retinoblastoma.
- **Murray TG** et al. Intra-arterial melphalan dosing regimens for the treatment of retinoblastoma

Retina Canada, Niagra Falls, Canada, September 27-30, 2012

45<sup>th</sup> Retina Society, Washington D.C, October 4-7, 2012

American Society of Retinal Specialists, Chicago, Illinois, January 11-13, 2013

International Retinal Imaging Symposium, Dana Point, California, February 26, 2013

Macula Society 36<sup>th</sup> Annual Meeting, St. Regis Monarch Beach, Dana Point, California, February 27, 2013- March 2, 2013

41<sup>st</sup> Annual Aspen Meeting, Snowden, Colorado, March, 2013

Caymen Islands TV Interview, April 3, 2013

Vit- Buckle Society, Miami, Florida, April 11-13, 2013

3<sup>rd</sup> Annual Wills Eye Intraocular Tumor Symposium, April 26-27, 2013, Philadelphia, PA

American Society of Retinal Specialists Board Meeting, Chicago, Illinois, April 25-28, 2013

Vit-Buckle Society Meeting, Miami, Florida, April 11-14, 2013

Association for Research in Vision and Ophthalmology, Seattle, Washington, May 5-9, 2013

US Vitreoretinal Advisory Board, Chicago, Illinois, May 17-19, 2013

Retinal Physician Symposium, Las Vegas, Nevada, June 5-8, 2013

Alcon invitation to speak dinner meeting, Tampa, Florida, June 12-13, 2013

Shields Case, Philadelphia, Pennsylvania, June 24-25, 2013

Masters in Ophthalmology, Breakers Palm Beach, Florida, June 28-30, 2013

American Society of Retinal Specialists, Toronto, Canada, August 22-28, 2013

- **Murray TG** et al. Dislocated IOL's: Exchange, Reposition, Suture
- **Murray TG** et al. Treatment algorithm for retinal vein occlusion

International Society of Ocular Oncology, Cleveland, Ohio, September 30,2013- October 3, 2013

**Timothy G. Murray, M.D., M.B.A.**  
**Curriculum Vitae**

American Academy of Ophthalmology Mid-Year Forum, Washington, D.C., April 10, 2014-  
April 13, 2014

American Society of Retinal Specialists Board Meeting, Dallas, Texas, April 25<sup>th</sup>, 2014

Association for Research in Vision and Ophthalmology, Orlando, Florida, May 4<sup>th</sup>-May 8<sup>th</sup>, 2014

10<sup>th</sup> Annual Retinal Physicians Symposium, Washington, D.C., May 16<sup>th</sup>-May 18<sup>th</sup>, 2014

Pan-American Retina & Vitreous Society Congress, San Juan, Puerto Rico, June 11<sup>th</sup>-June 14<sup>th</sup>,  
2014

Masters In Ophthalmology, Ritz-Carlton Orlando, Grande Lakes, Florida, June 20<sup>th</sup>-June 22<sup>nd</sup>,  
2014

American Society of Retinal Specialists Annual Meeting, San Diego, California, August 9<sup>th</sup>-  
August 13<sup>th</sup>, 2014

XXIXth Club Jules Gonin Meeting, Zurich, Switzerland, September 3<sup>rd</sup>-September 6<sup>th</sup>, 2014

47<sup>th</sup> Annual Retina Society Scientific Meeting, Philadelphia, Pennsylvania, September 11<sup>th</sup>-  
September 14<sup>th</sup>, 2014

American Academy of Ophthalmology Annual Meeting, Chicago, Illinois, October 17<sup>th</sup>-October  
21<sup>st</sup>, 2014

U.S. Retina Advisory Council, Denver, Colorado, November 7<sup>th</sup>-November 9<sup>th</sup>, 2014

Alcon Advisory Board Meeting, San Francisco, California, November 14<sup>th</sup>, 2014

Atlantic Coast Retina Club Macula Meeting, Boston, Massachusetts, January 9<sup>th</sup>-January 10<sup>th</sup>,  
2015

New Orleans Academy of Ophthalmology 64<sup>th</sup> Annual Symposium “Reflections on the Bayou”,  
New Orleans, Louisiana, January 30<sup>th</sup>-February 1<sup>st</sup>, 2015

43<sup>rd</sup> Annual Aspen Retinal Detachment Society Meeting, Aspen, Colorado, February 28<sup>th</sup>-March  
4<sup>th</sup>, 2015

American Academy of Ophthalmology Mid-Year Forum, Washington, D.C., April 15<sup>th</sup>-April  
18<sup>th</sup>, 2015

ARVO Annual Meeting, Denver, CO May 2<sup>nd</sup>-May 7<sup>th</sup>, 2015

ISOO Biennial Meeting, Paris, France June 16<sup>th</sup>-June 19<sup>th</sup>, 2015



**Timothy G. Murray, M.D., M.B.A.**  
**Curriculum Vitae**

Masters in Ophthalmology FSO Annual Meeting, The Breakers Palm Beach, Florida, June 26<sup>th</sup>-June 28<sup>th</sup>, 2015

48<sup>th</sup> Annual Retina Society Scientific Meeting, Paris, France, October 7<sup>th</sup>-October 11<sup>th</sup>, 2015

American Academy of Ophthalmology Annual Meeting, Las Vegas, Nevada, November 13<sup>th</sup>-November 17<sup>th</sup>, 2015

World Ophthalmology Congress, Guadalajara, Mexico, February 5<sup>th</sup>-February 8<sup>th</sup>, 2016

Annual Macula Society Meeting, Miami, Florida, February 24<sup>th</sup>-February 27<sup>th</sup>, 2016

Aspen Retinal Society Meeting, Aspen, Colorado, March 5<sup>th</sup>-March 9<sup>th</sup>, 2016

ASRS, Denver, Colorado, March 10<sup>th</sup>-March 13<sup>th</sup>, 2016

VBS, Miami, Florida, March 18<sup>th</sup>-March 20<sup>th</sup>, 2016

APRS – Pediatric Retina Society, Cabo San Lucas, March 30<sup>th</sup>-April 3<sup>rd</sup>, 2016

AAO Mid-year Forum, Washington DC, April 15<sup>th</sup>-April 17<sup>th</sup>, 2016

ARVO, Seattle, Washington, May 1<sup>st</sup>-May 3<sup>rd</sup>, 2016

Masters in Ophthalmology 2016 Annual Meeting, Orlando, Florida, June 10<sup>th</sup>-June 12<sup>th</sup>, 2016

XXX Meeting of Club Jules, Bordeaux, France, July 6<sup>th</sup>-July 9<sup>th</sup>, 2016

ASRS, San Francisco, California, August 9<sup>th</sup>-August 14<sup>th</sup>, 2016

Retina Society Meeting, San Diego, California, September 14<sup>th</sup>-September 17<sup>th</sup>, 2016

American Academy of Ophthalmology Annual Meeting, Chicago, Illinois, October 15<sup>th</sup>-October 18<sup>th</sup>, 2016

Optometric Management Meeting, Orlando, Florida, December 1<sup>st</sup>-December 4<sup>th</sup>, 2016

Retina Society Interim Meeting, Boston, Massachusetts, February 17<sup>th</sup>-February 18<sup>th</sup>, 2017

Retina World Congress, Fort Lauderdale, Florida, February 23<sup>rd</sup>-February 26<sup>th</sup>, 2017

45<sup>th</sup> Annual Aspen Retinal Society Meeting, Aspen, Colorado, March 4<sup>th</sup>-March 8<sup>th</sup>, 2017

Washington Academy of Eye Physicians and Surgeons Annual Meeting, Seattle, Washington, March 29<sup>th</sup>-March 31<sup>st</sup>, 2017

VBS 5<sup>th</sup> Annual Meeting, Las Vegas, Nevada, April 6<sup>th</sup>-April 8<sup>th</sup>, 2017

Mid-year Retina Forum, Washington, D.C., April 26<sup>th</sup>-April 29<sup>th</sup>, 2017

ARVO Baltimore, Maryland, May 7<sup>th</sup>-May 11<sup>th</sup>, 2017

FSO Trump International Doral, Florida, June 2<sup>nd</sup>-June 4<sup>th</sup>, 2017

ASRS Annual Meeting, Boston, MA, August 11<sup>th</sup>-August 15<sup>th</sup>, 2017

50<sup>th</sup> Anniversary Meeting of The Retina Society, Boston, MA, October 5<sup>th</sup>-October 8<sup>th</sup>, 2017

AAO New Orleans, LA, November 10<sup>th</sup>-November 14<sup>th</sup>, 2017

FSO Orlando, Florida, June 8<sup>th</sup>-June 10<sup>th</sup>, 2018

World Ophthalmology Conference, Barcelona, Spain, June 16<sup>th</sup>-June 19<sup>th</sup>, 2018

ASRS Annual Meeting, Vancouver, Canada, July 20<sup>th</sup>-July 25<sup>th</sup>, 2018

Pan-American Retina & Vitreous Society Congress, Cancun, Mexico, August 29<sup>th</sup>-September 1<sup>st</sup>, 2018

Retina Society Annual Meeting, San Francisco, CA, September 12<sup>th</sup>-September 15<sup>th</sup>, 2018

AAO Annual Meeting, Chicago, IL, October 27<sup>th</sup>-October 30<sup>th</sup>, 2018

Alcon, Dallas, TX, November 16<sup>th</sup>, 2018

ASRS Annual Meeting, Scottsdale, AZ, January 31<sup>st</sup>-February 2<sup>nd</sup>, 2019

42<sup>nd</sup> Annual Macula Society Meeting, Bonita Springs, FL, February 13<sup>th</sup>-February 16<sup>th</sup>, 2019

Aspen Retinal Detachment Society Meeting, Snowmass, CO, March 2<sup>nd</sup>-March 6<sup>th</sup>, 2019

Retina World Congress, Fort Lauderdale, FL, March 21<sup>st</sup>-March 24<sup>th</sup>, 2019

ISOO Biennial Conference, Los Angeles, CA, March 22<sup>nd</sup>-March 26<sup>th</sup>, 2019

Advancements in Retina Technology Symposium, Fort Worth, TX, June 21<sup>st</sup>-June 22<sup>nd</sup>, 2019

ASRS Annual Meeting, Chicago, IL, July 25<sup>th</sup>-July 30<sup>th</sup>, 2019

Retina Society Scientific Program, London, UK, September 11<sup>th</sup>-September 15<sup>th</sup>, 2019

18<sup>th</sup> Annual Downeast Ophthalmology Symposium, Bal Harbour, ME, September 20<sup>th</sup>-  
September 22<sup>nd</sup>, 2019

Mexico Retina Association Annual Retina Meeting, Pueblo, Mexico, October 2<sup>nd</sup>-October 5<sup>th</sup>,  
2019

AAO Annual Meeting, San Francisco, CA, October 12<sup>th</sup>-October 15<sup>th</sup>, 2019

FDA Meeting (DO DAC), Washington D.C., December 13<sup>th</sup>, 2019

ASRS Mid-year Board Meeting, Miami, FL, January 17<sup>th</sup>-January 19<sup>th</sup>, 2020

48<sup>th</sup> Annual Aspen ARDS Meeting, Aspen, CO, February 29<sup>th</sup>-March 5<sup>th</sup>, 2020

ASRS Annual Business Meeting, Virtual, July 24<sup>th</sup>, 2020

Aspen Retinal Detachment Society Annual Meeting, Aspen, CO, March 7<sup>th</sup>-March 11<sup>th</sup>, 2021

**Committees:**

American Academy of Ophthalmology

- Preferred Practice Pattern-Retina/Vitreous Panel

Collaborative Ocular Melanoma Study

- Executive Committee 1994-present.
- Chairman, Small Tumor Working Group 1995-present

NIH/NEI – Data Safety & Monitoring Committee (AMDRT Trial)

NIH/NCI – ACOSOG Eye Site working Committee

NIH/NCI – Common Toxicity Criteria Group

American Society of Retinal Specialists (Vitreous Society)

- Chairman, Education Subcommittee 2010
- Chairman, Communications Committee 2010
- AAO Councilor Representative 2003 - 2009
- Chairman, Research & Development Committee 2001
- Program Committee 1999, 2000, 2001

Association for Research in Vision and Ophthalmology (ARVO)

- Program Committee 2004

Retina Society

- Executive Board, 2012
- Chairman, Nominating Committee 2011 – 2012
- Award Committee, 2012
- Nominating Committee 2008 – 2009

## **VI. TEACHING**

### **27. Teaching Awards Received:**

Teacher of the Year  
Bascom Palmer Eye Institute/University of Miami

### **28. Teaching Specialization:**

Medical and Surgical Retina  
Ocular Oncology

### **29. Thesis and Dissertation Advising/Post-doctoral student supervision:**

Feasibility of Laser Interstitial Thermotherapy (LITT) of Breast Cancer  
By: Xochitl Gonzalez-Cirre, June 1997

## **VII. SERVICE**

### **30. University Committee and Administrative Responsibilities:**

Tumor Registry Committee  
University of Miami/Jackson Memorial Hospital

Residency Selection Committee  
Bascom Palmer Eye Institute; University of Miami School of Medicine

Vitreoretinal Selection Committee  
Bascom Palmer Eye Institute; University of Miami School of Medicine

Steering Committee  
Bascom Palmer Eye Institute; University of Miami School of Medicine

Ophthalmology Chair Search Committee  
University of Miami School of Medicine

Governing Board

University of Miami Medical Group

Medical Director

Echography Department, Bascom Palmer Eye Institute; University of Miami School of Medicine

Medical Director

Retinal Oncology, Bascom Palmer Eye Institute, University of Miami School of Medicine

Research Council Committee

Bascom Palmer Eye Institute; University of Miami School of Medicine

**31. Community Activities:**

1994 Medical Director & Chairman - National Retinoblastoma Research and Support Foundation, Miami, FL

1994 Guest Speaker - National Eye Institute: Vision: A Traveling Exhibit. Museum of Discovery & Science; Miami, FL

1995 Board Member - Lighthouse for the Blind, Miami, FL